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Summary
Despite the benefit tamoxifen has provided for millions of breast cancer 
patients worldwide, almost all patients with metastatic disease and as many as 
40% of patients receiving adjuvant tamoxifen treatment will acquire resistance 
to the drugs inhibitory effect on breast cancer cell growth. Previous studies in 
the Tenovus Centre have demonstrated that the development of anti-oestrogen 
resistance in vitro is associated with aberrant growth factor signaling which 
facilitates a more aggressive cell phenotype. The aim of the present study was 
to determine whether the undesirable characteristics of tamoxifen resistant 
cells were maintained following withdrawal from the drug. Interestingly, the 
accelerated rate at which resistant cells proliferated was sustained following a 
6 month withdrawal period despite decreased expression of epidermal growth- 
factor receptor and reduced sensitivity to gefitinib. Following the assessment 
of long-term tamoxifen exposure on classically regulated oestrogen gene 
targets progesterone receptor and trefoil factor 1, it was apparent that the 
genes were no longer inducible by oestradiol following the acquisition of 
resistance. In contrast, when cells were co-treated with a demethylation agent 
in combination with oestradiol, genes were once again responsive to oestrogen 
stimulation, providing proof of principle that long-term tamoxifen exposure 
can silence oestrogen regulated gene expression through promoter hyper- 
methylation. Importantly, this combination treatment was shown to 
significantly reduce cell growth, inferring that a proportion of the genes that 
were reactivated by this treatment were associated with a tumour suppressive 
function. Using microarray technology, methylight analysis and polymerase 
chain reaction validation, several genes with tumour-suppressive ontology 
were identified as being silenced by promoter hypermethylation in tamoxifen- 
I withdrawn tamoxifen-resistant cells, including p53 gene target, prostate 
differentiation factor, and inhibitor of Ras signaling, Ras protein activator-like
1. It is therefore proposed that anti-hormone induced epigenetic modification 
of tumour-suppressor genes, alongside aberrant growth factor signaling, can 
promote resistant cell survival and progression.
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Chapter 1 Introduction
1. INTRODUCTION
1.1 Cancer
Cancer is a group of diseases characterised by the inappropriate management 
of the regulatory circuits that govern normal cell proliferation and 
homeostasis, permitting cells to divide uncontrollably and gain otherwise 
restricted metastatic function, leading to invasion and erosion of surrounding 
tissues. This phenomenon can occur within all major components of the 
human anatomy, with over 100 different forms of cancer identified which are 
further sub-categorised according to the specific organ affected. It has been 
estimated that cancer was the cause of 7.6 million deaths worldwide in 2007 
[American Cancer Society, 2007], which equates to around 20,000 cancer 
related deaths per day. In the UK, one in three people are expected to develop 
cancer [Office for National Statistics, 2007]. In 2005, 239,000 people were 
diagnosed with the disease which claimed the lives of 126,600 patients in the 
same year, accounting for 29% of all deaths in males and 24% in females 
[Office for National Statistics, 2007].
While cancer accounts for an increasing proportion of deaths in the UK due to 
the decline of other main causes such as heart disease, stroke and infectious 
disease, cancer-related mortality decreased by 12% for men and 9% for 
women between 1997-2006, with significant reductions in cervix, stomach, 
bowel, lung and breast cancer patient mortality [Cancer Research UK, 2008a]. 
Reduced cancer death is primarily the result of improved primary prevention
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of cancer, earlier detection and better treatment. However, the multitude of 
molecular events governing the genetic changes observed in cancer onset 
remains a hugely active area of scientific research. Insight into the underlying 
mechanisms that dictate malignant cell growth, commonly identified as self- 
sufficient growth signalling, insensitivity to growth-inhibitory signals, evasion 
of programmed cell death (apoptosis), limitless replicative potential, sustained 
angiogenesis, and tissue invasion and metastasis [Hanahan & Weinberg,
2000], will provide essential therapeutic targets; imperative to relinquishing 
the grasp cancer has on the health of global society.
1.2 Breast cancer- Incidence and risk factors.
Breast cancer is now considered the most prevalent cancer amongst women, 
with over 1 million cases diagnosed per year worldwide [Ferlay et al, 2005]. 
Approximately 44,000 women and 300 men are diagnosed with breast cancer 
every year in the UK, and 12000 female and 100 male breast cancer patients 
will die from the disease annually [Cancer Research UK, 2008b]. Over the 
twenty five year period between 1981 and 2005, the incidence rate increased 
by 57% [Cancer Research UK, 2008c]. This was, in part, due to the 
introduction of a national screening programme in 1988, leading to a transient 
additional increase in breast cancer incidence in women aged 50-64, as early 
undiagnosed cancers were detected [Quinn & Allen, 1995]. Approximately 
14,000 cases are annually diagnosed as a result of the NHS breast screening 
programme, and it is thought to have saved the lives of approximately 1400 
women per year [Advisory Committee on Breast Cancer Screening, 2006].
2
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Indeed, since 1980, mortality rates have reduced by a third, and since 1999, 
breast cancer was superseded by lung cancer as the most common cause of 
death from cancer in women in the UK [Cancer Research UK, 2008d].
The greatest risk factor in the development of breast cancer is age; with 8 out 
of 10 newly diagnosed cancers in women over the age of 50 [Office for 
National Statistics, 2005]. There is considerable evidence that associates the 
increased breast cancer risk in individuals of this age with long-term exposure 
to elevated oestrogen levels [Key et al, 2001]. A catalogue of events over a 
women’s life time can contribute to this phenomenon; such as early menarche 
and late menopause [Kelsey et al, 1993], late first full-term pregnancy and 
reduced parity [Layde et al, 1989], and the choice not to breast-feed [Lipworth 
et al, 2000]. Oral contraceptives [Collaborative Group on Hormonal Factors in 
Breast Cancer, 1996] and oestrogen-replacement therapy [Beral, 2003] have 
also been implicated in breast cancer risk. In addition, other modifiable risk 
factors include obesity [Van den Brandt, 2000], alcohol consumption 
[Hamajima, 2002] and lack of exercise [Key et al, 2001], although their true 
involvement in breast cancer remains to be determined.
Although over 85% of women who develop breast cancer have no family 
history of the disease, evidence suggests that a genetic pre-disposition to 
breast cancer can be passed on through generations of women. An individual 
with one affected first degree relative (mother or sister) has approximately 
double the risk of breast cancer of a woman with no family history of the 
disease; if two (or more) relatives are affected, her risk increases further 
[Collaborative Group on Hormonal Factors in Breast Cancer, 2001]. Several
3
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genes have been identified as major contributors to familial breast cancer, 
most significantly, the breast cancer susceptibility gene, BRCA1, which is 
aberrantly expressed in 2-5% of all breast cancer cases. Women carrying a 
BRCA1 mutation have a 50-80% chance of developing the disease [Ford et al,
1998].
Breast cancer incidence and mortality varies significantly across the world, 
with highest rates recorded in more economically developed areas such as the 
US and affluent European nations, where incidence is five-fold higher than in 
the less economically developed countries of Africa and Asia [Key et al,
2001]. Worryingly, in areas of the world with historically low rates of breast 
cancer, such as Eastern Europe and the Far East, incidence has begun to rise 
rapidly as countries adopt western ideals and consequently, the breast-cancer 
related risk factors associated with this way of life. Interestingly, migrants 
from low to high risk countries acquire the risk of the host country within two 
generations [Key et al, 2001], highlighting the role of life-style, socio­
economic status and environmental factors in the development of breast 
cancer.
1.2.1 Oestrogen and breast cancer.
The circulating oestrogens, of which 17(3-oestradiol (E2) is biologically the 
most important, are members of a unique family of aromatic steroids that are 
produced primarily by the aromatase enzyme system in the ovaries, as well as 
in other tissues such as the brain, liver and body fat, which become the main 
sites of oestrogen synthesis in women following the menopause [Dowsett et al
4
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2005]. Oestrogens serve to maintain the homeostasis of many different tissues, 
such as bone, blood vessels, urinogenital tissues, and breast [White and 
Parker, 1998]. Although the actions of oestrogen are primarily beneficial to 
health of normal female development, experimental and clinical data dating 
back over 100 years indicate that a significant proportion of breast cancers are 
dependent on oestrogens for their development. In 1896, George Beatson first 
demonstrated that removal of the ovaries resulted in regression of the primary 
tumour in a proportion of women [Beatson, 1896]. Four years later, a study 
reported by Stanley Boyd established that a third of patients could expect 
regression of their disease following this surgery [Boyd, 1900]. The 
mechanism by which this phenomenon occurred was not identified until 1962, 
when the first oestrogen receptor (ER) was described by Jensen and Jacobson 
in the uterus of rats [Jensen and Jacobson, 1962]. Following extensive 
biochemical analysis, Jensen and colleagues translated the basic science into 
clinical utility by formulating the first ER assay, to determine whether patients 
would respond to endocrine ablation either by oophorectomy in pre­
menopausal women, or by adrenalectomy in post-menopausal women [Jensen 
et al, 1971]. It was observed that women with ER-rich tumours responded to 
endocrine ablation, whilst women with ER negative breast tumours were 
unlikely to respond and were faced with a poorer prognosis [McGuire et al, 
1975]. It is now established that approximately 70% of breast cancers are 
initially dependent on oestrogen and functional ER for their growth and 
development [Clark et al, 1984].
5
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1.3 The oestrogen receptor- Structure and activation.
There are two main forms of human ER, ERa and ER(3, both of which are 
members of the nuclear hormone receptor family. ERa was cloned and 
sequenced from MCF-7 human breast cancer cells in 1986 by Green et al 
[Green et al, 1986]. It was 10 years later that the second receptor, ERp, was 
identified and cloned from a rat prostate complementary DNA library [Kuiper 
et al, 1996]. The human ER a gene resides on chromosome 6q sub band 25.1 
and is transcribed as a single mRNA of 6.5kb that encodes a protein of 595 
amino acids, with an approximate molecular mass 66kDa. The ERp gene is 
located on chromosome 14q22-24 and encodes a protein of 530 amino acids, 
with a molecular mass of around 60kDa. Both receptors have been separated 
into six functional domains which were designated A -  F, from N- to C 
terminus and share substantial homology [Kumar et al, 1987] [Fig 1.1].
The A/B domain contains one of the two activation functions (AF1) present in 
ER, which is responsible for the activation of gene expression by ER in the 
absence of ligand. AF-1 is constitutively active and often works in synergy 
with the second, ligand-dependent activation function of ER (AF-2), to further 
activate gene transcription in a promoter- and cell -specific manner 
[Tzukerman et al, 1994]. However, post-translational modifications to AF-1 
such as phosphorylation can increase its activity, permitting independent 
activation of gene transcription [Chen et al, 1999]. The amino terminal A/B 
domain is the site of greatest variability between ERa and ERp, sharing a 
homology of only 18% [Hall and McDonnell, 2005]. A comparison of the AF- 
1 domain in the two ERs has revealed that AF-1 is very active in ERa on a
6
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variety of oestrogen responsive promoters, but under identical conditions, the 
activity in ERp is minimal [Barkhem et al, 1998].
The C region contains both the DNA binding domain (DBD) and the 
dimerisation domain. The DBD consists of two zinc-fingers that fold into two 
helical structures; one directly binds to the major groove of the DNA helix, 
while the other serves to support this interaction [Schwabe et al, 1993]. ER 
that lacks the DBD cannot bind DNA in-vitro or in-vivo which is crucial for 
genomic, ER-regulated gene activation [Kumar et al, 1987]. The dimerisation 
domain has been discovered equally critical for ER activation, as mutations 
that prevent or impede dimerisation result in receptors that are insoluble or 
transcriptionally inactive [Tamrazi et al, 2002]. The C-domain shares a 
homology of 97% between ERa and ERp, indicative of this regions 
importance in ER function [Hall and McDonnell, 2005].
The D domain functions as a hinge region between the DBD and the ligand 
binding domain (LBD), and also contains sequences for dimerisation, nuclear 
localisation signal (NLS) function and interactions with receptor co-activator 
and co-repressor proteins [Klinge, 2001].
The C- terminal E domain is the largest of the six regions and comprises of the 
LBD, which is intrinsically linked to the ligand-dependent activation function 
of ER, AF2, located in the same region [Parker et al, 1993]. The LBD has a 
compact three layer structure comprising of 12 a-helices, 5 of which (H3, H6, 
H8, H ll ,  and H I2) form a hydrophobic ligand binding pocket [Sommer and 
Fuqua, 2001]. Binding of endogenous ligand 17-P oestradiol (E2) to the LBD 
alters its conformation, with helix 12 forming a lid over the pocket that secures
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the ligand. The agonist induced positioning of H I2, together the with amino- 
acid residues in H3, H4 and H5, provides an adequate co-activator interaction 
surface permitting the recruitment of the co-factors necessary for efficient AF- 
2 mediated, ER transcriptional activity [Brzozowski et al, 1997]. The E- 
domain also contains sequences for heat-shock protein 90 binding, ligand 
independent nuclear localisation signalling (NLS) function, and a dimerisation 
domain [Parker et al, 1993].
Though less is known about the F domain, it is thought to play a role in 
distinguishing between ER agonists and antagonists through interactions with 
cell specific factors [Klinge, 2001].
ERa and ERp share poor to moderate homology of these C-terminal domains; 
D - 24%, E - 58%, F - 12%, highlighting the potential for varying patterns of 
gene expression incurred following endogenous/exogenous ligand-dependent 
activation of ERa and ERp [Hall and McDonnell, 2005].
The understanding of the role of ERP in breast cancer is rapidly expanding, 
though still in its infancy compared to ERa; thus for the purpose of this thesis, 
ERa will be the focus of the investigation, and is hereafter referred to as ER.
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Fig 1.1 Comparison o f the ER-a and ER-(3 functional domains.
Trans activation domains 
l
AF2
ERa
ERp
180 263 302 533 595aa
A/B C D E F
/  /  /  /  /  /
18% ✓ 97%
y  /  /
/  /
58% 12%
/ ✓ ✓ S
A/B | C D ]3 [ F
142 226 254
Protein function DNA binding
 v —
Ligand Binding
502 530*i
1.3.1 Genomic oestrogen receptor signalling.
In the absence o f ligand, ER is sequestered in cell nuclei within a large 
inactive oligomeric complex containing heat shock proteins HSP90, HSP70, 
and cyclophilin-40 and p23 [Pratt and Toft, 1997]. E2 diffuses through the cell 
plasma-membrane, translocates to the nucleus, and binds to ER [Rao, 1981] 
causing conformational alterations to the LBD and phosphorylation o f ER 
residues, releasing o f ER from the inhibitory protein complex and permitting 
maximal AF-1 activity. Receptors rapidly dimerise and translocate to the 
oestrogen response element (ERE) in the promoter sequence o f an oestrogen 
responsive gene [Osborne and Schiff, 2005]. The ERE consists o f inverted 
repeats o f the sequence GGTCA separated by three variable nucleotides, e.g. 
5 ’- CAGGTCAnnnTGACCTG-3,’ however, most oestrogen-regulated genes
9
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contain imperfect, non-palindromic ERE sequences [Driscoll et al, 1998]. 
Once bound to the DNA, the receptor complex can either positively or 
negatively regulate target gene transcription through the specific recruitment 
of co-regulatory transcription factors. Co-regulators can influence the 
recruitment of general transcription machinery as well as other co-factors, and 
can also modify the chromatin environment surrounding the promoter of the 
targeted gene to further facilitate gene activation/inactivation (further 
discussed in section 1.3.1.1) [Klinge, 2001]. This is referred to as the classical 
model of ER signalling. Ligand bound ER can also regulate gene expression 
by tethering to other DNA bound transcription factors and acting as a co­
activator by strengthening DNA binding and recruiting other co-activators to 
the transcription-factor complex. For example, by associating with the c-fos 
and c-jun transcription factors, ER can promote the expression of genes that 
contain the AP-1 response element in their promoter region, such as cyclin D l, 
ovalbumin, collagenase, and the growth factor ligand IGF-1 [Kushner et al, 
2000].
1.3.1.1 Co-regulation o f  genomic oestrogen receptor activation.
Co-Activators
Co-activators (CoAs) are proteins that interact with steroid receptors and 
enhance transcription of their target genes by further facilitating recruitment of 
general transcription machinery and other CoAs, stabilising the transcription 
complex and importantly, some are capable of post-translational modification
10
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to the chromatin environment within which the target gene is organised, 
leading to efficient ER-regulated gene transcription.
Three related co-activators, collectively known as the p i60 co-activators, 
contribute to ligand bound ER activity through direct interaction with AF2; 
nuclear-receptor co-activator 1 (NCoAl; also known as SRC1), NCoA2 (also 
known as TIF2 or GRIP1) and NCoA3 (also known as P/CIP, ACTR, AIB-1, 
RAC3 or TRAM1) [McKenna et al, 1999]. They contain a conserved motif 
called the nuclear receptor (NR) box, which comprises of an a-helical LxxLL 
structure (L represents leucine and x represents any amino acid) in which the 
leucines create a hydrophobic surface that fits into the major groove of the 
receptor4 s AF-2 [Hall and McDonnell, 2005]. Other co activators contain NR 
boxes, including the SWI/SNF complexes [Sudarsanam & Winston, 2000], 
p300/CBP-associated factor (PCAF) [Vo & Goodman, 2001], and the 
TRAP/DRIP/SMCC complex [Ito & Roeder, 2001].
A common feature of the co-activators recruited by ER is that of intrinsic 
histone-acetylase (HAT) activity [Ogryzko et al, 1996; Spencer et al, 1997]. 
The positive charge on un-acetylated (tri-methylated) lysine residues of the 
histone protein-octamer round which DNA is tightly wrapped is highly 
attracted to the negatively charged DNA phosphate backbone, producing a 
compact chromatin state that limits access to general factors of transcription, 
and thus limits the efficiency of gene activation. HAT initiates local hyper- 
acetylation of the lysine-rich tails of histones H3 and H4, removing the 
positive charge and resulting in a less condensed chromatin environment, 
facilitating gene transcription [Tsukiyama & Wu, 1997]. Histone deacetylase
11
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(HDAC) removes the acetyl groups from the lysine residues, which reverses 
this process and reduces gene activation [Fig 1.2].
In addition to the CoAs that enhance receptor activity by interacting with the 
LBD, AF-1-interacting CoAs have also been described, specifically steroid 
receptor RNA-activator (SRA) and p68RNA helicase [Lanz et al, 1999; Endoh 
etal, 1999].
Co-Repressors
Co-repressors (CoRs) interact with nuclear receptors and serve to reduce 
transcription of the gene to which the receptor/CoR is tethered. This is 
achieved through a wide variety of mechanisms including chromatin 
remodelling, binding competition with CoAs, sequestration of ER in the 
cytoplasm, and interference with DNA binding [Dobrzycka et al, 2003]. The 
first CoRs to be identified were the nuclear receptor co-repressor (NCoR) 
[Horlein et al, 1995] and silencing mediator for retinoid and thyroid hormone 
receptor (SMRT) [Chen and Evans, 1995]. The interaction between these 
CoRs and the LBD is mediated by two NR-interacting domains (CoR-NR 
boxes) similar to those found in the NR boxes of CoAs [Hu and Lazar, 1999]. 
NCoR and SMRT both serve to suppress transcriptional activation of ER in 
the absence of ligand by the recruitment of other CoRs, such as mSin3 which 
associate with HDACs [Hu and Lazar, 2000]. Other recently described CoRs, 
including repressor of oestrogen receptor activity (REA) [Montano et al,
1999], interact with the ER at novel interaction sites, confirming the existence 
of additional binding motifs, other than CoR-NR boxes.
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NCoR and SMRT are functionally similar as they interact with un-liganded 
receptors, enhance repression, dissociate upon agonist binding, and contain 
intrinsic silencing domains [Horlein et al, 1995; Chen and Evans, 1995]. 
However, other CoRs of ER, such as nuclear receptor-interacting protein 1 
(RIP 140), associate with ligand bound ER, and occlude access of CoAs to the 
AF-2, whilst interacting with HDAC complexes [Smith & O’Malley, 2004]. 
Thus the existence of CoRs that moderate agonist activities of oestrogens 
provides an additional mechanism for the fine tuning of the expression of ER 
target genes and attenuating the physiological output in situations where there 
are chronically elevated levels of the hormone.
13
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Fig 1.2 N-terminal histone tails contain several lysine residues which have a 
positively charged amino group in their side chain. This amino group can be 
acetylated by histone acetyletransferase (HAT), a reaction that can be reversed 
by histone deacetylase (HDAC). The presence o f a positive charge on the 
lysine amino acids o f the histone tails increases electrostatic interactions with 
the negatively charged phosphate backbone o f the DNA, and hence serves to 
condense the chromatin environment. The removal o f this positive charge (by 
acetylation) opens the chromatin structure, permitting gene transcription. 
Thus, active genes are usually located in hyperacetylated chromatin, whilst 
inactive genes are found in hypoacetylated chromatin.
Condensed ‘ silent’ 
chromatin formation
Electrostatic binding
H4 N-terminus
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1.3.2 Non-nuclear oestrogen receptor signalling.
It is evident that in some oestrogen responsive tissues, such as bone and the 
epithelium, non-nuclear, membrane bound-ER is predominant in these cells 
[Nemere et al, 2003]. In breast cancer cells, data indicates that in addition to 
nuclear ER, cytoplasmic and membrane ER are present [Losel et al, 2003]. 
Significantly, GPR30, the newly described membrane ER, can activate key 
growth-factor signalling pathways, such as epidermal growth factor receptor 
(EGFR) [Filardo et al, 2000], to initiate a rapid primary cellular response to 
hormonal signalling [Gee et al, 2005; Levin, 2003]. Such interaction leads to 
the downstream activation of mitogen activated protein kinase (MAPK) and 
serine/threonine protein kinase (Akt) signalling pathways, which up-regulate 
the transcriptional activity of E2-bound nuclear ER by phosphorylating Seri 18 
and Seri 67 residues present within the AF1 domain of the receptor [Kato et al, 
1995; Martin et al, 2000]. Thus, non-nuclear ER can deliver pro- 
transcriptional signals to ER-responsive genes rapidly, and in a fashion 
complementary to nuclear ER activation through crosstalk with growth factor 
signalling.
The ER activation pathways are summarised in [Fig 1.3].
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Fig 1.3 ER Activation: Upon ligand binding (E), nuclear ER activates 
transcription either by direct DNA binding to its own response element (ERE) 
in the targeted gene promoter followed by co-activator (CoA) and general 
transcription factor (TF) recruitment (classical mode), or by tethering to other 
transcription factors, such as the Fos/Jun activating protein-1 (A PI) complex 
(non-classical mode). Ligand-bound membrane ER (GPR30) can interact with 
different signalling intermediates at the vicinity o f the membrane causing 
rapid induction o f key growth-factor-dependent kinases, which phosphorylate 
nuclear ER at specific residues in the AF-1, promoting receptor activity (non­
nuclear action).
mRNA
Membrane
receptor
Nuclear
receptor
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1.4 Oestrogen receptor activation of cell growth.
In order to achieve E2 mediated cell proliferation, the E2/ER transcription 
complex up-regulates the expression of a variety of genes which directly 
promote breast cancer cell growth, including key components of the insulin­
like growth factor (IGF) signalling system, IGF-1R and insulin-receptor 
substrate-1 (IRS-1) [Ye, 1998]. In addition, promoters of the cell-cycle, like 
cyclin D1 [Wilcken et al, 1997] and cMyc [Dubik et al, 1987] (which can also 
regulate genes associated with proliferation and/or apoptosis -  reviewed in 
Oster et al, 2002), genes associated with DNA synthesis, such as replication 
factor C4 (RFC4) and minichromosome maintenance genes (MCM2, MCM3, 
MCM6), and genes encoding proteins for anti-apoptotic signals, like survivin, 
are all up-regulated by E2 in ER-positive breast cancer cells [Frasor et al, 
2003].
In parallel to the up-regulation of oncogenes, recent studies have shown that 
the ability of the E2/ER transcription complex to act as a suppressor of gene 
expression also facilitates oestrogen activation of ER-positive breast cancer 
cell growth. In a study conducted by Frasor et al (2003), E2-induced 
enhancement of cell proliferation was shown to be significantly reliant on the 
down-regulation of numerous factors that are known to inhibit the cell cycle 
such as B-cell translocation gene 1 and 2 (BTG-1, BTG-2), and cyclin G2, a 
gene known to induce cell cycle arrest and to be up-regulated in cells during 
apoptosis [Frasor et al, 2003]. Other down regulated genes included 
transcriptional repressors, such as Max dimerization protein-4 (Mad4), which 
inhibits Myc action by competing for their binding partner Max [Grandori et
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al, 2000]. Thus, E2 could enhance Myc activity not only by up-regulating c- 
Myc, but additionally by down-regulating an inhibitor of Myc.
E2 was also shown to down-regulate the expression of growth factors that are 
known to inhibit cell proliferation, such as members of the transforming 
growth factor beta (TGF6) family members TGFJ3-3 and bone morphogenic 
protein 4 (BMP4), and pro-apoptotic genes, B-cell lymphoma protein 2 (BCL- 
2) interacting killer (BIK), BCL-2 antagonist/killer 1 (BAK-1), and caspase-9. 
These findings highlight the variety of molecular functions that activated ER 
manipulates to enhance cell growth, and in particular the emerging 
significance of E2/ER mediated gene suppression. The underlying molecular 
biology of this phenomenon remains poorly understood. One mechanism 
proposed is that the E2/ER complex enters into protein/protein interactions 
with further transcription factors (e.g. NFkB) leading to repression at diverse 
response elements [Stein and Yang, 1995]. There are also data to suggest that 
the E2/ER complex may recruit repressors to some gene promoters. For 
example, the E2/ER complex recruits NCoR and interestingly, HDACs to the 
promoter of the anti-proliferative gene cyclin G2, in association with release of 
RNA polymerase II and transcriptional repression of the gene’s oestrogen responsive- 
half-ERE [Stossi et al, 2006]. There is emerging data that such repressive events 
can occur at other ERE-bearing promoters in breast cancer cells [Kaipparettu 
et al, 2008; Ye et al, 2008].
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1.5 Anti-oestrogen therapy
Having established the extensive involvement of oestrogen in breast cancer, it 
is hardly surprising that traditional therapies for ER-positive breast cancer 
patients have included hormone-ablative surgery, such as oophorectomy, 
adrenalectomy and hypophysectomy. Such procedures have largely been 
superseded by current endocrine therapies which are based on the targeting of 
the ER signalling pathway by either partial antagonism of ER function with 
selective modulators of ER activity (SERMs), down-regulation of ER using 
pure anti-oestrogens (SERDs) or reducing oestrogen synthesis with aromatase 
inhibitors (AIs).
1.5.1 Clinical use of tamoxifen.
The most commonly used anti-hormone treatment for patients with ER- 
positive breast cancer is tamoxifen. Tamoxifen was first approved in the UK 
in 1973 and by the Food and Drug Administration (FDA) in the USA in 1977 
for the treatment of advanced breast cancer. The drug has since been approved 
as an adjuvant therapy with chemotherapy (1986), as a single adjuvant therapy 
in postmenopausal patients with metastatic disease (1988), and in pre- and 
postmenopausal ER-positive non-metastatic breast cancer patients [Park and 
Jordan, 2002]. Its widespread use over the last 30 years in all stages of ER- 
positive breast cancer has significantly contributed to the decrease in national 
breast cancer mortality rates observed during this period [Jaiyesimi et al, 
1995].
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1.5.2 Selective oestrogen receptor modulation by tamoxifen.
The ability of tamoxifen to act either as an agonist or antagonist in an 
oestrogen-sensitive cell specific context can be explained by the fact the 
tamoxifen only blocks ER activation through one of its two main activation 
functions. Contrary to the initial understanding that tamoxifen simply stopped 
ER activation upon receptor binding, it is now established that tamoxifen- 
bound ER is able to dissociate from its inhibitory protein complex and 
dimerise in a manner equivalent to E2-bound ER [Nicholson et al, 2002]. The 
binding of ER to its natural ligand causes a conformational change to the 
LBD, whereby H I2 of the LBD seals the ligand into the receptor, forming an 
active AF-2 domain by providing the necessary surface required to recruit 
general components and co-activators of transcription (see section 1.3). 
However, when tamoxifen binds to the LDB, helix 12 is prevented from 
sealing the binding pocket due to the bulky alkylaminoethoxyphenyl side 
chain of tamoxifen interacting with the Asp 351 residue of the LBD [Shiau et 
al, 1998]. Therefore co-facilitators of transcription cannot bind to the LBD of 
tamoxifen-bound ER and AF-2 activation of gene transcription is prevented. 
Furthermore, tamoxifen induced conformational changes to the LBD have 
been shown to facilitate the recruitment of co-repressors to the site of 
transcription, further repressing AF-2 gene activation [Lavinsky et al. 1998]. 
Tamoxifen however does not inhibit ER’s constitutively active, ligand 
independent activation function AF-1; therefore it has been proposed that for 
genes where AF-2 is required for ER transcriptional activity, tamoxifen 
functions as a pure antagonist, and conversely, genes for which AF-1 is
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sufficient for ER transcriptional activity, tamoxifen can act as an agonist 
[Tzukerman et al, 1994].
1.5.3 Tamoxifen resistance.
Despite the obvious benefit tamoxifen has provided for millions of breast 
cancer patients worldwide, almost all patients with metastatic disease and as 
many as 40% of patients receiving adjuvant tamoxifen will acquire resistance 
to the drugs inhibitory effect on breast cancer cell growth [Schiff et al, 2003]. 
Unfortunately, patients who experience disease relapse may develop a more 
aggressive form of the disease, and face a poorer prognosis and premature 
death [Hiscox et al, 2004]. The biological mechanisms underlying acquired 
resistance to tamoxifen are therefore of considerable clinical significance. 
Originally it was thought that the acquisition of anti-oestrogen resistance was 
caused by a loss or mutation of the ER, as is often the case in patients with 
intrinsic anti-hormone resistance [Ring, and Dowsett, 2004]. However, it has 
since been shown that breast cancer cell lines that have lost anti-oestrogen 
sensitivity can retain an ER positive phenotype with normal ER functionality 
[Brunner et al, 1993]. Indeed tamoxifen-resistant breast cancer remains 
sensitive to other hormonal therapies that target the ER such as the pure anti­
oestrogen fulvestrant (Faslodex®) [Robertson, 2001]; although it too is subject 
to the development of resistance mechanisms (see section 1.6).
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1.5.3.1 Positive growth signals up-regulated in tamoxifen resistant breast 
cancer.
Many mechanisms have been associated with tamoxifen resistance in ER 
positive breast cancer (reviewed in Ring and Dowsett, 2004). Significantly, 
the up-regulation of growth factor receptors, e.g. EGFR and HER2, and their 
downstream kinases, notably Ras/Raf/MAP kinases and phosphoinositide 3- 
kinase [PI3K]/Akt signalling, has been extensively associated with both de- 
novo and acquired tamoxifen resistant breast cancer cell growth [Gee et al, 
2005; Nicholson et al, 2007]. These growth factor signalling pathways can be 
directly and indirectly activated by tamoxifen binding to membrane-bound ER 
[Shou et al, 2004]. The subsequent activation of the multiple signalling 
kinases leads to the phosphorylation of nuclear ER at specific sites in the AF-1 
domain and promotes ER activity. Significantly, phosphorylation of ER serine 
118 by the MAPKs extracellular signal-regulated kinase (ERK) 1 and ERK2, 
down-stream components of the EGFR/HER2 pathway, and phosphorylation 
of serine 167 by ribosomal S6 kinase (RSK) (activated by ERK1 and ERK2) 
enhances sensitivity of the ER to oestrogenic stimulation and have been 
cumulatively implicated in promoting the agonistic behaviour of tamoxifen in 
resistance [Nicholson et al, 2004b].
Other activated kinases serve to phosphorylate co-regulators of ER, further 
propagating their ability to activate ER-regulated gene transcription. For 
example, NCoA3 is phosphorylated by multiple kinases including 
p42/44MAPK, which can be activated by HER2 [Font de Mora & Brown, 
2000]. Therefore, high levels of activated Co As like NCoA3 could profoundly
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limit the efficiency of anti-hormone treatment of tumours that also overexpress 
tyrosine kinase receptors [Osborne et al, 2003]. In contrast, phosphorylation of 
CoRs can result in their nuclear export, preventing their recruitment to the ER 
transcriptional complex, and therefore limiting gene suppression [Arpinol et 
al, 2008].
In addition to activation of ER-regulated growth pathways, some kinase 
activity can independently stimulate proliferation via activation of their 
associated gene networks. For example, Akt, which is directly activated as a 
consequence of ER interaction with the p85a regulatory subunit of PI3K, can 
promote cell growth, survival and motility [Vivanco & Sawyers, 2002].
EGFR and HER2 expression and activity have been found to be considerably 
increased in several in vitro models of tamoxifen-resistance, including the 
MCF-7 cell based model developed at the TCCR. The contribution to 
resistant-cell growth has been highlighted in studies using the EGFR specific 
tyrosine kinase inhibitor, gefitinib (Iressa®), and the HER2 monoclonal 
antibody trastuzumab (Herceptin®). Tamoxifen resistant cells exhibited 
significant growth inhibition in response to these agents compared to 
tamoxifen-responsive MCF-7 cells [Nicholson et al, 2001; Nicholson et al, 
2004a]. The use and success of these drugs in both experimental and clinical 
representations of anti-hormone resistant cancer are discussed in section 1.6.1.
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1.5.3.2 Inactivation o f  tumour suppressor genes in tamoxifen resistant breast 
cancer.
In addition to the activation of oncogenes, it has become clear that the in­
activation of tumour suppressor genes like p53 is at least as important in the 
development and progression of breast cancer. In many cases, gene 
inactivation is the result of genetic events such as of loss of heterozygosity and 
mutation, however, it also been shown that functional inactivation of tumour 
suppressor genes can be caused by epigenetic mechanisms [Jones and Baylin, 
2002]. Epigenetic changes differ from genetic changes mainly in that they 
occur at a higher frequency, are reversible upon treatment with 
pharmacological agents and occur at defined regions in a gene [Jones and 
Laird, 1999]. Epigenetic gene inactivation is a heritable trait that is not based 
upon a change in primary DNA sequence, but rather alterations that impact on 
chromatin organisation and gene promoter accessibility, like histone 
modification and DNA hypermethylation of promoter CpG islands.
Promoter hypermethylation has been revealed as one of the most frequent 
mechanisms of loss of gene function in human neoplasia, and in the specific 
example of breast cancer, genes involved in every step of tumour development 
have been shown to be silenced by this epigenetic mechanism (reviewed by 
Widschwendter and Jones, 2002).
CpG island methylation is catalysed by a family of DNA methyl-transferases 
(DNMTs) by use of the universal methyl donor S-adenosyl-methionine, and 
inhibits transcription by interfering with recruitment and function of basal 
transcription factors or co-activators [Tate & Bird, 1993]. It has also been
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suggested that the hypermethylation of CpG dinucleotides near the 
transcriptional regulatory region may initiate recruitment of members of the 
methyl-CpG binding domain (MBD) protein family, which may mediate 
silencing of genes through reducing chromatin accessibility to co-activating 
complexes [Wade et al, 2001].
Literature indicates that by suppressing E2-stimulated genes, long-term ER 
signalling disruption has the capacity to completely silence gene transcription 
through hypermethylation of CpG islands in their promoters [Leu et al, 2004]. 
Proof of principle studies describe the impact of ER siRNA on the ER- 
regulated genes progesterone receptor (PR) and trefoil-factor 1 (pS2), where 
initial repressive chromatin modifications with longer-term progressive 
accumulation of DNA methylation at the EREs of the promoters were 
observed. Their expression could be restored by treatment with a methylation 
inhibitor and E2 treatment. Subsequently, evidence has been generated to 
suggest that epigenetic modifications to E2-stimulated gene promoters can 
occur following long-term anti-hormone induced gene ER-signalling 
disruption [Badia et al, 2000]. In addition, a study conducted by Fan et al 
(2006) showed that 75% of genes that were identified as up-regulated in 
oestradiol treated wt-MCF-7 breast cancer cells (>2 fold increase in 
expression), were no longer inducible in the tamoxifen-resistant cell sub-line, 
highlighting the potential scale of this phenomenon.
In section 1.5.2, it was mentioned briefly that the conformational changes 
induced in the LBD by ER binding tamoxifen served to provide docking sites 
for co-repressors of transcriptional activity. Interaction studies showed that
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various corepressors including NCoR/SMRT [Lavinsky et al. 1998], REA 
[Montano et al, 1999], repressor of tamoxifen transcriptional activity (RTA) 
[Norris et al. 2002], scaffold attachment factor-Bl (SAFB1) [Oesterreich et al. 
2000], and Smad4 [Wu et al, 2003] which recruit different HD AC protein 
complexes as part of their co-repressive function, bind more strongly to ERa 
in the presence of tamoxifen. During tamoxifen-induced suppression of the 
classically regulated oestrogen responsive gene, pS2, the time course of 
recruitment of the HDAC complexes precisely coincided with that of 
deacetylation of histone H3 and H4 tails at the target promoter, providing 
crucial support for the hypothesis that tamoxifen functions as an antagonist in 
the breast cells by inducing epigenetic modification [Liu et al, 2004]. 
Interestingly, significant crosstalk between the histone code and gene 
promoter methylation has been established. DNMT-1 and DNMT3a/DNMT3b 
have been shown capable of binding HDAC2 and HDAC1 respectively to 
achieve effective gene silencing [Fuks et al, 2000; Rountree et al, 2000; 
Bachman et al, 2003]. Although several studies have shown that long-term 
tamoxifen treatment can induce distinct global gene expression and promoter 
DNA methylation profiles in breast cancer cells [Fan et al, 2006; Badia et al, 
2000], few studies have whether this event could contribute to anti-hormone 
resistant cell growth. Interestingly, a study by Treeck et al (2004) reported that 
long-term tamoxifen treatment of MCF-7 cells decreased levels of several pro- 
apoptotic genes and impaired subsequent apoptotic response to etoposide 
treatment. Another study conducted by Wu et al (2007) used SAGE analysis 
to show that the expression of the tumour suppressor gene retinoblastoma
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binding protein 8 (CtIP) was decreased in acquired tamoxifen resistant 
models, where its knockdown in MCF-7 cells promoted tamoxifen resistance, 
and induction restored response. Although promoter methylation of the 
tumour suppressor genes identified in these studies was not confirmed, data 
supports the concept of anti-hormonal silencing of potential tumour 
suppressors.
1.6 Over coming tamoxifen resistance in the clinic -  Alterative anti­
hormone therapies.
The successful use of tamoxifen over the last 30 years as first-line treatment 
for ER-positive breast cancer has established ER modulation as an effective 
therapeutic strategy for this disease. However, as discussed in section 1.5.3, 
approximately 40% of patients receiving tamoxifen acquire resistance to the 
drug, and frequently relapse with worsened outlook. Failure to continue a 
response to tamoxifen therefore, does not mean patients remain at the same 
prognostic level; they are faced with a more life-threatening disease. 
Consequently, huge efforts have been made to identify more effective 
alternative SERMs with better efficacy. First generation SERMs, like 
toremifene and idoxifene, were closely related to the chemical structure of 
tamoxifen and were entered into clinical trials in the early 1990s. Phase III 
trials showed postmenopausal women with advanced breast cancer treated 
with these agents produced similar objective response rates to tamoxifen 
[Pyrhonen et al, 1997; Arpinol et al, 2003]. Second generation SERMs, which 
featured an altered triphenylethylene ring structure, such as raloxifene and
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arzoxifene, were then introduced following preclinical studies that suggested 
that these agents possessed less agonist activity than tamoxifen [Black et al, 
1982; Sato et al, 1998]. Unfortunately these findings were not supported by 
Phase II trials with the drugs [Budzar et al, 1988; 2001]. Paradoxically 
however, the agonist effect of raloxifene helped to preserve bone mineral 
density and the drug is now used in the prevention of osteoporosis [Ettinger et 
al, 1999].
Having established that the new generation SERMs were no more effective 
than tamoxifen in advanced breast cancer, and that alternative SERMs shared 
a high level of cross-resistance with tamoxifen, attention was turned to 
developing other methods of ER signalling attenuation. One such method is 
the pure antagonism of ER signalling with the steroidal analogue of 17|3- 
oestradiol, fulvestrant (Faslodex®). Fulvestrant binds to the ER with a similar 
affinity (89%) to oestradiol, but unlike SERMs, it has no agonist potential due 
to the steric hindrance caused by the alkylsulphinyl side-chain [Howell, 2006]. 
This causes an abnormal conformation of the ER protein, inhibiting receptor 
dimerisation and nuclear localisation. In addition, the ER-fulvestrant complex 
is unstable and leads to the subsequent rapid degradation of ER [Osborne et al,
2004]; hence fulvestrant is classified as a selective oestrogen receptor down- 
regulator (SERD). Fulvestrant was the first pure anti-oestrogen to enter 
clinical development; disappointingly it failed to demonstrate superiority over 
tamoxifen or aromatase inhibitors (AIs) in the treatment of advanced breast 
cancer possibly due to delivery problems [Robertson et al, 2002; 2003]. 
However, fulvestrant is the only drug of its class to be licensed for the
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treatment of advanced breast cancer in postmenopausal women with disease 
recurrence or progression following anti oestrogen therapy, as both patients 
with acquired tamoxifen resistance and acquired Al-resistance, have been 
shown to gain clinical benefit from the drug when used as a second-line 
therapy [Howell et al, 2002; Ingle et al, 2006].
Aromatase inhibitors have been developed to suppress the activity of 
aromatase cytochrome P450, thereby reducing oestradiol synthesis [Smith & 
Dowsett 2003]. Through this mechanism AIs circumvent oestradiol-induced 
regulation of transcription via nuclear and non-nuclear pathways. They do not, 
however, directly target any contribution that oestrogen-independent ER 
activation may play in the development and progression of breast cancer. 
Although the first and second generations of aromatase inhibitors failed to 
show any statistical benefit compared to tamoxifen in clinical trials, the third 
generation of more potent aromatase inhibitors have now been developed that 
almost completely inhibit aromatase activity, leading to a substantial reduction 
in oestrogen production [Geisler et al, 2002]. These include the steroidal 
aromatase inhibitor exemestane (Aromasin®), which binds to the p450 site of 
the aromatase complex, and the non-steroidal aromatase inhibitors anastrazole 
(Arimidex®) and letrozole (Femara®), which bind to the enzymes substrate 
binding pocket [Lonning, 2004]. Data from the phase III ATAC (anastrazole, 
tamoxifen and combination) clinical trial suggested that adjuvant anastrozole 
was superior to tamoxifen in terms of disease-free survival, time to recurrence, 
time to distant recurrence and prevention of contralateral breast cancer in 
postmenopausal women with early ER-positive breast cancer [Howell et al,
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2005]. They are therefore set to challenge the status of tamoxifen as current 
first-choice treatment for these patients, pending further investigation into the 
effect that long-term inhibition of oestrogen synthesis has on other oestrogenic 
tissues. Interestingly, the combination treatment arm of tamoxifen and 
anastrozole showed no clinical benefit compared to tamoxifen alone, and was 
terminated early. This was thought to be due to the weak oestrogenic 
properties of tamoxifen activating growth signalling pathways, circumventing 
the growth inhibitory effect of oestradiol deprivation. AIs have also proven 
effective as a second-line therapy in post-menopausal patients with acquired 
tamoxifen resistant ER-positive breast cancer; although both fulvestant and Al 
acquired resistance have been reported in tamoxifen sensitive and resistant 
ER-positive breast cancer patients, as well as in numerous experimental 
models [Nicholson and Johnston, 2005].
1.6.1 Overcoming tamoxifen resistance in the clinic -  Growth factor signalling 
pathway inhibitors.
As mentioned in section 1.5.3.1, the growth of tamoxifen resistant MCF-7 
cells can be inhibited following the inactivation of the EGFR signalling 
pathway with gefitinib (Iressa®), or the inactivation of HER2 pathway using 
trastuzumab (Herceptin®). Pre-clinical studies in tamoxifen-resistant MCF-7 
cells (TAM-R) developed in the TCCR showed that gefitinib treatment 
subsequently induced a concentration dependent inhibition of TAM-R cell 
growth, where lpM  gefitinib reduced proliferation by approximately 60% in 
correlation with a loss of phosphorylated EGFR [Nicholson et al. 2002,
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2004b, Knowiden et al. 2003]. Phosphorylation of its heterodimerisation 
partner HER2 was also reduced in TAM-R cells together with pMAPK. Cell 
loss, however, was not achieved following gefitinib challenge, and ultimately 
resistance developed in association with a further gain in aggressive behaviour 
[Jones et al. 2004]. Treatment with trastuzumab similarly reduced pMAPK 
activity in TAM-R cells and temporarily inhibited cell growth. In the clinical 
setting, responses to trastuzumab as a single agent only occur in approximately 
30% of HER2+ patients, and again, relapse is inevitable [McKeage and Perry, 
2002].
The failure of sequential delivery of anti-hormone therapy followed by growth 
factor signaling inhibition to sufficiently block tumour progression has raised 
the possibility of combinational treatments being the most effective form of 
therapy for ER-positive breast cancer patients. In the specific example of 
tamoxifen and gefitinib combination treatment, the onset of tamoxifen 
resistance was significantly delayed in MCF-7 cells treated with both drugs, 
compared to cells receiving only tamoxifen; however, once again, cell loss 
was not achieved and resistance eventually developed [Gee et al, 2003]. 
Diverse clinical studies are also exploring the value of blocking downstream 
signalling components using including MAP kinase inhibitors, 
famesyltransferase inhibitors and mammalian target of rapamycin [mTOR] 
inhibitors, however, to date many of these studies have proved relatively 
disappointing, with therapeutic resistance again a pervading problem 
[Johnston et al, 2007].
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It is therefore apparent that blocking the up-regulated growth pathways 
featured in tamoxifen resistant cells, either singularly or in combination, may 
not be sufficient to cause complete tumour regression. In this context it is 
therefore possible that the cells are able to continue to grow as a result of a 
concurrent loss of growth ‘braking mechanisms’, i.e. loss of tumour 
suppressor/pro-apoptotic gene expression. Although the loss of tumour 
suppressor genes is a phenomenon identified in all stages of breast cancer, it is 
the ability of anti-hormone treatment, specifically tamoxifen, to permanently 
alter the expression of such genes by epigenetic mechanisms, as a contributing 
factor to tamoxifen-resistant cell growth that provides the focus of 
investigation for this thesis.
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1.7 Aims
The aim of the current study will be to investigate whether the long-term 
tamoxifen treatment can cause the epigenetic silencing of oestrogen 
responsive genes associated with tumour suppressor / pro-apoptotic function, 
enhancing the cells ability to survive and potentially limiting the effect of 
second-line treatments.
In order to test this hypothesis, the following aims were pursued;
• The establishment of a tamoxifen-resistant cell sub-line, withdrawn 
from tamoxifen for up to 6 months, to determine the permanency of the 
aggressive tamoxifen-resistant cell phenotype, as assessed by cell 
morphology, growth and motility.
• The characterisation of ER, EGFR and IGF-1R mRNA and protein 
expression levels by real-time PCR, and Western 
blotting/immunocytochemistry (ICC) respectively, and their 
contribution to MCF-7, TAM-R and tamoxifen withdrawn TAM-R 
(TAM-Wd) cell growth using signalling inhibitors.
• The provision of proof of principle data to assess whether long-term 
tamoxifen treatment permanently silences well characterised, 
classically regulated ER-gene targets, pS2 and PR, using real-time 
PCR and ICC.
• The determination of whether genes silenced following long-term 
tamoxifen exposure could be re-expressed with the de-methylation
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agent 5-Azacytidine (5-Aza) +/- oestradiol (E2) using real-time PCR 
and ICC in correlation with methylight analysis.
• The determination of whether the re-expression/activation of 
demethylated genes in tamoxifen withdrawn TAM-R cells effects cell 
growth.
• The use of micro-array technology to identify oestrogen responsive 
genes whose ontology and array profiles following 5-Aza + E2 co­
treatment associate with cell growth (as determined above).
• The confirmation of gene expression profiles of the candidate genes 
identified in the microarray analysis, using semi-quantitative PCR.
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2. MATERIALS AND METHODS
The equipment and disposables used throughout this study are listed below 
alongside the supplier from which they were sourced. Equipment is only 
referenced once, but may have been used in more than one experimental 
procedure.
Tissue Culture
Equipment Manufacturer
0.2pm Supor membrane VacuCap 60 
filter unit
Gellman Laboratory Pall, Ann 
Arbour, USA
Aspiration pump Gardner Denver Alton Ltd, Alton, 
UK
Cecil CE 2041 Spectrophotometer CECIL, Cambridge, UK
Cell scrapers Greiner Bio-One Ltd, 
Gloucestershire, UK
Class II biological safety cabinet MDH Intermed Airflow from 
Bioquell, Andover, UK
Coming Standard Transwell® inserts 
(6.5mm diameter, 8pm pore size)
Fisher Scientific, Leicestershire, UK
Coulter Counter counting cups and 
lids
Sarstedt AG and Co., Numbrecht, 
Germany
Coulter Multisizer II Beckman, High Wycombe, UK
Cryo Storage Chamber Taylor Wharton, Alabama, USA
Denly BA852 Autoclave Thermoquest Ltd, Basingstoke, UK
Gilson Pipettes (l-10pl, 5-50pl, 20- 
200pl, lOOpl-1000ml and 500pl-5ml)
Gilson, Luton UK
Glass coverslips (thickness no. 2, 
22mm2)
BDH Chemicals Ltd, Poole, Dorset, 
UK
Hamamatsu C4742-96 digital camera Hamamatsu Photonics UK Ltd, 
HERTS, UK
Hoffman Condenser Leica Microsystems Imaging 
Solutions Ltd, Cambridge, UK
Improvision OpenLab V4.04 software Improvision, Coventry, UK
Jouan C312 Centrifuge Thermo Fisher Scientific Inc., MA, 
USA
Leica DM-IRE2 inverted microscope Leica Microsystems Imaging 
Solutions Ltd, Cambridge, UK
Multiskan MCC/340 plate-reader Titertek, USA
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Nikon Eclipse TE200 Phase Contrast 
Microscope
Nikon, Kingston-upon Thames, UK
PowerMAC G5 computer Apple Computer Inc., CA, USA
Quartz Cuvettes Sigma-Aldrich, Poole, Dorset, UK
Sanyo MCO-17AIC incubator Sanyo E&E Europe BV, 
Loughborough, UK
Sterile Syringe Needles (BD 
microbalance™ 3 characteristics: 25 
G5/8 (0.5 X 16)
Becton Dickinson (BD) Biosciences 
Ltd, Oxford, UK
Syringes (5ml and 10ml) Sherwood Medical Davis and Geek, 
Gosport, UK
Tissue culture plasticware (24, 96- 
well plates, filter flasks, 35mm, 
60mm and 100mm dishes)
Nunc Int., Roskilde, Denmark
Vacuum flask Gardner Denver Alton Ltd, Alton, 
UK
Semi-Quantitative and Real-time PCR
Equipment Manufacturer
Alpha Digidoc RT Densitometry 
Software
Alpha Innotech Corp. California, 
USA
GeneQuant RNA/DNA Calculator Biochrom Ltd Cambridge, UK
IBM Personal Computer IBM, UK
IEC Micromax RF Micro-centrifuge Thermo Electron Corporation, 
Hampshire, UK
Labconco Purifier PCR Enclosure GRI, Rayne, UK
Olympus 8mp Digital Camera Olympus, Oxford, UK
Opticon 2™ real-time PCR machine MJ Research Ltd, Massachusetts, 
USA
OpticonMONITOR™ Version 2.01 MJ Research Ltd, Massachusetts, 
USA
Powerpac 1000 power pack Bio-Rad Laboratories Ltd, HERTS, 
UK
PTC-100 thermocycler MJ Research Ltd, Massachusetts, 
USA
Sanyo 950W Microwave Sanyo Europe, Loughborough, UK
Sub-cell® Agarose Electrophoresis 
System
Bio-Rad Laboratories Ltd, HERTS, 
UK
UV Transilluminator Alpha Innotech Corp. California, 
USA
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SDS-PAGEAVestern Blotting
Equipment Manufacturer
HyperCassette™ developing cassette Amersham, Little Chalfont, UK
DRI Block DB2A - Heating block Techne, New Jersey, USA
IEC Micromax RF micro-centrifuge Thermo Electron Corporation, 
Hampshire, UK
Magnetic Stirrer Fisher Scientific UK Ltd, 
Loughborough, UK
Mini-Protean ® 3 electrophoresis 
apparatus
BioRad Laboratories Ltd 
(Hertfordshire, UK)
MXB Autoradiography Film (Blue 
Sensitive; 18 X 24 cm)
Genetic Research Instrumentation 
(GRI), Rayne, UK
Nitrocellulose membrane 
BA85(0.45|iM)
Schleicher and Schuell, Dassell, 
Germany
Platform Rocker STR6 Stuart Scientific, Bibby Sterilin Ltd. 
(Stone, UK)
Powerpac Basic™ power pack BioRad Laboratories Ltd 
(Hertfordshire, UK)
Roller Platform Stuart Scientific, Bibby Sterilin Ltd. 
(Stone, UK)
X-O-graph Compact X2 x-ray 
developer
X-O-graph Imaging System, Tetbury, 
UK
Immunocytochemistry
Equipment Manufacturer
Olympus BH-2 phase contrast 
microscope
Olympus, Oxford, UK
Olympus DP-12 digital camera 
system
Olympus, Oxford, UK
37
Chapter 2 Material and Methods
Other Plastics and Disposables
Equipment Manufacturer
15-ml Phase Lock Gel (PLG) tubes Eppendorf, Hamburg, Germany
Bijou tubes (5ml) Bibby Sterilin Ltd., Stone, UK
Cryotube™ vials (1.8ml, starfoot, 
round)
Nunc Int., Roskilde, Denmark
Disposable Cuvettes Fisher Scientific UK Ltd, 
Loughborough, UK
Eppendorf tubes Eppendorf, Hamburg, Germany
Filter Paper (No. 4), Filter Paper 
(grade 3; 460 X 370mm)
Whatman, Maidstone, UK
General laboratory glass- and 
plasticware
Fisher Scientific UK Ltd, 
Loughborough, UK
Glass coverslips (thickness no. 2, 
22mm2)
BDH Chemicals Ltd, Poole, Dorset, 
UK
Glass slides Fisher Scientific UK Ltd, 
Loughborough, UK
Micro-centrifuge tubes (0.5ml and 
1.5ml)
Elkay Laboratory Products, 
Basingstoke, UK
Pipette Tips Greiner Bio-One Ltd, Gloucestershire, 
UK
Pipette tips Greiner BioOne Ltd, Gloucestershire, 
UK
Sterile disposable pipettes (5ml, 10ml 
and 25ml), Falcon tubes (50ml), 
Coulter Counter lids and cups
Sarstedt AG and Co., Numbrecht, 
Germany
Sterile Falcon tubes (15ml and 50ml) Sarstedt AG and Co., Numbrecht, 
Germany
Sterile universal containers (30ml) Greiner Bio-One Ltd, Gloucestershire, 
UK
Sterile, disposable serological 
pipettes (5ml, 10ml and 25ml)
Sarstedt AG and Co., Numbrecht, 
Germany
White 96 well qPCR plates and caps Bio-Rad Laboratories Ltd, HERTS, 
UK
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The chemicals and reagents used throughout this study are listed below 
alongside the supplier from which they were sourced. Chemicals are only 
referenced once, but may have been used in more than one experimental 
procedure.
Tissue Culture
Reagent Manufacturer
3-(4,5-dimethylthiazol-2-yl)-2,5- 
diphenyl-tetrazolium bromide (MTT)
Sigma-Aldrich, Poole, Dorset, UK
Activated charcoal Sigma-Aldrich, Poole, Dorset, UK
Amphotericin B (Fungizone) Invitrogen, Paisley, UK
Antibiotics (penicillin/streptomycin) Invitrogen, Paisley, UK
Bovine Trypsin Lome Laboratories Ltd, Reading, 
UK
Cell culture medium: RPMI 1640 and 
Phenol-red-free RPMI 1640
Invitrogen, Paisley, UK
Crystal violet Sigma-Aldrich, Poole, Dorset, UK
Dimethyl sulphoxide (DMSO) Sigma-Aldrich, Poole, Dorset, UK
Ethylene diamine tetraacetic acid 
(EDTA)
Sigma-Aldrich, Poole, Dorset, UK
Fibronectin (from Human Plasma; 
1 mg/ml in 0.05M TBS; pH 7.5)
Sigma-Aldrich, Poole, Dorset, UK
Foetal calf serum (FCS) Invitrogen, Paisley, UK
Isoton® II azide-free balanced 
electrolyte solution (sodium chloride at 
7.9g.l-l, disodium hydrogen 
orthophosphate at 1.9g.l-l, EDTA 
disodium salt at 0.4g.l-l, sodium 
dihydrogen orthophosphate at 0.2g.l-l 
and sodium fluoride at 0.3g. 1-1)
Beckman Coulter Ltd, High 
Wycombe, UK
L-glutamine Invitrogen, Paisley, UK
Phenol/Chloroform/Isoamyl (25:24:1) Sigma-Aldrich, Poole, Dorset, UK
Proteinase-K Sigma-Aldrich, Poole, Dorset, UK
Sodium Acetate (NaOAc) Sigma-Aldrich, Poole, Dorset, UK
Solvents (acetone, chloroform, ethanol, 
formaldehyde, isopropanol and 
methanol)
Fisher Scientific UK Ltd, 
Loughborough, UK
Sterile phosphate buffered saline 
(PBS)
Invitrogen, Paisley, UK
TRI-Reagent Sigma-Aldrich, Poole, Dorset, UK
Tris HC1 Sigma-Aldrich, Poole, Dorset, UK
Triton X-100 Sigma-Aldrich, Poole, Dorset, UK
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Semi-Quantitative and Real-time PCR
Reagent Manufacturer
Agarose Bioline Ltd, London, UK
Di-thiothreitol (DTT) Sigma-Aldrich, Poole, Dorset, UK
dNTPs (dGTP, dCTP, dATP, dTTP; 
lOOmM)
Amersham, Little Chalfont, UK
DyNAmo™ qPCR kit Finnzymes Oy, Espoo, Finland
Ethidium bromide (EtBr) Sigma-Aldrich, Poole, Dorset, UK
Glacial Acetic Acid Fisher Scientific UK Ltd, 
Loughborough, UK
Hyperladder™ I and Hyperladder™ 
IV
Bioline Ltd, London, UK
Magnesium chloride (MgC12) Sigma
Molony-murine leukaemia virus 
(MMLV) reverse transcriptase
Invitrogen, Paisley, UK
QIAquick PCR purification kit QIAGEN Ltd, Crawley, UK
Random hexamers (RH) Amersham, Little Chalfont, UK
RNase-free H20 Sigma-Aldrich, Poole, Dorset, UK
RNasin® ribonuclease inhibitor Promega, Southampton, UK
SDS-PAGEAVestern Blotting
Reagent Manufacturer
Acrylamide/bis-acrylamide (30% 
solution (v/v), 29:1 ratio)
Sigma-Aldrich, Poole, Dorset, UK
Ammonium persulphate (APS) Sigma-Aldrich, Poole, Dorset, UK
Aprotinin Sigma-Aldrich, Poole, Dorset, UK
Bio-Rad DC Protein Assay (Reagents 
A, B and S)
Bio-Rad Laboratories Ltd, HERTS, 
UK
Bovine serum albumen (BSA) Sigma-Aldrich, Poole, Dorset, UK
Bromophenol blue (BPB) BDH Chemicals Ltd, Poole, UK
Di-potassium hydrogen 
orthophosphate anhydrous (K2HP04)
Fisher Scientific UK Ltd, 
Loughborough, UK
Di-thiothreitol (DTT) Sigma-Aldrich, Poole, Dorset, UK
Glycerol Fisher Scientific UK Ltd, 
Loughborough, UK
Glycine Sigma-Aldrich, Poole, Dorset, UK
Leupeptin Sigma-Aldrich, Poole, Dorset, UK
Lower buffer for SDS-PAGE Gels 
(Tris 1.5M, pH 8.8)
Bio-Rad Laboratories Ltd, HERTS, 
UK
N,N,N’,N’-tetramethylene-diamine
(TEMED)
Sigma-Aldrich, Poole, Dorset, UK
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Perbio Chemiluminescent 
Supersignal® West Pico, Dura and 
Femto
Pierce and Warriner Ltd, Cheshire, 
UK
Phenylarsine oxide Sigma-Aldrich, Poole, Dorset, UK
Phenylmethylsulfonyl fluoride 
(PMSF)
Sigma-Aldrich, Poole, Dorset, UK
Polyoxyethylene-sorbitan 
monolaurate (Tween 20)
Sigma-Aldrich, Poole, Dorset, UK
Rainbow protein size markers (10- 
250 kDa)
Amersham, Little Chalfont, England
Sodium chloride (NaCl) Sigma-Aldrich, Poole, Dorset, UK
Sodium dodecyl sulphate (SDS) Sigma-Aldrich, Poole, Dorset, UK
Sodium fluoride (NaF) Sigma-Aldrich, Poole, Dorset, UK
Sodium molybdate (Na2Mo04) Sigma-Aldrich, Poole, Dorset, UK
Sodium ortho vanadate (NaV04) Sigma-Aldrich, Poole, Dorset, UK
Trizma (Tris) base Sigma-Aldrich, Poole, Dorset, UK
Upper buffer for SDS-PAGE Gels 
(Tris 0.5M, pH 6.8)
Bio-Rad Laboratories Ltd, HERTS, 
UK
Western Blocking Reagent Roche Diagnostics, Mannheim, 
Germany
Immunocytochemistry
Reagent Manufacturer
Anti-rabbit/Anti-mouse EnVision™+ 
System, Peroxidase (DAB) kits
DAKO, Cambridgeshire, UK
Di-butylpthalatexylene (DPX) Raymond A Lamb Ltd, Eastbourne, 
UK
Liquid DAB+ substrate chromogen 
system
DAKO, Cambridgeshire, UK
Methyl green Sigma-Aldrich, Poole, Dorset, UK
Sucrose Fisher Scientific UK Ltd, 
Loughborough, UK
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2.1 Tissue Culture
2.1.1 Cell Seeding from Cryogenically Stored Cell Reserves.
ER positive, MCF-7 breast cancer cells, kindly given to our laboratory by 
AstraZeneca Pharmaceuticals (Cheshire, UK), were stored in liquid nitrogen 
in RPMI-1640 based medium containing 5% (v/v) fetal calf serum (FCS), 
antibiotics (streptomycin (10pg/ml), penicillin (lOIU/ml), fungizone 
(2.5pg/ml) (RPMI+5%) with the addition of 7.5% DMSO. Upon removal 
from liquid nitrogen, 1ml aliquots of cell solution, containing approximately 
106 cells, were rapidly defrosted and vials were sterilised with 75% EtOH 
before opening. Cells were re-suspended in 9mls of RPMI+10% cell culture 
medium and were centrifuged at 1340g for 5 minutes at room temperature. 
The supernatant was aspirated and the cell pellet was re-suspended in 3ml of 
medium through gentle pipetting with a 10ml pipette until no clumping of 
cells was visible. The cell suspension was then seeded in a 12.5 cm filter flask 
and incubated at 37°C in a humidified atmosphere of 5% CO2 in air. The 
culture medium was refreshed the following day, and subsequently twice a 
week, until cell confluency was reached. Cells were then passaged at a ratio of 
1:2 with RPMI+5% medium until cell reserves were sufficient to permit 
routine culture (described below).
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2.1.2 Routine MCF-7 Cell Passage Procedure
All cells were routinely cultured in 75cm flasks (T75) containing 15mls of 
culture medium, refreshed twice weekly; upon reaching 70-80% confluency 
the cells were passaged as follows. The culture medium was aspirated and 
replaced with lOmls of pre-warmed (37°C) trypsin (0.05%)/EDTA (0.02%) in 
PBS. The flask was returned to an incubator at 37°C for approximately 5 
minutes, until the cells had detached from the flask surface. The trypsinised 
cell suspension was then mixed with an equal volume of pre-warmed 
RPMI+5% culture medium and centrifuged at 1340g for 5 minutes at room 
temperature. The supernatant was aspirated and the cells were resuspended 
into lOmls of RPMI+5% by gently pipetting through a 10ml pipette, ensuring 
no clumping of cells was visible. 1ml of cell suspension was then seeded into 
14mls of RPMI+5% in T-75 flasks and put in an incubator (5% CO2 at 37°C).
2.1.3 Experimental Cell Media and Passage procedure
T75 flasks containing MCF-7 cells at 70-80% confluency were trypsinised and 
centrifuged as described in the routine cell passage procedure. The pellet 
obtained was then resuspended in 10ml of oestrogen depleted experimental 
media. Experimental media was necessary to avoid the unwanted oestrogenic 
properties of both the phenol red in standard RPMI-1640 medium, and the 
steroidal hormones present in the standard FCS. Therefore, standard RPMI 
was replaced with a phenol red free equivalent medium (wRPMI), and FCS 
was charcoal-stripped to produce steroid-depleted FCS (csFCS). The csFCS 
was prepared by firstly aliquoting the standard FCS (100ml) and adjusting the
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pH to 4.2 using 5M HCL. This was then allowed to equilibrate for 30 minutes 
at 4°C. A charcoal/dextran solution was prepared using distilled water with 
Norit A (charcoal, 11.1%) and Dextran C (0.06%). This mixture was then 
stirred vigorously for 1 hour. 5ml of charcoal solution (5% v/v) was added to 
each 100ml aliquot of FCS and incubated with gentle agitation for 16 hours at 
4°C. The charcoal was then removed by centrifugation (12,000g for 40 
minutes) and the solution was filtered with filter paper (grade 4) to remove 
any traces of charcoal. The pH of the solution was then readjusted to pH7.2 
and sterilised by filtering with a 0.2pM membrane filter to remove fine 
impurities and contaminating micro-organisms. The experimental media for 
all cell-lines used in this study comprised of wRPMI containing 5% (v/v) 
csFCS, antibiotics (same as routine culture media) and glutamine (4mM) 
(wRPMI+5%).
To ensure that equivalent cell numbers were obtained for each experiment, the 
cells were counted and diluted appropriately prior to plating into the selected 
experimental receptacle. The cell pellet obtained by centrifugation was 
resuspended into lOmls of wRMPI+5% using a syringe with a 25 G5/8 0.5 X 
16 needle, to separate the cells and achieve a single-cell suspension. lOOpl of 
this solution was then added to 10ml of Isoton solution in a counting cup and 
counted using a Beckman Coulter counter Multisizer II. Cell counts were 
carried out in duplicate, and an average was calculated. An appropriate 
volume of RPMI+5% was then added to a known number of cells to obtain a 
suitable cell density.
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2.1.4 Establishment of the tamoxifen resistant cell-line (TAM-R).
A tamoxifen-resistant MCF7 cell-line was generated by the long-term culture 
of MCF-7 cells in wRPMI+5% containing 4-OH-tamoxifen (10‘7M) (TAM). 
During the first two months of this culture regime, cell growth was 
significantly inhibited. However, cell growth rate then began to steadily 
increase following the emergence of cells capable of overcoming the growth 
inhibitory effects of TAM. After six months culture, the resultant tamoxifen 
resistant-MCF-7 derived cell sub-line (TAM-R) was characterised [Knowiden 
et al, 2003; Hutcheson et al, 2003; Hiscox et al, 2004]. Large stocks were 
generated and cells were periodically brought up from frozen for experimental 
analysis. Cells were routinely cultured for up to 25 passages under the same 
conditions described for the MCF-7 cells (section 2.1.2), with wRPMI+5% 
+TAM medium.
2.1.5 Establishment of the tamoxifen withdrawn TAM-R cell-line (TAM-Wd). 
In order to establish a cell model representative of tamoxifen-resistant breast 
cancer cells which have subsequently been withdrawn from the drug, TAM-R 
cells were maintained in wRPMI+5% in the absence of tamoxifen for up to six 
months. Cells were frozen in liquid nitrogen after a tamoxifen withdrawal 
period of either 1, 3 or 6 months. Briefly, cells were harvested from T75 flasks 
and counted as previously described in section 2.1.3. The cell suspension was 
centrifuged and cells were resuspended in wRMPI+5% + 7.5% DMSO at a 
cell density of 106cells/ml. 1ml aliquots were transferred to freezer vials, 
labelled and placed into a lag box which was transferred to a -80°c freezer.
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Vials were transferred to liquid nitrogen storage after at least 24hours. The 
resultant tamoxifen-withdrawn TAM-R cell sub-lines, TAM-Wd 1 Month 
(TAM-Wd 1M), TAM-Wd 3M and TAM-Wd 6M, were simultaneously 
brought up from frozen (as described in section 2.1.1 with wRMPI+10%), and 
were routinely cultured (as described for MCF-7 cells in section 2.1.2) with 
wRPMI+5% medium for up to ten passages before being discarded. See 
Fig.2.1 for a time-line depicting the establishment of experimental cell- 
models.
Fig 2.1. Time-line of established experimental cell-lines.
6 Months + TAM -M - -6 Months - TAM-
MCF-7 TAM-R
1 Month 3 Month
TAM-Wd
6 Month
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2.2 Cell Behaviour Analysis
2.2.1 Morphology
T75 flasks containing cells at around 50-60% confluency were visualised at 
20x magnification using an inverted microscope fitted with a Hoffman 
condenser. Representative images of live cells were obtained using a digital 
camera and Improvision® OpenLab software.
2.2.2 Growth Assays
Cells from T75 flasks were passaged as described in section 2.1.3. The cell 
suspension was diluted to a suitable density (4xl04 cells/ml unless otherwise 
stated), and cells were seeded in 24-well plates (1 ml/well). Cells were 
incubated for 24 hours prior to treatment, with each condition and/or time- 
point allocated triplicate wells. Concentration-response assays were run for 7 
days, while growth assays were assessed over an 11-14 day period, typically 
taking cell counts every 2-3 days. In both instances, the medium was refreshed 
every 3-4 days. To record the number of cells per well, the medium was firstly 
removed and replaced with 1ml of trypsin solution. The plate was returned to 
the incubator until the cells could be detached with gentle rocking (usually 3-5 
minutes). Using a 5ml syringe with a 25 G5/8 0.5 X 16 needle, the detached 
cells were pipetted up and down twice to encourage a single-cell suspension 
for accurate analysis of cell number. 1 ml of Isoton solution was added to the 
well and the solution was pipetted up and down twice more before being 
drawn into the syringe. This process was repeated twice to give a total volume
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of 4ml. The cell suspension was transferred to a counting pot containing 6ml 
of Isoton, to give a final volume of 10ml. The number of cells in each pot was 
then determined in duplicate using the Coulter™ Multisizer II set to count the 
number of cells in 500pl. Pots were counted a minimum of twice, with gentle 
agitation between each count to resuspend the cells. Duplicate counts for the 
three wells/condition were averaged and multiplied by the dilution factor of 20 
to give the average number of cells per well. All growth/concentration- 
response assays were carried out as independent triplicate experiments unless 
otherwise stated. Treatments are summarised in table 2.1.
2.2.2.1 MTT Cell Proliferation Assay
Cells were harvested as previously described in section 2.1.3 and seeded into 
96-well plates at a density of 5x10 cells/well. Cells were incubated for 24hrs 
prior to treatment, with each condition allocated 8 wells. Following a further 7 
days of culture (with 1 medium change) medium was removed, and cells were 
washed gently with PBS. Sterile-filtered 3-(4,5-dimethylthiazol-2-yl)-2,5- 
diphenyl-2H-tetrazolium bromide (MTT) in wRPMI (0.5mg/ml; 150pl) was 
added to the cells and plates were left to incubate at 37°C for 4 hours. During 
this time, the MTT compound was metabolised by mitochondrial 
dehydrogenase enzymes in the cells to produce insoluble purple formazan 
crystals. The MTT solution was then removed and cells were lysed in 10% 
(v/v) Trition-XlOO in PBS (150pl/well) for 12hrs at 4°C. Cell lysis causes the 
formazan crystals to dissolve and the absorbance of the resultant solution is 
proportional to cell number. Plates were warmed to room temperature and
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gently tapped before being read on a Multiskan® MCC/340 plate-reader at 
540nm.
2.2.3 Wound Healing Assay
Cells were harvested and seeded into 24-well cell-culture plates as described 
in section 2.2.2. After confluent cell mono-layers were established, cells were 
wounded by running a pipette tip across the diameter of the base of the well, 
manually removing cells. The well was rinsed with 1ml sterile PBS, refreshed 
with new medium, and incubated for a further 48 hours. Cells were then fixed 
with 3.7% formaldehyde, and stained with crystal violet (0.5% in PBS). Wells 
were visualized on a phase contrast-microscope and were photographed using 
a digital camera at x4 magnification. An allocation of wells that had not been 
wounded 48hours previous, were wounded on the day of fixing to provide a 
positive control. Three independent experiments were carried out for this 
analysis, with images presented representative of the average degree of wound 
recovery.
2.2.4 Cell Migration
To analyse a cells capability to migrate, 24-well plate inserts 6.5mm in
diameter with an 8 pm pore membrane, were basally coated with fibronectin
(lOpg/ml in wRPMI+5%) by submerging an insert into a well containing
200pl of fibronectin solution for 2 hours at 37°C. The inserts were then
washed with PBS and allowed to air-dry.
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Cells from T75 flasks were passaged as described in section 2.1.3 and the cell 
suspension was diluted with experimental medium to a density of 
2.5x105cells/ml. 200pl of cell suspension was seeded into the upper 
compartment of the insert. Each cell-line was seeded in duplicate per 
experiment, and independent experiments were carried out in triplicate. 650pl 
of media was then added to the lower compartment of each insert and the plate 
was incubated at 37 °C for 24 hours. The medium in the upper compartment of 
the inserts was then aspirated. Non-migratory cells attached to the upper- 
surface of the membrane were manually removed using a cotton swab. 
Migratory cells, attached to the basal membrane surface were fixed with 3.7% 
(v/v) formaldehyde in PBS for 10 minutes. Cells were then washed with PBS 
and stained with crystal violet (0.5% w/v in water) for 30 minutes. PBS was 
then used to thoroughly remove excess crystal violet stain and the inserts were 
air-dried at room temperature. Inserts were visualised at lOx magnification 
using a phase contrast microscope, and the number of migratory cells present 
in 5 random fields of view was recorded for each insert. Data is presented as 
mean cell count/field (n=3).
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Table 2.1 - Treatments Used in Cell Culture Procedures.
Treatments for Concentration-Response and Growth Assays
Treatment Classification Target Typical Cone. Used Vehicle Manufacturer
17P-Oestradiol Hormone ER InM EtOH Sigma-Aldrich
4-hydroxytamoxifen Anti-hormone ER lOOnM EtOH Sigma-Aldrich
Fulvestrant (Faslodex™) Anti-hormone ER lOOnM EtOH AstraZeneca
Gefitinib (Iressa™) Inhibitor EGFR lpM DMSO AstraZeneca
ABDP (4-anilino-5- 
bromo-2-[4-(2-hydroxy- 
3-(N,N-dimethy lamino) 
propoxy) anilino] 
pyrimidine)
Inhibitor IGF-1R lpM DMSO AstraZeneca
5-Azacytidine De-methylationagent - lpM dH20 Sigma-Aldrich
Treatments for RNA/DNA Extractions
Treatment Classification Target Typical Cone. Used Vehicle Manufacturer
17P-Oestradiol Hormone ER InM EtOH Sigma-Aldrich
4-hydroxytamoxifen Anti-hormone ER lOOnM EtOH Sigma-Aldrich
5-Azacytidine De-methylationagent - lpM dH20 Sigma-Aldrich
Treatments for ICC Analysis
Treatment Classification Target Typical Cone. Used Vehicle Manufacturer
17P-Oestradiol Hormone ER InM EtOH Sigma-Aldrich
5-Azacytidine De-methylationagent - lpM dH20 Sigma-Aldrich
51
Chapter 2 Material and Methods
2.3 Gene Expression Analysis
Gene expression in wt-MCF7, TAM-R and TAM-Wd cell-lines was analysed 
using both semi-quantitative reverse transcription-polymerase chain reaction 
(RT-PCR) and real-time (quantitative) PCR (qPCR). For both procedures, 
RNA and DNA were prepared using RNA/DNase free reagents and autoclaved 
disposables, and ethanol rinsed gloves were worn at all times.
2.3.1 Cell Culture Procedure for RNA Harvest
Cells were harvested and counted as described in section 2.1.3, and 
resuspended in fresh experimental medium at cell density of 3xl06 cells/ml. 
lml of cell suspension was seeded into a 150mm petri-dish containing 9mls of 
pre-warmed wRPMI+5%. Cells were incubated at 37°C for 24hr before 
treatments were added (treatments are summarised in table 2.1). Cells 
remained in culture for a further six days before RNA harvest, with media 
typically refreshed every 2-3 days.
2.3.2 RNA Extraction
Media was drained from the petri-dish, and cells were rinsed with xl PBS 
three times to ensure removal of all traces of cellular debris and media 
components. Petri-dishes were drained thoroughly and lml of TRI-reagent 
was distributed across the cell-monolayer. Dishes were gently rocked to 
ensure total-surface coverage, and then left to incubate for 5 minutes at room 
temperature. Dishes were gently tapped to dislodge cells, and a cell scraper
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was used to ensure all cells had detached. The viscous cell solution was 
transferred to a 2-ml eppendorf tube and placed on ice (at this point, cell- 
lysates were stored at -80°C for at least 24 hours before the RNA extraction 
was carried out). 0.2mls of Chloroform was added to the cell lysate, and the 
solution was vortexed to ensure complete mixture. Samples were incubated for 
lOmins at room temperature before centrifugation at 13000g, 4°C for 10 mins. 
Samples separated into two phases; 0.5ml aliquots of upper (aqueous) phase 
which contained the RNA were transferred to fresh 1.5ml eppendorf tubes, to 
which 0.5ml isopropranol was added. Samples were vortexed for 5secs, and 
incubated for a further 10 mins at room-temperature before a repeat 
centrifugation step.
The supernatant was carefully removed and the remaining RNA pellet was 
resuspended in lml 75% ethanol (EtOH). Samples were centrifuged at the 
same speed and temperature as before for 5 mins, after which the EtOH was 
carefully removed. Pellets were briefly air-dried and re-dissolved into 50pl 
dH20. Samples were stored at -80°c prior to analysis.
2.3.3 RNA Quantification
Total RNA was typically diluted 1: 200 in TE buffer pH 8.0 (10 mM Tris-Cl, 
1 mM EDTA) and measured in a quartz cuvette using a spectrophotometer. 
Optical densities (OD) observed at wavelengths of 260 and 280nm were 
recorded and subsequently used to produce the A260/A280 ratio as an 
indicator of nucleic acid purity, with a ratio of 1.8-2.1 representing an 
acceptable RNA solution. The RNA integrity was checked by running RNA
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through a 2% agarose gel. The following calculation was used to obtain the 
RNA concentration:-
[RNA] = O D 260 x 200 x 40 = pg/ml (RNA - 40pg = 1 0 D 26o)
2.3.4 Reverse Gene Transcription
To generate complementary DNA (cDNA) from Total RNA obtained, lpg of 
total RNA was made up to 7.5pl with RNase-free H20. This RNA solution 
was then added to 1 lp l of RT master mix comprising 5pi dNTP (0.625mM of 
dGTP, dCTP, dATP and dTTP), 2pl 10X PCR buffer (containing 25mM 
MgCl2), 2pl di-thiothreitol (DTT; 0.1M) and 2pl random hexamer 
oligonucleotides (RH; lOOpM). Samples were placed in a thermal cycler and 
denatured by heating to 95°C for 5 minutes. Samples were then removed and 
cooled on ice for 5 min. 1 pi MMLV (reverse transcriptase enzyme (200U/pl) 
and 0.5pi RNase inhibitor (40U/pl) were added to each tube to give a final 
volume of 20pl. Tubes were mixed gently and centrifuged briefly to collect 
volume and then returned to the thermal cycler and reverse transcribed using 
the cycle program below. The resultant cDNA was stored at -20°C.
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Thermocycling Procedure for RT
1 Annealing
2 RT Extension
3 Denaturing
4 Short-term 
storage
Temp Duration
22°C 10 minutes
42°C 42 minutes
95°C 5 minutes
4°C No more than
12hrs
2.3.5 Polymerase Chain Reaction
The reaction mixture for the amplification of genes by semi-quantitative PCR 
consisted of 2.5pl lOx PCR buffer, 2pl dNTP mix (2.5mM), forward primer 
(20pM), 0.6pl gene reverse primer (20pM), 0.1 pi Taq polymerase (5U/pl) and 
0.5pl cDNA (equivalent to 25ng of RNA used in RT assuming 100% 
efficiency of reaction), with the final volume made up to 25 pi with sterile 
H2O. A negative control in which cDNA was substituted with an equal volume 
of sterile H2O was also run for each experiment. All primers used were 
synthesised at Invitrogen and were micro-column purified. Primer sequences 
for all genes amplified can be found in table 2.2. The reaction tubes were 
mixed gently, pulsed in a micro-centrifuge and placed in a thermal cycler. The 
PCR reaction was then run for the optimal cycle number for gene 
identification using the temperature cycling conditions stated below. PCR data 
was normalised using amplification of the P-actin housekeeping gene.
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Thermocycling Procedure for PCR:
Temp Duration
1 Denaturing 95°C 5 minutes
2 Annealing 55-60°C 1 minute
3 Extension 72°C 1 minute
4 Denaturing 95°C 1 minute
5 Annealing 55-60°C 1 minute
6 Extension 72°C 1 minute
7 Final Extension 72°C 10 minutes
8 Short-term 4°C No more than
storage 12hrs
j
x 1
x 24-32
2.3.6 Agarose Gel Electrophoresis and Gel Densitometry 
Samples were resolved using a 2% (w/v) agarose gel made up with Tris- 
Acetate-EDTA (TAE) buffer (Tris-base 2M, Glacial acetic acid 1M, EDTA 
0.05M (stock is 50x) -pH 8.3- made up to 1L with distilled H2O, diluted 1:50 
before use) containing ethidium bromide (lp l of a lOmg/ml solution per 
100ml gel solution). The agarose was firstly dissolved in the TAE buffer by 
heating in a microwave at full power for 1 minute, with intermittent mixing. 
The gel was left to cool to approximately 40°C and the ethidium bromide was 
added. The gel was cast and a comb was added and the gel was left to set. The 
solidified gel was then submerged in an electrophoresis tank containing TAE 
buffer, and lOpl of each PCR product was mixed with 5 pi loading buffer and
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dispensed into a well of the gel. A lOObp DNA size marker was run in parallel 
with the samples. The gel was run at 100V constant voltage for approximately 
45-60 minutes. Gels were visualised using a UV trans-illuminator and 
photographed with a digital camera attached to a shroud for densitometric 
analysis. Using the spot density application within the Digidoc computer 
software, the light intensity of the UV fluorescence of ethidium-bromide 
chelated DNA was standardised and quantified relative to P-actin. 
Densitometry data is representative of 3 independent experiments. Single gels 
that reflect the observations from three independent experiments are also 
presented.
2.3.7 Real-Time PCR
Quantitative PCR (qPCR) uses fluorescence to measure the amount of DNA 
material present in a PCR reaction after each temperature cycle and, thus, 
follows the amplification of a gene in ‘real-time’ until the system becomes 
saturated. Following the reaction, the amount of starting template material in 
an unknown sample can be quantified by comparing its fluorescence at a 
suitable cycle number to that of a pre-defined standard curve. The present 
study used the DyNAmo™ SYBR Green qPCR Kit according to the 
manufacturer’s instructions. SYBR green is an intercalating DNA dye that is 
only fluorescent when bound to double-stranded DNA. Briefly, each reaction 
mix contained 12.5pl SYBR Green PCR Mastermix (hot start taq DNA 
polymerase, lx SYBR Green PCR buffer, SYBR Green 1, dNTPS, and 
MgCh), 0.375pl forward- and reverse specific primers (20pM) (table 2.2), and
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11.3 pi sterile H2O, giving a total volume of 24.5 pi of master mix which was 
aliquoted into the wells of a 96 well qPCR plate, to which 0.5pi of cDNA 
product (equivalent to 0.05 pg RNA starting material) was added. Serial 
dilutions of specific cDNA-amplicon preparations of known concentration 
were extracted from freshly purified PCR product using a QIAquick PCR 
purification kit according to manufacturer’s instructions. They were then 
quantified using a RNA/DNA calculator and used to produce a standard curve 
from which experimental samples could be quantified. Final standard 
concentrations ranged from 0.001-lOng/pl. Each standard/sample was 
analysed in duplicate. The wells of the plate were capped and gently tapped to 
ensure complete mixture of the reaction components. Plates were lightly 
pulsed in a centrifuge to collect volume and placed into an Opticon 2™ real­
time PCR machine. Throughout the set-up procedure, effort was made to 
protect the master-mix from light, due to the photo-sensitive nature of its 
constituents. The thermocycling protocol was as below. Each qPCR reaction 
was set to run for 50 cycles to ensure product saturation.
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Thermocycling Procedure for qPCR:
Temp Duration
1 Initial denaturing 
phase
95°C 15 minutes
2 Annealing 55°C 30seconds
3 Extension 72°C 30seconds
4 Denaturing 95°C 30seconds
5 Annealing 55°C 30seconds
6 Extension 72°C 30seconds
7 Final Extension 72°C 10 minutes
8 Cooling period 4°C _
x 1
x 50
Plate fluorescence readings were collected after each 72°C extension time. 
The concentrations of starting template material in the samples were 
extrapolated from the standard curve using Opticon 2™ computer software. 
The quantities of cDNA recorded were then corrected against B-actin 
expression to normalise the data. Data presented shows cDNA detected, 
normalised to actin for 3 independent experiments, run on the same qPCR 
plate. After each run, melting curves were inspected to ensure valid product 
specificity.
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Table 2.2. Primers used in Semi-Quantitative and Quantitative PCR
Primers Used in Semi-Quantitative PCR
Gene Primer Sequence Amplicon size (bp)
Annealing
Temp(°c)
Cycle
no.
ADCY9
For 5’- ctgctgcccttatccaacat -3’
60 28
Rev 3’- ctgggaaacactgagcacac -5’
4 5  /
p-Actin
For 5’- ggagcaatgatcttgatctt -3’
55 24ZUo
Rev 3’- ccttcctgggcatggagtcct -5’
CA12
For 5’- atgggatgcactctcagacc -3’
60 25
Rev 3’- aaagcttggagaagcagcag -5’
JUO
COL6a3
For 5’- tcaatccaaattccctctgg -3’
4 ^ 6 60 28
Rev 3’- gggcagggaatgaaaaagtt -5’
4 0 0
CXCL12
For 5’- agagatgaaagggcaaagac -3’
1 77 56 30
Rev 3’- cgtatgctataaatgcaggg -5’
1 j Z
GDF15
For 5’- actgctggcagaatcttcgt -3’
60 32
Rev 3’- cacatggtcacttgcacctc -5’
7 7 0
HBA2
For 5’- caagacctacttcccgcact -3’
4 7 60 25
Rev 3’- aggcagtggcttaggagctt -5’
KAZRIN
For 5’- ggcagaggatgtggtctgtt -3’
^47 60 29
Rev 3’- acaaacccagccaagacaag -5’
7 4 7
RASAL1
For 5’- ctgtgtgccttgagtccaga -3’
 ^1 4 60 28
Rev 3’- cagctgtatccagcagctca -5’
7 1 4
RGC32
For 5’- ctgccactgtcactcctcag -3’
4 8 6 58 30
Rev 3’- ttgagtgcacgtctttgtcc -5’
4 o 0
ST6
For 5 ’ -tgttcaatataggacaccccagctt-3 ’
7 7 ^ 58 28
Rev 3 ’ -catcctgttggtgacaaggtggtga-5 ’
Z / 3
WISP2
For 5’ -ggtctgtctggacgagtatgg -3’
1 Q1 60 27
Rev 3’- ggactgcttgtcccatctcttgcc -5’
i y i
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Table 2.2. Continued
Primers Used in Quantitative PCR
Gene Primer Sequence Ampliconsize
Annealing
Temp(°c)
Cycle
no.
(3-Actin
For 5’- ggagcaatgatcttgatctt -3’
204 55 50
Rev 3’- ccttcctgggcatggagtcct -5’
EGFR
For 5’- caacatctccgaaagcca -3’
636 55 50
Rev 3 ’- cggaactttgggcgactat-5 ’
ERa
For 5’- ggagacatgagagctgccaac -3’
432 55 50
Rev 3’- ccagcagcagcatgtcgaagatc -5’
IGFR
For 5’- actgacctcatgcgcatgtg -3’
285 55 50
Rev 3’- ctcgttcttgcggcccccgt -5’
PR
For 5’- ccatgtggcagatcccacaggagtt -3’
320 55 50
Rev 3’- tggaaattcaacactcagtgcccgg -5’
pS2
For 5’- catggagaacaaggtgatctg -3’
336 55 50
Rev 3’- cagaagcgtgtctgaggtgtc -5’
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2.4 Protein Expression Analysis
Protein expression in wt-MCF7, TAM-R and TAM-Wd cell-lines was 
analysed using both SDS PAGE-Western blotting and Immunocytochemistry 
(ICC).
2.4.1 Cell Culture Procedure for Protein Harvest
Cells were harvested as described in section 2.1.3, counted and resuspended in 
fresh experimental media at a cell density of 2xl06 cells/ml. lml of cell 
suspension was seeded into a 100mm petri-dish containing 9mls of pre- 
warmed wRPMI+5%. Cells remained in culture until they had reached 
approximately 60-70% confluency (typically 6-7 days), with media refreshed 
every 3-4 days. Media was then aspirated and cells were washed twice with 
lxPBS (lOmls). Dishes were drained thoroughly and transferred to ice, and 
cells were lysed using 250pl of ice-cold lysis buffer (50mM Tris-HCL, 5mM 
EDTA, 150mM NaCl, 1% Triton X-100 (v/v) in distilled water, pH7.5) 
supplemented with protease and phosphatase inhibitors (2mM Na3V04, 
20mM NaF, ImM PMSF, 10 pg/ml leupeptin, 20pM phenylarsine oxide, 
lOpg/ml aprotinin and lOmM sodium molybdate), which was distributed 
evenly across the cell monolayer. Following 2 minute incubation on ice, 
cellular material was collected using a cell-scraper and transferred to a 1.5ml 
micro-centrifuge tube. The solution was homogenised briefly using a pipette 
and left on ice for 20 minutes, with occasional mixing. Lysates were then 
centrifuged at 13,000g for 15 minutes (4°C) to clear cell debris, and the 
supernatants were stored at -20°C until required.
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2.4.2 Protein Concentration Assay
The total protein concentration of the cell lysates was determined using the 
Bio-Rad DC Protein Assay kit. Lysates were diluted 1:4 in lysis buffer to give 
a final volume of 50pl, prepared in disposable cuvettes. A standard curve was 
constructed for spectrophotometric quantification using known concentrations 
of bovine serum albumin (BSA), diluted in lysis buffer to obtain 50pl of 
solution at protein concentrations of 0, 0.25, 0.5, 0.75, 1 and 1.45mg/ml. 250pl 
of reagent A (from BioRad kit) was added to each cuvette, supplemented with 
substrate S (20pl in lml of reagent A) followed by 2ml of reagent B. Each 
cuvette was then briefly vortexed and colour was allowed to develop for a 
minimum of 15 minutes. The absorbance at 750nm for each BSA sample of 
known concentration was then read on a spectrophotometer and a calibration 
curve was plotted (absorbance versus concentration). Each protein sample was 
then processed and its concentration was determined from the standard curve.
2.4.3 Sodium-Dodecyl-Sulphate-Polyacrylamide Gel Electrophoresis (SDS- 
PAGE)
Electrophoresis was carried out using Biorad Mini-Protean® 3 electrophoresis 
apparatus from BioRad Laboratories. Glass plates were thoroughly cleaned 
with ethanol and assembled to provide the gel cast. Resolving gel and stacking 
gel were prepared as follows; resolving gel: 7.5% acrylamide/bisacrylamide, 
375mM lower buffer (pH8.8), 0.1% (w/v) SDS, 0.1% (w/v) APS and 70pM of 
TEMED, stacking gel: 5% acrylamide/bisacrylamide, 125mM upper buffer 
(pH6.8), 0.1% (w/v) SDS, 0.05% (w/v) APS and 116pM TEMED.
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The constituents of the resolving gel, with the exception of TEMED, were 
added to a universal container and mixed thoroughly. TEMED was then 
added to the gel solution immediately before casting the gel as it catalyses the 
polymerisation and cross-linking of the acrylamide/bis-acrylamide, causing 
the gel to set. The gel was dispensed between the glass plates until the level 
reached approximately 1.5cm below the top of the exterior plate (to allow 
room for the stacking gel). 0.05% (w/v) SDS in H2O was carefully dispensed 
over the exposed gel surface to ensure the formation of a level gel front and 
the exclusion of any air bubbles. The gel was left for approximately 30 
minutes at room temperature to set.
The SDS solution was then removed from the resolving gel surface, and 
distilled water was used to rinse the gel. Excess water was drained with a strip 
of filter paper. The stacking gel solution was prepared and poured onto the 
resolving gel, filling the remaining volume of space between the glass plates. 
A 10-well comb was inserted into the stacking gel solution and the gel was 
allowed to set for 45-60 minutes at room temperature.
After the stacking gel had polymerised, the comb was gently removed and the 
casting apparatus was transferred to an electrophoresis tank, the upper and 
lower chambers of which the were then filled with running buffer (250mM 
Trizma base, 2M Glycine, 40mM SDS - pH8.8).
Forty pg of protein from each quantified protein sample was then mixed with 
lOpl of loading buffer (4% (w/v) SDS, 20% (v/v) glycerol, 120mM upper 
buffer (pH6.8), 0.1% (W/V) bromophenol blue, plus lOOmM DTT). The 
protein samples, combined with loading buffer, were heated to 100°C for 10
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minutes to denature and reduce the proteins in the sample and were allowed to 
cool before loading onto the gel. Rainbow protein marker (10-250 kDa) was 
loaded into the first lane of each gel. Electrophoresis was carried out at a 
constant voltage of 150volts until the dye front had reached the base of the gel 
(approximately 45 minutes).
2.4.4 Western Blotting
Proteins were transferred from SDS-PAGE gels to a nitrocellulose membrane 
using the Bio-Rad Mini-Protean® III transfer apparatus according to 
manufacturer’s instructions. Two pieces of grade 3 filter paper and one piece 
of nitrocellulose membrane (0.45 pm pore size) cut to the same size as the gel, 
along with two Teflon sponge pads, were pre-soaked in transfer buffer (0.2M 
of glycine, 25mM of Trizma base, 20 %(v/v) of methanol in distilled water, 
pH 8.3) for 30 minutes.
Gels were removed from the electrophoresis plates and carefully transferred to 
a tray containing distilled H2O to wash off any excess SDS. The stacking gel 
was gently separated from the resolving gel and discarded.
The resolving gel was assembled with the other components of the western 
blot transfer cassette according to the manufacturer’s instructions [Fig 2.2]. 
Gentle pressure was applied to the complete cassette assembly to ease out any 
air bubbles that may formed between the layers. The cassette was then placed 
into the transfer apparatus which was loaded into a tank along with an ice- 
block to prevent over-heating of the gel during transfer, and a magnetic flea.
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The tank was then filled with transfer buffer, placed on a magnetic stirrer, and 
the transfer was run at 100V constant voltage for 1 hour.
Afterwards, nitrocellulose membranes were blocked in a solution of 5% (w/v) 
skimmed milk in TBS-Tween (lOmM Tris, 0.1M NaCl, 0.05% (v/v) Tween 
20, pH 7.5) for at least 1 hr to prevent non specific binding. Blots were then 
incubated in the appropriate primary antibodies overnight. A list of the 
primary antibodies used in this study, along with their corresponding dilutions 
is shown in table 2.3.
Membranes were then washed three times with TBS-Tween at 5 minute 
intervals, and incubated for 1 hour with the required secondary antibody 
labelled with horseradish peroxidase (anti rabbit or anti mouse) diluted 
1/10000 in TBS-Tween (l:20mls). Membranes were then washed TBS-Tween 
(3xl0minutes).
Detection was performed by applying a thin film of enhanced 
chemiluminescence (ECL) reagent (Supersignal™ West Pico, Supersignal™ 
West Dura) to the membrane, which was then sealed within a plastic sheath in 
a development cassette. After 5 minutes, cassettes were taken to a dark room, 
where a sheet of x-ray film was placed on top of the sealed membrane. The 
cassette was closed, and left for a suitable duration of time until blots could be 
visualised on the developed film. Blots presented reflect the observations from 
three independent experiments and were standardised using (3-actin detection.
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Fig 2.2 Western Blot Transfer Cassette Assembly
____ ■
White Cassette Wall (+ electrode) 
Teflon Sponge Pad 
Filter Paper
Nitrocellulose Membrane
SDS-PAGE Gel
Filter Paper
Teflon Sponge Pad
Black Cassette Wall (- electrode)
2.5 Immunocytochemistry ICC
2.5.1 Experimental tissue culture
Cells were harvested as described in section 2.13, counted and resuspended in 
fresh experimental media at cell density of lxlO5 cells/ml. 1ml of cell 
suspension was seeded onto 22-mm2, 3-aminopropyltriethoxysilane (APES)- 
coated glass coverslips (coverslips were submerged in 2% APES in acetone 
for 60secs followed by 1x10 minute wash and 2x 1 minute washes with water- 
air-dried and sterilised at 180°C for 2 hours), resting in 35mm culture dishes. 
Dishes were incubated for 24hrs to allow cells to settle. Treatments were then 
applied where appropriate (see table 1 for treatments) and cells were routinely 
cultured for up to seven days. Media was then removed and cells were fixed 
by a procedure most appropriate to the immunocytochemical assay to be
67
Chapter 2 Material and Methods
performed. All ICC antibodies and corresponding fixing methodologies used 
are shown in table 2.3.
2.5.2 Oestrogen-receptor immunocytochemical assay (ER-ICA) fixation. 
Coverslips were placed in a rack and submerged in a bath containing 3.7% 
(v/v) formaldehyde in PBS for 15 minutes. They were then transferred to a 
bath containing PBS at room temperature for 5 minutes to remove excess 
formaldehyde. Coverslips were then immersed in methanol (-10°C to -30°C) 
for 5 minutes, then acetone (-10°C to -30 °C) for 3 minutes. The coverslips 
were then washed in PBS at room temperature for at least 5 minutes and stored 
at -20°C in sucrose storage medium (SSM).
2.5.3 Formal-Saline (F/S) Fixation
Medium was removed from the coverslips and replaced with 1ml formal- 
saline solution (3.7% formal-saline -  4.5g NaCl, 50ml 37% Formaldehyde 
solution diluted in 450ml of tap water) for 10 minutes. The cells were then 
washed with 100% ethanol (5 minutes, followed by a quick ethanol rinse) and 
PBS (5 minutes, followed by a quick PBS rinse). Coverslips were stored in 
SSM at -20°C before use.
2.5.4 Phenol Formal-Saline (PFS) Fixation
Medium was removed from the coverslips and replaced with 2ml 2.5% phenol 
in formal-saline solution for 5 minutes. The cells were then washed with 
100% ethanol (5 minutes, followed by a quick ethanol rinse) and PBS (5
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minutes, followed by a quick PBS rinse). Coverslips were stored in SSM at - 
20°C before use.
2.5.4 Immunocytochemical processing of coverslips.
The SSM in which the fixed cells were stored was removed by gently rinsing 
with PBS. The coverslips were then submerged in PBS containing 0.02% 
(v/v) Tween-20 (PBS/Tween) for a few seconds to provide a surface that 
permits the primary antibody solution to spread evenly over the coverslip. 
50pl of primary antibody (diluted in PBS) was added to each coverslip and 
incubated in a humidified atmosphere at 23 °C. Antibody dilutions and 
incubation times varied between proteins (table 2.3).
Following primary antibody incubation, coverslips were washed with 
PBS/Tween ( 2 x 5  minutes) and incubated with DAKO EnVision+ system- 
HRP-labelled polymer, conjugated to goat anti-rabbit or goat anti-mouse 
immunoglobulins for up to 2hours at 23°C. Coverslips were washed with 
PBS/Tween ( 2 x 5  minutes), and staining was visualised using the DAKO 
Liquid DAB+ substrate and chromogen system. Colour development took 6- 
10 minutes depending on signal strength. Coverslips were rinsed with distilled 
water and cells were counter-stained with methyl-green (0.5% (w/v) in H2O) 
for 5 minutes. Coverslips were then thoroughly rinsed with distilled water to 
remove excess methyl-green. Coverslips were dried and mounted onto glass 
slides using DPX, a xylene-based mounting medium, and left to set over night 
at room temperature. They were later analysed with an Olympus BH2 phase-
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contrast microscope (at 20x magnification unless otherwise stated) and images 
were produced using a digital camera.
Table 2.3. Antibodies used in Western Blot and ICC procedures
Antibodies Used in Western Blot-Protein Detection System
Antibody Source Dilution Manufacturer
tEGFR Rabbit 1/1000 Cell Signaling Technologies
ERa Rabbit 1/10000 Santa Cruz Biotechnology
tIGFR Mouse 1/1000 Santa Cruz Biotechnology
p-actin Mouse 1/20000 Sigma-Aldrich
Antibodies Used in ICC Detection System
Antibody Source Dilution IncubationConditions Fixation Req. Manufacturer
tEGFR Mouse 1/140 Overnight at 23 °c Phe/Form/Sal NeoMarkers
ERa Mouse 1/75 90minutes at 23° ER-ICA Vector
tIGFR Rabbit 1/125 Overnight at 23 °c Form/Sal Santa Cruz
PR Mouse 1/75 60 minutes at 23° ER-ICA NovaCastra
pS2 Rabbit 1/500 90minutes at 23° ER-ICA NovaCastra
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2.6 Methylight Assay
The DNA material was generated in Tenovus as described below, and sent to 
Dr H. Fiegl o f the University o f Innsbruck for Methylight analysis.
2.61 Phenol / Chloroform / Isoamyl Alcohol extraction of DNA 
Cells were harvested and were seeded on to 100mm2 culture plates, as 
previously described in section 2.4.1. They were incubated at 37°C for 
24hours before treatments were added (see table 1). Cells were cultured for a 
further 7 days with media refreshed every 3-4 days. On the day o f harvest, 
media was removed from the dish and the cells were thoroughly washed twice 
with lOmls PBS. Dishes were drained, and 1.5 ml SDS lysis buffer (0.1 M 
EDTA, 0.5 % SDS, 100 pg/ml Proteinase K) was added. Dishes were 
incubated at room temperature for approximately 2 minutes before cells were 
scraped off with a sterile cell scraper. The viscous solution of cells was then 
transferred to a 15ml universal tube and incubated in a pre-warmed water bath 
at 65°C for two hours to allow Proteinase-K digestion.
An equivalent volume of alkaline-calibrated phenol (pH 7.9) was then added 
to the cell solution, which was then mixed gently. Samples were then 
centrifuged at 4000g for lOminutes at 4°C. The aqueous phase containing the 
genomic DNA was transferred to a fresh 15-ml phase lock gel (PLG) tube 
using a plastic pipette. The organic phase was back extracted by adding 1ml 
TE buffer pH 8.0 (10 mM Tris-Cl, 1 mM EDTA), mixing gently and re­
centrifugation. The aqueous phases were pooled, and an equivalent volume of 
Phenol/Chloroform/Isoamyl alcohol (25:24:1) solution was added to each
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sample, and mixed gently. Samples were then centrifuged for 4000g for 
lOminutes at 4°C, and supernatants were transferred to a fresh 15ml universal 
tube. 1/10 of the equivalent volume of NaOAc (2.5M, pH5.2) was added to the 
supernatant and mixed. Twice the equivalent volume of 100% EtOH was 
subsequently added. Gentle inversion of the tubes eluted fine DNA strands. 
Samples were then centrifuged (using the conditions described in the previous 
step) and the supernatant was discarded. Pellets were air-dried and re­
dissolved in 50-200pl DNAse and RNAse-free sterile H2O at 4°C overnight, 
then stored at -20°C prior to analysis.
2.6.2 DNA Quantification:
DNA extractions were allowed to thaw thoroughly. 5 pi of sample was 
transferred to a quartz cuvette containing 995pi TE buffer (pH8) (i.e. 1:200). 
The solution was gently inverted and optical densities (OD) were recorded at 
wavelengths of 260 and 280nm using a UV spectrophotometer. The 
A260/A280 ratio was calculated as an indicator of nucleic acid purity, with a 
ratio of 1.6-2.0 representing an acceptable DNA solution. The following 
calculation was used to obtain the DNA concentration for each sample:-
[DNA] = OD260 x 200 x 50 = pg/ml (DNA - 50pg = 1OD260)
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2.6.3 Methylight Assay -  Conducted by Dr H Fiegl at Innsbruck University 
Methylight is a sensitive, fluorescence-based real-time PCR technique that is 
capable of quantifying DNA methylation at a particular locus using DNA 
oligonucleotides that anneal differentially to bisulfite-converted DNA.
Briefly, DNA samples were firstly treated with sodium bisulphate which 
converts the unmethylated cytosine bases to uracil whilst methylated cytosines 
remain unaffected, using the EZ DNA Methylation-Gold Kit (Zymo Research, 
Orange, CA, USA) according to the manufacturer’s instructions. Methylight 
analysis was carried out as previously described by Eads et al (2000) using 
two sets of primers and probes, designed specifically for bisulfite-converted 
DNA; a set for the gene of interest and a set for collagen, type II, alpha 1 
(COL2A1), an internal reference gene, that would be amplified regardless of 
the methylation status of the DNA to normalise the differences in the amount 
of genomic template present in each reaction. Specificity of the reactions for 
methylated DNA was confirmed separately using CpG methylating enzyme 
Sssl-methylase (M.SssI) (New England Biolabs) treated human white blood 
cell DNA, which is heavily methylated. The percentage of fully methylated 
molecules at a specific locus was then calculated by dividing the 
GENE:COL2Al ratio of a sample by the GENE:COL2Al ratio of M.SssI- 
treated human white blood cell DNA (in which the gene of interest is fully 
methylated) and multiplying by 100.
Primer and probe sets for TFF1, PGR, COL2A1, SAT2, and ALU (markers of 
global DNA methylation) have been described recently [Widschwendter et al,
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2004; Weisenberger et al, 2005]. Primer and probe sets for ADCY9, CA12, 
CXCL12, GDF15, HBA2, Kazrin, RGC32 and ST-6 are listed in Table 4.
LA
Primers Used in Methylight Analysis
Gene Primer Sequence Primer Location Probe Oligo Sequence
ADCY9
For 5’- cctcgacgtcccaaaaacc -3’
Promoter 6F AM-ccgcccgaaatcccgaccct -BH Q1
Rev 3’- tttttacggtaggcgtttttaggt -5'
CA12
For 5'- ctctccaactacacaccgaaacc -3'
Exon-1 6F AM-cgtacgcgcaacctaaataccg -BH Q1
Rev 3’- aagggcggacgtattcgtt -5'
CXCL12
For 5’ -actcgccacctacc cgactt-3’
Promoter 6F AM-cgacgcaaccgccgacaaaact-BH Q1
Rev 3 ’ -gttac gttgattgtaaagac gggttt- 5 ’
GDF15
For 5’- cgactcgcctcgaccaaa -3’
Exon-1
6F AM-ccatacgacaaccacgaaaacaccaacaa-BH Q1
Rev 3’- gtaagaatttaggacggtgaatggttt -5’
HBA2
For 5’- ccgccccgacctaacac -3’
Promoter
6F AM-cgctaaacgcgcatcgactccaa-BH Q1
Rev 3’- gaagtttttcggttc gtattc gtt -5’
KAZRIN
For 5’- cgaacgaacgccgaaaact -3’
Promoter
6F AM-cgcgcgccaccaaacactctt-BH Q1
Rev 3’- cggcgaatggtaggttttattt -5’
RGC32
For 5’- taaatcctacgaaataacaaccgaaa -3’
Pro mote r/Exon-1
6F AM-aacttactatcccgcacacttcaaccctacca-BH
Q iRev 3’ -tttagga attc gagt c ggtggta- 5 ’
ST6
For 5’ -ctccccgcgcc ctaat-3’
Exon-1 6F AM-cctacgccctcccgctctacgct-BH Q l
Rev 3 ’ -tttgtttac ggttgtttgtt c gg- 5 ’
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2.7 Affymetrix gene analysis -  Conducted at Central Biotechnology Services, 
Cardiff University, Heath Park.
RNA extractions were prepared and quantified as described in sections 2.3.2 
and 2.3.3. 5pg of total RNA per sample was sent in triplicate to Central 
Biotechnology Services, who performed RNA integrity analysis, reverse- 
transcription and labelling and hybridisation of cDNA fragments to the HG- 
U 133A.2 Affymetrix® gene chip. The chip was washed and scanned and 
signal intensities were determined using Mas.5 Affymetrix software. Data was 
exported in a variety of file formats enabling subsequent uploading and profile 
analysis using Genesifter® on-line software.
2.7 Statistical analysis
Where data allowed, the statistical significance of the results obtained when 
comparing between cell-lines or when comparing treated cells versus controls 
was analysed using independent, two-tailed Student’s t-test. Where multiple 
data points were present, data were analysed using ANOVA with post-hoc 
tests. These analyses were conducted using the statistical analysis program, 
SPSS V12.0.2 (SPSS Inc.).
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3. RESULTS
The anti-hormone tamoxifen has been the gold standard therapy for the 
treatment of ER-positive breast cancer in post-menopausal women for almost 
thirty years. Although an estimated 50% of patients benefit from tamoxifen 
treatment, resistance to the anti-hormonal properties of this drug develops in a 
high proportion of initially responsive patients, leading to disease recurrence. 
The failure of tamoxifen to prevent tumour progression can be also be 
accompanied by the disease spreading to life threatening sites and hence a 
poorer patient prognosis; thus representing a significant obstacle in the 
treatment of breast cancer in the clinic. In order to investigate the changes that 
occur within breast cancer cells following the acquisition of tamoxifen 
resistance, the Tenovus Centre for Cancer Research has developed an in-vitro 
model of acquired tamoxifen resistance using the ER-positive MCF7 breast 
cancer cell-line.
MCF-7 cells, first derived by the Michigan Cancer Foundation in 1973 from a 
pleural effusion obtained from an invasive ductal carcinoma, are one of the 
most commonly used ER-positive breast cancer cell lines [Soule et al, 1973]. 
They display many characteristics of mammary epithelium, including the 
expression of oestrogen and progesterone receptors and the ability to 
synthesize and process oestradiol for growth, making them an ideal cell-model 
for the study of ER-positive breast cancer in-vitro. The tamoxifen resistant 
MCF7 cell-subline (TAM-R) was developed following the long-term culture
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of MCF7 cells in the presence of 4-hydroxytamoxifen as described in 
materials and methods (section 2.1.4). Previous ‘in-house’ characterisation of 
the TAM-R cell sub-line revealed fundamental changes in response to 
hormonal manipulation when compared to the parental MCF-7 cells. Although 
the TAM-R cells were found to be ER-positive, they were shown to be largely 
unresponsive to either the growth-stimulatory effects of E2 or to the growth- 
inhibitory effects of tamoxifen previously seen in the parental cell-line. 
However, TAM-R cells retained a partial role for ER in the regulation of cell 
growth, as evidenced by their sensitivity to receptor attenuation achieved 
through challenge with the pure anti-oestrogen, fulvestrant (Faslodex®) 
[Hutcheson et al, 2003].
Previous observations have also highlighted an essential role for growth-factor 
receptor signalling in TAM-R cells; with both EGFR and erbB2 being over­
expressed and demonstrating increased activity compared to the parental MCF 
cells [Knowlden et al, 2003]. Data suggests that TAM-R cells are significantly 
dependent on the EGFR/HER-2 signalling pathway to drive proliferation in 
contrast to the parental MCF-7 cells, as evidenced by considerable growth 
inhibition following challenge with EGFR-selective tyrosine kinase inhibitor, 
gefitinib (Iressa®), and HER-2 antibody, trastuzumab (Herceptin®). This 
contribution to cell growth may be amplified by cross-talk mechanisms that 
exist between growth-factor and ER signalling pathways and also, between 
different growth-factor signalling pathways, noticeably the IGF-1R pathway 
interplaying with EGFR via c-SRc [Knowlden et al, 2005].
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In parallel with the emergence of growth-factor signalling pathways in the 
MCF-7 cells following the acquisition of tamoxifen resistance, cells attain a 
more aggressive phenotype, demonstrating enhanced growth and motile 
capabilities [Hiscox et al, 2004]. In this chapter, we aim to determine whether 
the presence of tamoxifen is necessary to sustain these undesirable features of 
TAM-R cells, or whether permanent alterations to the cells phenotype have 
also occurred. In order to achieve this, TAM-R cells were withdrawn from 
tamoxifen for up to 6 months (as described in section 2.1.5). During this 
period, any agonistic contribution of the drug to TAM-R cell morphology, 
growth or motility would be depleted, whilst the effects of permanent heritable 
cell re-programming caused by the previous long-term tamoxifen treatment 
would remain. These tamoxifen-withdrawn (6-month) TAM-R cells (TAM- 
Wd), were then used to investigate the impact withdrawal had on the 
expression of components associated with the growth signalling pathways 
manifest in TAM-R cells, as well as analysing the effect that chronic 
tamoxifen exposure had on classically activated down-stream gene targets of 
the ER.
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3.1 Assessment of TAM-R cell behaviour following tamoxifen withdrawal.
3.1.1 Cell morphology.
The morphology of MCF7, TAM-R and TAM-R cells withdrawn from 
tamoxifen for a period of 1, 3 and 6 months was assessed by phase contrast 
microscopy using a Leica DM-IRE2 inverted microscope fitted with a 
Hoffman condenser, permitting image capture of live cells. In contrast to the 
MCF-7 cells, the TAM-R cells appeared more angular, featuring enhanced 
lamellipodia and filopodia formation; indicative of their highly motile and 
invasive phenotype [Fig 3.1]. In addition, MCF7 cells grew in tightly packed 
cell colonies, in contrast to the TAM-R cells, which tended to favour growing 
independently before being forced to combine to form loosely packed cell 
colonies when approaching confluency. Following the withdrawal of 
tamoxifen of up to 6 months, cells appeared to retain the morphological 
characteristics associated with the acquisition of tamoxifen resistance, 
demonstrating increased lamellipodia and filopodia formation, though cells 
appeared less angular than TAM-R cells, and grew in loosely packed colonies 
rather than independently.
3.1.2 Cell growth rate.
The growth rates of MCF7, TAM-R and TAM-Wd (1 ,3  and 6month) cell- 
lines were measured using anchorage dependent cell counting experiments as 
described in section 2.2.2. Growth curve analysis showed that compared to 
the parental MCF-7 cells, the TAM-R cell-line demonstrated a significantly
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elevated rate of growth from the fourth day of culture (pO.OOl), which 
continued until day 11, at which point the cells had reached confluency. This 
elevated growth rate was sustained in all TAM-Wd cell sub-types over the 14 
day culture period [Fig 3.2].
3.1.3 Cell Motility
Cell motility was assessed by the ability of MCF-7, TAM-R and TAM-Wd (6- 
month) cells to migrate through fibronectin coated, polycarbonate membranes, 
as a simulation of their affinity for matrix-components. Migratory cells were 
stained with crystal violet and quantified by counting the number of stained 
cells present in five random fields of view at lOx magnification for each insert. 
Fig 3.3 shows the number of migratory TAM-R cells observed exceeded that 
of the MCF-7 cells, with an approximate 4-fold increase in the number of 
stained cells counted over three independent experiments (pO.OOl). 
Following the tamoxifen withdrawal period of 6 months, the number of 
migratory cells fell (p<0.001), and cell counts were reduced to those recorded 
for the MCF-7 cells. Wound-healing assay analysis (see section 2.2.3) showed 
that TAM-R cells were significantly more able to achieve wound closure 
compared to both MCF-7 and tamoxifen withdrawn TAM-R cells, confirming 
the loss of TAM-R cell motility in the absence of tamoxifen [Fig 3.4] whilst 
cell proliferation was maintained [Fig 3.2]; emphasising the differential 
regulation of these events in breast cancer cells.
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Fig 3.1 Cell Morphology: Capture of live-cell images using a Leica DM-IRE2 
inverted microscope (20x magnification) fitted with a Hoffman condenser, as 
an assessment of morphological status in MCF-7, Tam-R, and Tam-Wd cells 
(1,3 and 6 months).
MCF-7 TAM-R
TAM-W d 1 Month
TAM-Wd 3 Month TAM-Wd 6 Month
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Fig 3.2 Anchorage dependent growth assay: MCF-7, TAM-R, and TAM-Wd 
(1,3 6 months) cells were seeded at a similar density (lxlO4 cells/ well) on 24- 
Well Coming Co-star plates. Cells were trypsinised and counted using Coulter 
Counter apparatus on days 2, 4, 7, 11 and 14. The data shown represents actual 
cell number/well recorded over 3 independent experiments. Counts recorded 
for all resistant cell-lines were greater than MCF-7 cell counts from day 4 of 
culture (*p<0.001).
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Fig 3.4 Wound Healing Assay: Monolayer cultures of MCF-7, TAM-R and 
TAM-Wd (6 month) cells were wounded by manual scratching with a pipette 
tip, washed with PBS and fresh medium was added. Some wells were fixed 
with 3.7% formaldehyde and stained with crystal violet directly after 
wounding to provide a timed control. After 48 hours, the remaining cells were 
fixed and stained and photographed to monitor wound closure at *4 
magnification.
Non-wounded
MCF-7 TAM-R TAM-Wd
Wounded
Healed
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3.2 Growth Pathway Analysis in Tam-R cells following Tamoxifen 
withdrawal
Having shown that despite the long-term withdrawal of tamoxifen, Tam-Wd 
cells proliferated at the same rate as the TAM-R cells, we sought to determine 
whether the expression of key growth regulatory elements previously 
identified in TAM-R cells, namely ER, EGFR and IGF-1R, had been retained 
following tamoxifen withdrawal. We also investigated how these signalling 
pathways contributed to cell growth using target specific inhibitors.
3.2.1 Oestrogen Receptor a:
Levels of ER mRNA present in MCF-7, TAM-R and TAM-Wd resistant cell 
sub-lines were compared by means of Real-Time PCR analysis. It was 
observed that in TAM-R cells, the quantity of transcribed ER was significantly 
reduced from that expressed in the parental MCF-7 cells (p<0.005). 
Importantly, tamoxifen withdrawal restored TAM-R cell ER mRNA 
expression (pO.OOl) to the level detected in the MCF-7 cells [Fig 3.5a]. 
Westem-blot and ICC analysis confirmed that this phenomenon was also 
observed at the protein level [Fig 3.5b].
Having shown that ER mRNA and protein were restored to wt-expression 
levels in the TAM-Wd cell line, concentration response analyses were 
conducted using oestradiol (E2) and tamoxifen (TAM) in order to determine 
whether cells had also regained sensitivity to E2 growth stimulation, or TAM 
induced growth inhibition. E2 was shown to be highly mitogenic to the MCF-
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7 cells since growth was significantly promoted over a concentration range of
i y 710' to 10' M (pO.OOl). In contrast, E2 was not shown to be significantly 
mitogenic to TAM-R (in the absence of tamoxifen) or TAM-Wd cells [Fig 
3.6a]. MCF-7 cells were shown to be sensitive to the growth inhibitory effect 
of TAM treatment in a dose-dependant manner. Unsurprising, the TAM-R 
cells were less sensitive to tamoxifen compared to MCF-7 cells, even at a 
concentration as high as 10'6M (pO.OOl). Interestingly, despite having been 
withdrawn from tamoxifen for 6 months, re-challenge of the TAM-Wd cells 
with the anti-hormone had no significant effect on cell growth [Fig 3.6b]. 
However, following the removal of functional ER protein, using the pure-ER 
antagonist fulvestrant (10’7M), cell growth was shown to be inhibited in MCF- 
7, TAM-R and TAM-Wd cell lines as assessed by a series of three 
independent growth assays [Fig 3.7]. Importantly however, the extent to which 
fulvestrant inhibited growth varied between cell lines. TAM-Wd cells were 
shown to be the least sensitive (TAM-Wd vs TAM-R pO.OOl, vs MCF-7 
pO.OOl) (30% growth inhibition), in comparison to TAM-R (60%) and wt 
(80%) cells (TAM-R vs MCF-7 pO.OOl) following 11 days of culture with 
the anti-oestrogen. The data implies that the significance of ER signalling as a 
contributor to breast cancer cell growth decreases following the acquisition of 
tamoxifen resistance (presumable due to the emergence of alternative growth 
pathways like EGFR/IGFR), and further decreases following the withdrawal 
of the drug.
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Fig. 3.5 ERa expression A: Real-Time PCR evaluation of ER mRNA 
concentration in MCF-7, TAM-R and TAM-Wd cells. Data shown was 
normalised to actin, hence was represented by an arbitrary unit (n=3). B: ICC 
staining and western blot for total ER in MCF-7, TAM-R and TAM-Wd cells.
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Fig 3.6 MCF-7, TAM-R and TAM-Wd cell concentration responses to E2 (A) 
and TAM (B). Cells were seeded in 24-well plates at an initial density of 
4xl04cells/well. After 24hrs, cells were treated, and cultured for a further 
7days. Cell number was assessed using Coulter Counter analysis. Data is 
shown as cell number as a percentage of the counts recorded for non-treated 
cells (n=3). (*p<0.001)
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Fig 3.7 Cell growth inhibition in response to fulvestrant: MCF-7, TAM-R, and 
TAM-Wd (6 months) cells were seeded on 24-Well Coming Co-star plates. 
Following 24hrs incubation in control media, cells were treated with 0.1 pM 
fulvestrant. Cell media was changed every 4 days. Subsequent counts were 
taken on days 4, 6, 8 and 11 using Coulter counter apparatus and the data 
shown represents the percentage cell number relative to non-treated control 
cells, as a measurement of growth inhibition (*p<0.001).
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3.2.2 EGF-R Signalling Pathway
EGF-R expression has been previously shown to be elevated in TAM-R cells 
and represents a major determinant of their growth. In order to examine 
whether this signalling pathway contributes to cell growth in tamoxifen 
withdrawn TAM-R cells, levels of EGFR mRNA were assessed by Real-Time 
PCR in the TAM-Wd cell sub-line, relative to MCF-7 and TAM-R cells [Fig 
3.8a]. Analysis confirmed that in the TAM-R cells, the quantity of EGFR 
mRNA was significantly increased from that expressed in the parental MCF-7 
cells (p=0.012) and this phenomenon was also observed at the protein level as 
assessed by ICC and western blotting [Fig 3.8b]. Interestingly, it was observed 
that in TAM-Wd cells, EGFR expression at both the mRNA and protein level 
was reduced compared to the TAM-R cells, although values remained slightly 
higher than those seen in the MCF-7 parental cell line.
Having shown that EGFR expression was greatly reduced in tamoxifen 
withdrawn TAM-R cells, dose response and anchorage dependent growth 
studies were performed to determine the extent to which EGFR-signalling 
contributed to MCF-7, TAM-R and TAM-Wd cell growth, using the EGFR- 
specific tyrosine kinase inhibitor, gefitinib.
Significantly, while the highly EGFR-positive tamoxifen resistant cells 
showed a substantial (albeit incomplete) inhibitory response to gefitinib with a 
50% growth inhibition being achieved at lpM  (p<0.001), tamoxifen 
withdrawal was associated with a reduced sensitivity to TKI. Indeed, the 
growth inhibition achieved in the tamoxifen withdrawn TAM-R cells and 
MCF-7 cells was significantly lower than in the TAM-R cells (p<0.001) [Fig
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3.9]. This observation was confirmed in growth assays in which all cell-lines 
were cultured with gefitinib at lpM  for up to 11 days, taking cell-counts at 
days 4, 6, 8 and 11 [Fig 3.10]. TAM-R cells clearly demonstrated the greatest 
sensitivity to the drug, showing a 5-fold decrease in cell number compared to 
non-treated control cells by day 8 (p<0.001). MCF-7 and TAM-Wd cells again 
demonstrated their reduced sensitivity to gefitinib compared to the TAM-R 
cells following 11 days of culture (p<0.001).
Therefore, the withdrawal of tamoxifen from TAM-R cells caused a reduction 
of the EGF-R mRNA/protein expression detectable in these cells, which 
directly correlated with their loss of sensitivity to gefitinib, however, it is clear 
that their cell growth rate was not impeded [Fig 3.2]. Interestingly, the 
withdrawal of tamoxifen was also shown to reduce the motile capacity of the 
TAM-R cells [Figs 3.3 and 3.4], though the association of this event with 
reduced EGFR expression/signalling was not investigated.
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Fig. 3.8 EGFR expression A: Real-Time PCR evaluation of EGF-R mRNA 
concentration in MCF-7, TAM-R and TAM-Wd cells. Data shown was 
normalised to actin, hence was represented by an arbitrary unit (n=3). B: ICC 
staining/western blot analysis for total EGF-R in MCF-7, TAM-R and TAM- 
Wd cells.
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Fig 3.9 Gefitinib concentration response: MCF-7, TAM-R and TAM-Wd cells 
were seeded in 24-well plates at an initial density of 4xl04cells/well. After 
24hrs, cells were treated, and cultured for a further 7days. Cell number was 
assessed using Coulter counter analysis. Data is shown as cell number as a 
percentage of the counts recorded for non-treated cells (n=3) (pO.OOl).
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Fig 3.10 Cell growth inhibition in response to gefitinib: MCF-7, TAM-R, and 
TAM-Wd (6 months) cells were seeded on 24-Well Coming Co-star plates. 
Following 24hrs incubation in control media, cells were treated with lpM 
Gefitinib. Cell media was changed every 4 days. Subsequent counts were 
taken on days 4, 6, 8 and 11 using Coulter counter apparatus and the data 
shown represents the percentage cell number relative to non-treated control 
cells, as a measurement of growth inhibition.
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3.3.3 IGF-1R Signalling Pathway
Having established that EGFR expression was reduced in tamoxifen 
withdrawn TAM-R cells in parallel with the loss of their sensitivity to gefitinib 
growth inhibition, the role of IGF-1R signalling was next examined, since 
over-activation of this pathway has previously been associated with anti­
hormone resistant cell growth [Knowlden et al, 2005]. The expression levels 
of IGF-1R mRNA present in MCF-7, TAM-R and TAM-Wd cell sub-lines 
were compared by means of Real-Time PCR analysis. It was observed that 
IGF-1R mRNA was significantly reduced in TAM-R cells compared to wt- 
MCF-7 cells (p=0.013), though levels still remained detectable. Following 
tamoxifen withdrawal, IGF-1R expression increased in the TAM-R cells 
(p=0.005) (in concurrence with the decrease in EGFR expression [Fig 3.8a]) to 
a level similar of that detected in the wt-cells [Fig 3.11a]. Westem-blot and 
ICC analysis showed that this phenomenon was also seen at the protein level 
[Fig 3.1 lb].
Significantly, whilst tamoxifen withdrawal served to reverse the down- 
regulation of IGF-1R expression in TAM-R cells, this did not translate to an 
increased dependence on this signalling pathway for the growth of these cells. 
Concentration response analysis using IGF-1R inhibitor ABDP showed that 
compared to MCF-7 cells (which have higher IGF-1R expression than TAM-R 
cells), the TAM-R cells were less sensitive to the drugs growth inhibitory 
effect at a concentration of 0.25 pM, though were similarly effected at a dose 
of 0.5pM. Despite the restoration of IGF-1R expression following tamoxifen 
withdrawal, TAM-Wd cells were less sensitive to ABDP than wt-cells at both
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concentrations (p=0.002 for 0.5 pM), inferring tamoxifen withdrawn TAM-R 
cells maybe less sensitive to IGF-1R blockade [Fig 3.12].
3.4 Summary
In total, we have observed that tamoxifen withdrawal renders TAM-R cells 
less sensitive to growth inhibition in response to ER, EGFR and IGF-1R 
inhibitors, yet the elevated rate of TAM-R cell growth remains. This leads us 
to investigate other possible mechanisms by which long-term tamoxifen 
exposure could permanently alter rate of cell proliferation. In addition to 
tamoxifen up-regulating components associated with cell growth, such as 
EGFR, tamoxifen could also permanently suppress previously oestrogen- 
responsive pro-apoptotic or tumour suppressive genes, as part of the 
mechanistic events governing the acquisition of tamoxifen resistance.
In light of this, the focus of the remaining chapters was to determine whether 
tamoxifen was capable of permanently silencing the expression of genes 
previously up-regulated by oestrogen, and whether such changes in gene 
expression could contribute to cell growth in addition to alternate growth 
factor signalling.
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Fig. 3.11 IGF-1R Expression A: Real-Time PCR evaluation of IGF-1R 
mRNA concentration in MCF-7, TAM-R and TAM-Wd cells. Data shown was 
normalised to actin, hence was represented by an arbitrary unit (n=3). B: ICC 
staining/western blot analysis for total IGF-1R in MCF-7, TAM-R and TAM- 
Wd cells.
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Fig 3.12 ABDP Concentration Response: MCF-7, TAM-R and TAM-Wd cells 
were seeded in 24-well plates at an initial density of 4xl04cells/well. After 
24hrs, cells were treated, and cultured for a further 7days. Cell number was 
assessed using Coulter counter apparatus. Data is shown as cell number as a 
percentage of the counts recorded for non-treated cells (n=3).
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4. RESULTS
The inactivation of tumour suppressor genes is central to the development of 
all common forms of cancer. This inactivation often results from epigenetic 
silencing associated with promoter hypermethylation rather than intrinsic 
mutations [Widschwendter and Jones et al, 2002]. Hypermethylation of gene 
promoters associated with tumour suppressor factors, such as p53, has been 
shown to directly contribute to carcinogenesis in a wide range of tumours and 
as such, inhibitors of DNA methylation, such as 5-Azacytidine, are being 
investigated as a potential therapeutic avenue. In human cells, the mechanisms 
underlying locus-specific or global methylation patterns remains unclear, 
however, in the present study, current data has led us to investigate the 
possibility that chronic tamoxifen exposure may serve to permanently silence 
classically regulated ER gene targets, previously associated with pro-apoptotic 
or tumour suppressive function, as a contributing factor to tamoxifen-resistant 
cell survival.
4.1 Oestrogen receptor gene targets can be silenced following chronic 
tamoxifen exposure in MCF-7 cells.
To provide proof of principle that downstream oestrogen-receptor gene targets 
could be permanently silenced following tamoxifen exposure, real-time PCR 
and ICC analyses were conducted to assess pS2 and progesterone receptor
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(PR) expression in MCF-7, TAM-R, and TAM-Wd cells, pre-and post- 
oestradiol challenge. Interestingly, although all three cell lines shared a 
similarly low basal mRNA expression, pS2 and PR were up-regulated in the 
MCF-7 cells by 4 (p=0.049) and 40-fold (p=0.032) respectively following 
oestradiol challenge; in contrast to the TAM-R and TAM-Wd cells, in which 
no significant increase in pS2 or PR mRNA was detected (Figs 4.1a and 4.2a). 
Concurrently, ICC analysis showed that pS2 and PR protein staining was 
homogenous in all cell-lines, and that expression was only elevated in MCF-7 
cells following oestradiol challenge [Fig 4.1b and 4.2b]. This infers that the 
suppression of ER activation of these genes is maintained in the absence of 
tamoxifen following long-term exposure to the drug.
To investigate promoter methylation as the mechanism of this apparent gene 
inactivation, MCF-7 and TAM-Wd cells were exposed to the de-methylating 
agent, 5-Azacytidine (5-Aza) at a concentration of lpM, which has previously 
been used by other groups to provoke an effective DNA de-methylation 
response with minimal cell cytotoxicity [Van Agthoven et al, 1994; Sadikovic 
et al, 2004], for five days prior to E2 challenge (48hrs). Real-time PCR 
analyses showed that in TAM-Wd cells treated with 5-Aza, pS2 and PR 
mRNA expression increased 4 (p=0.001) and 16 fold (p<0.001) respectively 
following oestradiol challenge, in contrast to non-5-Aza treated cells, for 
which little up-regulation of these genes were observed with E2. The 
expression of both genes was up-regulated to a similar degree in E2-treated 
MCF-7 cells (compared to non-E2 treated cells) both in the presence and 
absence of 5-Aza [Fig 4.3a and 4.4a].
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5-Aza treatment alone appeared to have little effect on basal expression of pS2 
or PR, though it had restored oestrogen responsiveness at these gene promoter 
sites in TAM-Wd cells, permitting functional protein transcription [Fig. 4.3b 
and 4.4b], in contrast to E2-alone treated TAM-Wd cells [Fig 4.1b and 4.2b]. 
As part of an international collaboration with Dr Heidi Fiegl of the Medical 
University of Innsbruck, Austria, it was confirmed that 5-Aza was achieving 
the desired effect of gene promoter de-methylation using DNA samples 
harvested from similarly treated TAM-Wd cells. The methylation status of 
ALU and SAT-2 gene repeats, whose methylated status are highly correlative 
with global DNA methylation measurements, was assessed in TAM-Wd cells 
using a quantitative Taq-man based real-time PCR system. The expression of 
methylated ALU and SAT-2 (p=0.004) detected in TAM-Wd cells cultured 
with 5-Aza was reduced compared to non-treated cells (calculated as the 
percentage of methylated reference (PMR)) [Fig 4.5]. The presence of E2- 
alone in both treatment groups had no influence on gene methylation status. 
Methylight reactions to pS2 and PR were conducted in parallel to the 
assessment of global methylation markers to confirm their methylated status in 
TAM-Wd cells. Methylated pS2 gene promoter was readily detectable in non­
treated TAM-Wd cells, in contrast to the 5-Aza (+/- E2) treated cells, in which 
expression was reduced by approximately 4 fold (p<0.001) [Fig 4.6]. PR 
proved undetectable in the Methylight system since the quantity of PR 
expressed in these cells was too low.
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Control
+ E2
Fig. 4.1 Expression of pS2: A. Real-Time PCR evaluation of pS2 mRNA 
concentration in MCF-7, TAM-R and TAM-Wd cells ± E2 at 10‘9M for 48hrs. 
Data shown represents cDNA detected normalised to actin, hence was 
represented by an arbitrary unit (n=3). B. ICC analysis of pS2 in MCF-7, 
TAM-R and TAM-Wd cells ± E2.
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Fig. 4.2 Expression of PR: A. Real-Time PCR evaluation of PR mRNA 
concentration in MCF-7, TAM-R and TAM-Wd cells ± E2 at 10'9M for 48hrs. 
Data shown represents cDNA detected normalised to actin, hence was 
represented by an arbitrary unit (n=3). B. ICC analysis of PR in MCF-7, 
TAM-R and TAM-Wd cells ± E2.
PR mRNA 
(Gene to 
Actin Ratio)
100 r 
80
p=0.Q32
□ MCF-7
□ Tam-R 
■ Tam-Wd
p=0.01
p=0.006
60
40
20
0
B
MCF-7
Control +E2
TAM-R TAM-Wd
Control
+ E2
. J 5't *#♦ t *"*
.* .** ” * .* ,4 w
i * v a v  .-ta
— 24____ :■
104
Chapter 4 Tamoxifen Silences ER-Regulated Genes
Fig. 4.3 Expression of pS2: A. Real-Time PCR evaluation of pS2 mRNA 
concentration in MCF-7 and TAM-Wd cells ± 5-Aza for 5 days ± E2 at 10’9M 
for 48hrs before cell harvest. Data shown represents percentage increase in 
pS2 cDNA detected in cells ± 5-Aza, following E2 challenge. B. ICC analysis 
of pS2 protein expression in TAM-Wd cells treated with 5-Aza ± E2.
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Fig. 4.4 Expression of PR: A. Real-Time PCR evaluation of PR mRNA 
concentration in MCF-7 and TAM-Wd cells ± 5-Aza for 5 days ± E2 at 10'9M 
for 48hrs before cell harvest. Data shown represents percentage increase in PR 
cDNA detected in cells ± 5-Aza, following E2 challenge. B. ICC analysis of 
PR protein expression in TAM-Wd cells treated with 5-Aza ± E2.
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Fig. 4.5 Promoter methylation profile for global methylation marker genes, 
SAT2 and ALU, in TAM-Wd cells: MethylLight data specific for methylated 
SAT2 (A) and ALU (B), detected in cells cultured in the presence or absence 
of 5-Aza for 5 days, ± E2 for 48hrs before cell harvest (data expressed as 
percentage of methylated reference (PMR)) (*p=0.004).
A SAT2DNA 
methylation (PMR) 
4
*1is
Con E2 5-Aza 5-Aza + E2
B
ALU DNA 
methylation (PMR) 
100
Con E2 5-Aza 5-Aza + E2
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Fig. 4.6 Promoter methylation profile for pS2 in TAM-Wd cells: Methyl Light 
data specific for methylated pS2 detected in cells cultured in the presence or 
absence of 5-Aza for 5 days, ± E2 for 48hrs before cell harvest (data expressed 
as PMR) (*p<0.001).
pS2 DNA
methylation (PMR)
Con E2 5-Aza 5-Aza + E2
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4.2 The methylation of genes following chronic tamoxifen exposure 
contributes to TAM-Wd cell proliferation.
Having demonstrated that chronic tamoxifen exposure can be associated with 
diminished oestrogen-regulated gene expression through promoter 
methylation, a potential role for this phenomenon to contribute to the 
increased capacity of the TAM-Wd cells to proliferate was assessed. To 
determine whether E2-activation of gene promoters that were demethylated in 
TAM-Wd cells in response to 5-Aza treatment could effect cell growth, it was 
first necessary to assess the effect that 5-Aza (lpM ) had on cell growth when 
used as a single agent, due to its associated cytotoxic functions. Growth curve 
analysis over a 7 day period (taking counts at days 2 and 7) showed that 5-Aza 
did not effect TAM-Wd cell growth [Fig 4.7]. Concentration response 
experiments were then carried out using TAM-Wd cells cultured in the 
absence or presence of 5-Aza at lpM  for 7 days, to determine whether the 
presence of the demethylation agent had any effect on E2 response over a 
concentration range of 10‘12M to 10’7M. Surprisingly 5-Aza facilitated the role 
reversal of E2 as a mild mitogen, to an inhibitor of TAM-Wd cell growth. The 
maximal dose of E2 was shown to cause a 50% reduction in the number 5-Aza 
treated cells detected following 7 days culture compared to non-E2 (5-Aza) 
treated cells (p<0.001). In contrast, cells cultured in the absence of 5-Aza 
showed a 40% increase in cell number with E2 at 10'7M (compared to non-E2 
non-5-Aza treated control cells) (p<0.001) [Fig 4.8]. A concentration response 
to 5-Aza (0, 0.5 and lpM) showed that the magnitude of the growth inhibitory
n
response to E2 in TAM-Wd cells (10' M) increased in correlation with 5-Aza
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concentration [Fig 4.9]. Further experiments showed that the addition of 
tamoxifen (10’7M) to TAM-Wd cells cultured with 5-Aza (lpM ) and E2, 
reversed growth suppression [Fig 4.10].
Interestingly, growth analysis of MCF-7 cells treated +/- 5-Aza and E2 over 
the same concentration range indicated that E2 was unable to inhibit the 
growth of these cells despite the presence of the demethylation agent, as 
assessed by MTT cell detection assays [Fig 4.11].
TAM-Wd cells cultured with 5-Aza, 5-Aza and either E2 or tamoxifen, or 
both, were grown for two weeks, taking cell counts at days 4, 7, 10 and 14 to 
determine the extent of the growth inhibition achieved by activating de- 
methylated oestrogen responsive genes. Following the two week culture 
period, the number of cells treated with 5-Aza and E2 had fallen to 
approximately 60% of the cell seeding density (4xl04). Although cell counts 
appear to drop for 5-Aza and 5-Aza/E2/Tam treated cells after day 10 of 
culture (perhaps due to the initiation of cytotoxic events), cell populations 
remain significantly greater than the numbers recorded for 5-Aza + E2 treated 
cells at day 14 [Fig 4.12].
In total, these data provide evidence to suggest that a proportion of the genes 
silenced by promoter methylation as a consequence of pro-longed tamoxifen 
exposure are associated with a tumour-suppressive and/or pro-apoptotic 
function, and that demethylation and activation of such genes (using 5-Aza 
and E2 respectively) can induce tamoxifen-resistant cell growth inhibition.
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Fig 4.7 Anchorage dependent growth assay: TAM-Wd cells were seeded at a 
density of lx l0 4 cells/ well in 24-well plates. After 24hrs, cells were treated 
+/- 5-Aza (day 0), and cultured for a further 7days. Cell number was assessed 
using Coulter counter analysis. The data shown represents actual cell 
number/well recorded over 3 independent experiments.
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Fig. 4.8 Concentration response to oestradiol: TAM-Wd cells were seeded in 
24-well plates at an initial density of 4xl04cells/well. After 24hrs, cells were 
treated ± 5-Aza and E2 at a concentration ranging from 10'12M to 10'7M. Cell 
number was assessed on day 7 of culture using Coulter counter analysis. Data 
shown represents E2-treated cell counts as a percentage of count recorded for 
non-E2 treated control cells ± 5-Aza (Significantly different to control 
(100%); *p<0.001, +p=0.002, °p=0.017).
Cell Number
(% of control)
10-12M 10-11M 10-10M 10-9M 10-8M 10-7M
[E2]
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Fig. 4.9 Concentration response to 5-Aza: Tam-Wd cells were seeded in 24- 
well plates at an initial density of 4xl04cells/well. After 24hrs, cells were 
treated ± E2 (10'7M) and 5-Aza at a concentration of 0, 0.5 or lpM. Cell 
number was assessed on day 7 of cell culture using Coulter counter analysis. 
The data shown represents actual cell number/well recorded over 3 
independent experiments.
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Fig. 4.10 Concentration response to oestradiol in 5-Aza treated TAM-Wd cells 
in the presence and absence of tamoxifen: TAM-Wd cells were seeded in 24- 
well plates at an initial density of 4xl04cells/well. After 24hrs, cells were 
treated with 5-Aza +/- tamoxifen and E2 at a concentration ranging from 10' 
12M to 10'7M. Cell number was assessed on day 7 of culture using Coulter 
counter analysis. Data shown represents E2-treated cell counts as a percentage 
of counts recorded for non-E2 treated control cells. (Significantly different to 
control (100%); *p<0.001, +p=0.002, °p=0.026).
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Fig 4.11 MCF-7 cell concentration response to oestradiol: MCF-7 cells were 
treated ± 5-Aza and E2 at a concentration ranging from 10'12M to 10*?M. Cell 
number was assessed on day 7 by MTT cell detection assay (n=3). Data shown 
represents E2-treated cell counts as a percentage of counts recorded for non- 
E2 treated control cells.
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Fig. 4.12 TAM-Wd cell growth response to E2 +/- tamoxifen in the presence 
of 5-Aza: TAM-Wd cells were seeded on 24-well plates at a density of 
4xl04cells/well. Following 24hrs incubation in control media, cells were 
treated with 5-Aza, 5-Aza + E2 or 5-Aza + E2 + TAM. Cell media was 
changed every 4 days. Subsequent cell counts were taken on days 4, 7, 10 and 
14 using Coulter counter apparatus. The data shown represents actual cell 
number/well recorded over 3 independent experiments (*p<0.001).
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5. RESULTS
5.1 Identification of potential tumour-suppressor genes silenced in 
tamoxifen withdrawn TAM-R cells using an Affymetrix gene array 
approach.
Having demonstrated that the combination of 5-Aza and E2 causes TAM-Wd 
cells to proliferate at a slower rate than 5-Aza-treated (or E2 treated) controls 
and furthermore cause cell loss over a 14 day period, we sought to identify 
genes that were being up-regulated specifically by E2 challenge in the 
presence of the demethylation agent which could be associated with this 
growth suppressive phenomenon. According to the hypothesis, these genes 
would have to be readily up-regulated by E2 in the parental MCF-7 cells, not 
up-regulated or expressed below basal level following initial (10 day) TAM 
challenge, and have a comparable or ideally reduced basal expression in the 
TAM-R cell sub-type, in a similar fashion for that shown for pS2 and PR. 
Genes would also have to be shown to be free from EGFR-regulation, i.e. 
expression should not be reversible with EGFR inhibition, to confirm that 
gene suppression was independent from EGFR signalling input.
Using an existing Affymetrix database (HG-U133A platform) available to 
Tenovus, previously created from triplicate samples of MCF-7 cells treated to 
reflect the transition from anti-hormone responsive to cells with acquired
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resistance (in this instance tamoxifen) we were able to create a gene shortlist. 
A pattern navigation analysis was conducted using online Genesifter™ 
software to reveal genes that were up-regulated by E2 and suppressed by TAM 
in wt-MCF-7 cells, and also down-regulated in TAM-R cells relative to wt- 
MCF-7 (ie, wt=l, wt + E2 >2, wt + TAM <1 and TAM-R <1 with regards to 
fold-change relative to wt-cell gene expression), at a statistical cut off of 
p<0.001 using ANOVA. This analysis produced a list of 51 gene probes, 
although probes called ‘absent’ in the wt-MCF-7 cells were subsequently 
withdrawn from the list, leaving 33 potential gene probe candidates [Fig 5.1].
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Fig 5.1 Genesifter™ pattern navigation analysis: Identification of probes that 
were up-regulated by E2 and suppressed by TAM in wt-MCF-7 cells, and 
down-regulated in TAM-R cells relative to wt-MCF-7 (wt=l, wt + E2 >2, wt 
+ TAM <1 and TAM-R <1 (p<0.001). This analysis produced a list of 51 
probes, 33 of which were called ‘present’ in the wt-MCF-7 cells. ‘Absent’ 
called were discarded (gene names highlighted in grey). Data is represented by 
profile heatmaps, where green indicates gene suppression (-2) and red 
indicates up-regulation (+2) relative to wt-expression (black).
-2 +2
Gene Identifier Gene Title
1 AF061812 Keratin 16
2 NM_005978 SI 00 calcium-binding protein A2
3 NM_003881 WNT1 inducible signaling pathw ay protein 2
4 AI935123 AHNAK nucleoprotein 2
5 ABO 17493 Core promoter element binding protein
6 AF133207 Protein kinase H 11
7 BE675435 Kruppel-like factor 6
8 NM _006334 Olfactomedin 1
9 AF207990 Fer-1 (C.elegans)-like 3 (myoferlin)
10 U90304 Iroquois hom eoboxprotein 5
11 NM_030941 Exonuclease NEF-sp
12 AI812030 Throm bospondin 1
13 BC003629 RNA, U2 small nuclear
14 AF064771 Diacylglycerol kinase, alpha (80kD)
15 U26744 Dystrobrevin, alpha
16 NM _017459 M icrofibrillar-associated protein 2
17 NM _015675 Growth arrest and DNA-dam age-inducible, beta
18 NM _013451 Fer-1 (C.elegans)-like 3 (myoferlin)
19 U19495 Stromal cell-derived factor 1
20 NM_020672 SI 00-type calcium binding protein A 14
21 NM _014400 GPI-anchored m etastasis-associated protein homolog
22 AI826799 EGF-containingfibulin-like extracellular matrix protein 1
23 NM_012101 Tripartite m otif-containing29
24 AK000300 ATPase, C a++transporting, cardiac muscle, slow tw itch 2
25 AB002301 Microtubule associated serme/threonke kinase family member 4
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Fig 5.1 (Continued)
-2 +2
Gene Identifier Gene Title
26 NM_006 456 Sialyltransferase
27 BE972774 Unc-84 hom olog A (C. elegans)
28 ABO 11092 Adenylate cyclase 9
29 NM_006332 Interferon, gamma-inducible protein 30
30 U90339 Adenosine kinase
31 AI923984 Small pro line-rich protein 1A
32 AF280094 Interferon- indue e d protein 41, 30 kD
33 BE222901 Calmodulin regulated spectrin-associated protein 1
34 N M JJ21796 Placenta-specific 1
35 N3 6 408 FOS-like antigen 2
36 L42612 Keratin 6B
37 AI796169 GAT A binding protein 3
38 NM_004360 Cadherin 1, type 1, E-cadherin (epithelial)
39 AF131833 Family with sequence similarity 5, member B
40 B F 110421 Multiple EGF-like-do mains 9
41 A V 712733 Filamin B, beta (actin binding protein 278)
42 NM_017763 Ring finger protein 43
43 BF247371 CDNA clone IMAGE:4181418
44 NM _013440 Paired immunoglobulin-like receptor beta
45 NM_000602 Serpin peptidase inhibitor, clade E (nexin,
plasminogen activator inhibitor type 1), member 1
46 R38389 Olfactomedin 1
47 NM_003246 Thrombospondin 1
48 NM_000299 Plakoplulm 1 (ectodennal dyspksia/skin fragility syrdrome)
49 NM_004030 Interferon regulatory factor 7
50 NM_016337 RNB6
51 NM_024071 Zinc finger, FYVE dom ain contain ing21
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In addition, a global sweep of the Affymetrix database was carried out in order 
to identify any potential targets which had been overlooked due to the 
statistical stringency of the pattern navigation analysis. To do this, genes 
whose expression were significantly altered with 10-day E2 challenge versus 
wt-MCF-7 (p<0.05) were first selected using a T-test (n= 4376 probes). Only 
E2 induced genes were then selected from the list using the same selection 
process (n= 1691 probes). Heatmaps for these probes were then manually 
inspected and genes whose expression were not further induced or fell in 
TAM-R versus wt-MCF-7 cells were selected (n=202 probes). These probes 
were further filtered to select genes with a reported association with 
growth/proliferation, cell survival/cell death/apoptosis or transcriptional 
regulation using the “ontology” function available in Genesifter. A more 
detailed ontological selection was then carried out for probes specifically with 
any reported evidence of negative ontology (e.g. pro-apoptosis/cell cycle 
inhibitor, transcriptional silencing, co-repressor) or reported to be subject to 
hyper-methylation in any disease state using online Medline software (n=75 
probes). This list of 75 probes was fed into the previously-described pattern 
navigation with no statistical parameters applied, and heatmaps were then 
manually selected for those probes not showing any up-regulation in TAM 
treated-MCF-7 versus wt-MCF-7 cells (but E2 regulation and also minimal 
expression in TAM-R cells). This left 18 probes, 8 of which were called 
present in MCF-7s [Fig 5.2]. Seven of these 8 probes had not been identified 
using the pattern navigation analysis.
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Heat-maps were then generated for the list of 33 probes obtained by pattern 
navigation and the 7 additional probes from the broad sweep (40 probes in 
total) to analyse how their expression changed following gefitinib challenge in 
TAM-R cells. Genes showing any indication of recovery of expression in 
TAM-R + gefitinib versus TAM-R cells were discarded leaving 25 probes (24 
genes) [Fig 5.3].
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Fig 5.2 Heatmap expression profile for the 75 gene probes selected from the 
broad Affymetrix database analysis, in wt, wt + E2, wt + TAM and TAM-R 
cells (with no statistical stringency). Probe profiles were manually selected to 
identify probes that showed no up-regulation in response to TAM in wt cells, 
and that were called ‘present’ in wt-cells (high-lighted in green n=8 probes). 
Probes that were not up-regulated by TAM, but were called absent in wt-cells 
are high-lighted in grey (n=10).
-2 +2
H Gene Identifier Gene Title
i NM_002307 Lectin, galactoside-binding, soluble, 7 (galectin7)
2 AI824012 Nuclear receptor interacting protein 1
3 NM_006850 Interleukin 24
4 NMJ003489 Nuclear receptor interacting protein 1
HH 5 AW043713 Sulfatase 1
6 NM_016567 BRCA2 and CD KN1 A-inter acting protein
H I 7 NM_002894 Retinoblastoma-binding protein 8
8 NM_025180 Centrosomal protein of 63 kDa
9 NM_005815 Kruppel-type zinc finger (C2H2)
H I 10 NM_004430 Early growth response 3
11 NM_018976 Amino acid transporter 2
12 NM_018573 Solute carrier family 38, member 2
13 NM_016265 GIOT-3 for gonadotropin inducible transcription repressor-3
■ ■ 14 NMJD14720 Ste20-related serine/threonine kinase
■ ■ 15 NM_005885 M embrane- as s o ciate d ring finger (C 3 HC 4) 6
16 NM_014034 ASF1 anti-silencing function 1 homolog A
17 AWD43713 Sulfatase 1
H I 18 BE748755 Chro moboxhomolog3
19 AL132665 BCL2/adenovirus E1B 19 kD-interacting protein 3-like
20 ABO02306 Chro mo domain helic as e DNA binding protein 9
H I 21 NM_014035 Sorting nexin 24
h h 22 NM_002639 Serpin peptidase inhibitor, clade B (ovalbumin), member 5
H I 23 AI967961 Tripartite motif-containing 33
■ ■ 24 NM_006135 Capping protein (actin filament) muscle 2-line, alpha 1
H I 25 NM_001123 Adenosine kinase
26 NM_003358 UDP-glucose ceramide glucosyltransferase
WM 27 NM_016587 Chro mob ox homolog 3 (Drosophila HP 1 gamma)
■ n 28 D28586 CD58 antigen, (lymphocyte function-associated antigen!)
29 HM_005433 V-yes-1 Yamaguchi sarcoma viral oncogene homolog 1
30 NM_024612 DEAH (Asp-Glu-Ala-His) box polypeptide 40
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Fig. 5.2 (Continued)
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Gene Identifier Gene Titlemm 31 NM_017927 Mitofusin 1
H H H I 32 NMJ014415 Zinc finger protein
33 AW612574 Acidic (leucine-rich) nuclear phosphoprotein 32 family, member E
34 NM_004972 Janus kinase 2 (a protein tyrosine kinase)
35 NM_005802 Tumor protein p53-binding protein
36 NM_014899 Rho-relatedBTB domaincontaining3
37 NMJ06472 Thioredoxin interacting protein
38 AF208012 Tumor protein D 5 2-like 1
39 AU160695 BUB3 budding uninhibited by benzimidazoles 3 homolog
40 AL080111 NIMA (never in mitosis gene a)-related kinase 7
41 NMJJ04052 BCL2/adenovirus El B 19kD-interacting protein 3
42 NM_022133 Sorting nexin 16
43 Y09703 Pinirt, desmosome associated protein, some similarity to MDR protein
44 NM_012311 Antigenic determinant of recA protein (mouse) homolog
45 NM_015515 Type I intermediate filament cytokeratin
46 NM_000314 Phosphatase and tens in homolog (mutated in multiple advanced cancers 1)mm 47 NM_002956 Restin (Reed-Steinberg cell-expressed intermediate filament-associated protein
I f lH H il 48 BG253119 Dystonin
i 49 NMJD00321 Retinoblastoma 1 (including osteosarcoma)
50 BC000278 Carbonic anhydrase XII
IH H H H 51 NMJ24948 Chromosome 10 open reading frame 97
52 AI913365 Methyl-CpG binding domain protein 4
53 U83410 Cullin2
54 AF003934 Prostate differentiation factor
55 NM 000700 AnnexinAl
56 NM_016626 Mex-3homologC (C. elegans)
57 AF051851 Supervillin
58 NMJ04415 Desmoplakin (DPI, DPII)
59 NM_001909 Cathepsin D (lysosomal aspartyl protease)
60 AI084226 Fas apoptotic inhibitory molecule 3
61 NM_012101 Tripartite motif-containing 29
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Fig 5.2 (Continued)
Gene Identifier Gene Title
62 AW170602 Regulator of G-protem signaling 12
63 NM_002031 Fyn-related kinase (or RAK)
64 NM_004848 Basement membrane-induced gene
65 NM_022131 Calsyntenin-2
66 ABO 50468 Ortholog of mouse integral membrane glycoprotein LIG-1
67 BF514079 Kruppel-like factor 4 (gut)
68 NM_014890 Downregulated in ovarian cancer 1
69 NM_000165 Gap junction protein, alpha 1, 43kD (connexin 43)
70 NM_001562 Interleukin IS (interferon-gamma-inducing fact or)
71 AWD43713 Sulfatase 1
72 NM_006456 Sialyltransferase
73 NM_001218 Carbonic anhydrase XII
74 BC001012 Carbonic anhydrase XII
75 AI378979 Plakophilin 1
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Fig 5.3 Heatmap expression profiles for the 33 probes obtained by pattern 
navigation and the 7 additional probes from the broad sweep in wt, TAM-R 
and TAM-R cells + gefitinib (with no statistical stringency). Probe profiles 
were manually selected to identify probes that showed no up-regulation of 
expression in TAM-R cells treated with gefitinib (vs non-treated cells). Probes 
that were up-regulated by gefitinib were discarded (high-lighted in grey n=15).
oI
P-lO
2 Gene Identifier Gene Title
NM_005978 SI 00 calcium-binding protein A2
NM_003881 WNT1 inducible signaling pathway protein 2
AB017493 Core promoter element binding protein
AF133207 Proteinkinase H ll
B E67 5 435 Krupp el- like factor 6
AF207990 Fer-1 (C.elegans)-like 3 (myoferlin)
U90304 Iroquois homeobox protein 5
AI812 03 0 Thrombospondin 1
AF06 4771 Diacylglyc erol kinas e, alpha (8 OkD)
NM_015675 Growth arrest and DNA-damage -inducible, beta
NM_013 451 F er-1 (C. e le gans)-like 3 (myofe rlin)
U19495 Stromal cell-derived factor 1
NM_020672 SI 00-type calcium binding protein A14
NM_014400 GPI-anchored metastasis-associated protein homolog
AI826799 EOF-containing fibulin-like extracellular matrix protein 1
NM_012101 Tripartite motif-containing29
AK000300 ATP as e, Ca++ transporting, cardiac muscle, slow twitch 2
BE972774 Unc-84 homolog A (C. elegans)
ABO 11092 Adenylate cyclase 9
NM_006332 Interferon, gamma-inducible protein 30
U90339 Adenosine kinase
AF280094 Interferon-induced protein 41, 30kD
BE222901 Calmodulin regulated spectrin-associated protein 1
NM_02179 6 Plac enta- sp e cific 1
N3 6 408 FOS-like antigen 2
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Fig 5.3 (Continued)
+ Gene Identifier Gene Title
AI796169 GAT A b inding protein 3
NM_004360 Cadherin 1, type 1, E-cadhetin (epithelial)
BF 110421 Multiple EOF-like-do mains 9
AV712733 FilaminB, beta (actinbinding protein 27S)
BF247371 CDNA clone 1MAGE:4181418
NM_003246 Thrombospondin 1
NM_016337 RNB6
AF003934 Prostate differentiation factor
NM_000700 Annexin A 1
NM_001909 Cathepsin D (lysosomal aspartyl protease)
BF.314079 Kruppel-like factor 4 (gut)
NM_014890 Dowmegulatedin ovarian cancer 1
NM_000165 Gap junction protein, alpha 1, 43kD (connexin43)
NM_006436 Sialyltransferas e
NM_001218 Carbonic anhydrase XII
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In parallel to this study, another Affymetrix database was created later in this 
project using triplicate TAM-Wd cell mRNA samples, reverse transcribed and 
hybridised to a HG-U133A2 platform. TAM-Wd cells were treated with 5- 
Aza, E2, 5-Aza + E2 or 5-Aza + E2 in combination with TAM (versus non­
treated cells) for six days. The 25 probes (24 genes) identified from the first 
Affymetrix database were profiled within the new data set [Fig 5.4]. Out of the 
24 genes, 8 were shown to follow the expected expression profile in relation to 
the tumour-suppressor hypothesis, i.e. highest expression in 5-Aza + E2 
treated TAM-Wd cells, reversible with the co-addition of TAM. All of these 
genes (namely myoferlin, diacylglycerol kinase-a, unc-84 homolog A, 
interferon gamma-inducible protein 30, FOS-like-antigen 2, prostate 
differentiation factor, cathepsin-D and carbonic anhydrase XII) were taken 
forward as high-priority candidates.
In addition, a broad sweep of the second array database was then conducted in 
order to identify genes matching the desired profile, which could then be 
subsequently analysed to determine their status in MCF-7 cells treated with E2 
and TAM and TAM-R cells, ensuring all genes with a strong trend toward the 
required profile were taken forward for consideration for PCR analysis. The 
project was filtered for all gene probes significantly induced in TAM-Wd cells 
challenged with 5-Aza + E2 versus non-treated TAM-Wd cells (n=744 probes, 
p<0.05). Genes were further filtered by selecting probes whose expression 
were further induced with E2 + 5-Aza versus 5-Aza alone (n=240 probes), and 
subsequently, those genes whose re-expression could be reversed with TAM 
challenge (n=159) by manually selecting heatmaps. This 159 probe set was
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visualised in the first Affymetrix data set to identify the genes that showed a 
degree of suppression in TAM-R cells versus wt-MCF-7 (n=108 probes). Of 
these 108 probes, 43 probes (34 genes) were found to be regulated by E2 in 
MCF-7 cells [Fig 5.5]. On inspection it was observed that there was a degree 
of overlap between the 8 genes selected from the first method of analysis, and 
the 34 identified from the second, with 5 genes being present in both lists. 
Using a multi-layered points system produced in collaboration with Dr Julia 
Gee, the 37 genes were scored and filtered according to the classifications 
summarised in table 5.1. Total scores at this stage ranged from 2.5-12, out of a 
possible 13. Genes scoring 8 or higher, of which there were 13, were taken 
forward to a second scoring system based on information from screening the 
genes in the Oncomine online database. Genes were awarded scores for 
evidence of down-regulation in normal vs cancer (+1), relation to clinical 
profile and good prognosis (+1), evidence of E2 induction in-vitro and anti­
hormone suppression (+1) -  i.e. on a 0-3 scale. Total overall scores for the 13 
selected genes ranged from 9-13 (table 5.2).
The 8 highest scoring genes were selected for their confirmation of expression 
profile by semi-quantitative PCR and promoter methylation status by 
methylight assay. The final list of 8 genes consisted of 2 identified in both 
rounds gene of selection, prostate differentiation factor (GDF15) and carbonic 
anhydrase XII (CA12), and 6 from the second round of gene selection 
adenylate cyclase-9 (ADCY9), Kazrin (KIAA1026), haemoglobin alpha-2 
(HBA2), RAS-protein activator-like-1 (RASAL-1), collagen type VI alpha3 
(Col6a3) and response gene to complement-32 protein (RGC32).
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Fig 5.4 Heatmap expression profiles for the 25 probes identified from the first 
Affymetrix database in the TAM-Wd cells, + E2, +5-Aza, +5-Aza +E2 and + 
5-Aza +E2 + TAM (with no statistical stringency). Probe profiles were 
manually selected to identify probes that were most highly up-regulated by 5- 
Aza + E2 and down-regulated with TAM co-treatment (high-lighted in green 
n=9).
-2 +2
Gene Identifier
1 NM_005978
2 NM_003881
3 ABO 17493
4 AF133207
5 BE675435
6 AF20799
7 AF064771
8 NM_013451
9 NM_020672
10 NM_014400
11 NM_012101
12 AK000300
13 BE972774
14 ABO 11092
15 NM_006332
16 NM_021796
17 N3 6408
18 NM_016337
19 AF003934
20 NM_000700
21 NM_001909
22 BF514079
23 NM_000165
24 NM_006456
25 NM 001218
Gene Title
S 100 c ale ium-b inding protein A2
WNT1 inducible signaling pathway protein 2
Core promoter element binding protein
Protein kinase H ll
Kruppel-like factor 6
Fer-1 (C.elegans)-ike 3 (myoferf-h)
Diacylgjycerol kinase, alpha (SOkD)
Fer-i (C.elegans>Eke 3 (myoferlin)
SI 00-type calcium binding protein A14
GPI-anchored metastasis-associated protein homolog
Tripartite motif-containing 29
ATP ase, Ca++transporting, cardiac muscle, slowtwitch2 
Unc-34 homolog A (C. elegans)
Adenylate cyclase 9
Interferon, gamma-inducible protein 30
Placenta-specific 1
FOS-like antigen 2
RNB6
Prostate differentiation factor
Annexin A 1
CathepsiriD (lysosomal asp artyl protease)
Kruppel-like factor 4 (gut)
Gap junction protein, alpha 1, 43kD (connexin43) 
Sialyltransferas e 
Carbonic anhydrase XII
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Fig 5.5 Heatmap expression profiles for the 43 probes identified as being most 
highly expressed in the 5-Aza + E2 treated TAM-Wd cells, and down- 
regulated with TAM co-treatment from a broad sweep o f the second 
Affymetrix database (shown on left o f gene list). Probes were also profiled in 
MCF-7 cell +/- E2, and TAM-R cells (heatmaps on right o f gene list) to 
provide evidence o f E2 regulation in wt-cells. Genes that were also identified 
from previous rounds o f analysis are highlighted in yellow.
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Gene Identifier
NM_005253
23 BC000529
24 NM _000558
25 AF105974
26 AF349571
27 T50399
28 V00 489
29 BC005931
30 NM _006332
31 NM_001555
32 ABO28949
33 NM _015715
34 M 60411
35 AWD58148
36 NM _004658
37 N M _014059
38 NM_003051
39 AL162079
40 NM_Q03236
41 NM _024164
42 D87292
43 AL049370
Gene Title
FOS-like antigen 2 
Prostate differentiation factor 
Haemoglobin, alpha 2 
Haemoglobin, alpha 2 
Haemoglobin, alpha 2 
Haemoglobin, alpha 2 
Haemoglobin, a lp h a2 
Haemoglobin, alpha 2 
Interferon, gam ma-inducible protein 30 
Im m unoglobulin superfamily, m em ber 1 
Kazrin
Phospholipase A2, group III 
Phospholam ban
Recom bination activating gene 2 
RAS protein activator like 1 (GAP 1 like) 
RGC32 protein
Solute carrier fam ily 16, mem ber 1 
Solute carrier fam ily 16, m em ber 1 
Transform ing growth factor, alpha 
Tryptase beta 2
Thio sulfate sulfurtransferase (rhodanese) 
Unc-5 hom ologB  (C. elegans)
3era*
In
Oo3
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Table 5.1. Classifications for gene scoring system.
Classification Scoring
E2 induced in MCF-7 and E2/AZA induced 
in TAM-Wd cells +1 Yes, 0 No
Anti-hormone suppressed in MCF-7 cells
+ 1 Yes 
+ 0.5 Conflicting probes 
ONo
Scored according to Literature Ontology (i.e. 
tumour suppressive/growth inhibitory 
ontology).
No, possibly, yes, strongly 
yes - score 0-3
Replicate probe profile
-1 if conflicting, +1 if profile 
adequate, 2 if profile good
TKI regulation
-1 Up-regulated, +1 
Unaffected or down-regulated
TAM-R heatmap colour vs MCF-7 for all 
probes
+2 Green, +1 Black, 0 mixed 
including Red
Present (p), marginal (m) or absent (a) call 
over MCF-7 E2, TAMR, Tam-Wd, Tam- 
Wd+E2+5aza groups.
+1 pppp or aaaa or mmmm or 
aapp or aamm or mmpp (poor 
call profile);
+2 papp or mapp or pamm or 
pmpp (adequate call profile); 
+3 mamp or paap or aaap or 
aaam or maap (good call 
profile)
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Table 5.2 Total scores awarded to the list of 37 genes identified by Affymetrix 
analysis, following first and second round classifications. Genes scoring 8 or 
more points in the first round were carried over to the second round and are 
high-lighted in the table below (n=13) (green: highest 8 scoring genes carried 
forward for PCR analysis (n=8), blue: remaining 7 genes scoring 8 or over that 
were not selected for PCR.)
Gene Title 1st Round 2nd Round Total
Score Score
M itogen-activated protein kinase kinase kinase 2 4 -
Adenylate cyclase 1 (brain) 3.5 -
A denylate cyclase 9 9 3
Adenosine A2b receptor 7
Artemin 7 -
ATP as e, Ca++ transporting, plasma membrane 4 7 -
Carbonic anhydrase XII 10 8
Cathepsin D (lysosomal aspartyl protease) 7
Cero id-lip ofuscino sis, neuronal 6, late infantile, variant 5.5 -
Human BRCA2 region, mRNA sequence CG030. 7 -
CCR4-NOT transcription complex, subunit 8 2.5 -
Collagen, type VI, alpha 1 4 -
C o l l a g e n .^ M i a B a B ^ I > ^  M M  H 1 |  1 8 3 m m :..
Cytochrome P450, family 1, subfamily B, polypeptide 1 7 -
Diacylglycerol kinase, alpha (80kD) 6 -
Dual specificity phosphatase 7 4 -
Epidermal growth factor receptor substrate EPS15R 7 -
Epiregulin 8 1 9
Fer-l-like 3, m yoferlin(C . elegans) 6 -
Filamin B, beta (actin binding protein 278) 3 -
FOS-like antigen 2 7
1 n
-
Prostate diireientiatiun fa tte r  stMHIiBHHiUiaaaaBaaaoriBtfmHmHHmmOUnUi 1U
in
11
naeruogiooin, axpna^ ru
Interferon, gamma-inducible protein 30 9 0 9
Immunoglobulin superfamily, member 1 9 1 10
I l i i l l M M M f f l M i l M M M M o 3 11
Phospholipase A2, group III 7
Phospholamban 2.5 -
Recombination activating gene 2 9 1 10
RAS protein activator like 1 (GAP! Eke) 12 0 H H  i
m— BBHMHwawBBiggaKflttaaatigagiaHflHHgHBaggagiiiiiiirniiiiiiiiiiiiiiiiiiiiiniiniin 8 3 l i
Solute carrier family 16, member 1 7
Transforming growth factor, alpha 5 -
Tryptase beta 2 3 -
Thiosulfate sulfurtransferase (rhodanese) 7 -
Unc-5 hom ologB (C. elegans) S 1 9
Unc-84 hom olog A (C. elegans) 7 -
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5.2 Semi-Quantitative PCR for 8 candidate genes.
Triplicate samples of mRNA obtained from TAM-Wd cells treated with E2, 5- 
Aza, E2 and 5-Aza and E2 5-Aza and TAM were reversed transcribed and 
amplified using primers designed to the candidate gene fragment expressed on 
the HG-U133A Affymetrix array platform in a semi-quantitative PCR. 
Corresponding DNA extractions were sent to Dr Heidi Fiegl of the University 
of Innsbruck for Methylight analysis.
Of the 8 genes, the expression profile of 4 was shown to correlate with the 
corresponding array profile, as assessed by semi-quantitative PCR and 
densitometry. GDF-15, RGC-32, HBA2 and CA12 were all most highly 
expressed in TAM-Wd cells treated with E2 and 5-Aza, and were down- 
regulated with the co-addition of TAM [Fig 5.6b to 5.9b]. Methylight 
reactions performed for GDF-15 and HBA-2 showed a significant reduction in 
methylated gene promoter detected in TAM-Wd cells cultured with 5-Aza (± 
E2) compared to non-treated and E2 treated cells. Furthermore, the addition of 
TAM to 5-Aza + E2 cultured cells appeared to partially restore the methylated 
status of GDF-15, and to a less significant extent, HBA2 [Fig 5.6c and 5.8c]. 
Methylight assays showed that no methylated CA12 promoter was detected in 
TAM-Wd cell DNA, and signals for RGC-32 were too weak for accurate 
detection.
The PCR profile recorded for RASAL-1 and Col6a3 exhibited little 
resemblance to the array profile, both showing highest expression in cells co­
treated with E2, 5-Aza and TAM [Fig 5.10b and 5.11b]. The PCR profile for
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ADCY9 and Kazrin also did not match the corresponding array profile, as 
both genes were partially up-regulated by E2 (+/- 5-Aza) compared with non­
treated cells. Contrary to the array data, the highest expression of both genes 
was again observed in the E2, 5-Aza and TAM co-treated cells [Figs 5.12b 
and 5.13b].
Methylight reactions for ADCY9 showed no promoter methylation was 
detected in the DNA samples and signals for Kazrin were too weak for 
accurate readings. Reactions were not carried out for RASAL-1 and Col6a3.
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Fig 5.6 Prostate Differentiation Factor -  GDF-15: A Heatmap profile and gene 
probe box-plot from the Affymetrix database, to assess GDF-15 expression in 
TAM-Wd, +E2, + 5-Aza, + 5-Aza, +5-Aza + E2 and +5-Aza + E2 + TAM 
treated cells. B: PCR validation of array profile and corresponding 
densitometry data (n=3).
-2 +2
Intensity
-T -
T : i_L J
TAM-Wd +E 2 + 5-Aza + 5-Aza +E2 + 5-Aza+E2
+TAM
B
TAM-Wd + E2 + 5-Aza
+ 5-Aza 
+E2
+ 5-Aza 
+E2 
+TAM
GDF-15 -
(3 Actin -
35
300
|  25
-  20 c
1  15
T°
5
536 bp
208 bp
i i ■ I i
TAM-Wd +E2 + 5-Aza + 5-Aza + 5-Aza
+ET +'E2
+TAM
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Fig 5.6 C: Promoter methylation profile for GDF-15 in TAM-Wd cells: 
Methylight data specific for methylated GDF-15 promoter detected in TAM- 
Wd, +E2, + 5-Aza, + 5-Aza, +5-Aza + E2 and +5-Aza + E2 + TAM 5-Aza 
(data expressed as PMR).
GDF-15 DNA
methylation (PMR)
5.0
4.5
4.0
3.5
3.0
2.5
2.0
1.5 
1.0 
0.5 
0.0
X
TAM-W d
p=0.048
p=0.001
p=0.0Q2
I
+ E2 + 5-Aza + 5-Aza +E2 + 5-Aza +E2
+TAM
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Fig 5.7 Response gene to complement 32 protein - RGC32. A: Heatmap 
profile and gene probe box-plot from the Affymetrix database, to assess RGC- 
32 expression in TAM-Wd, +E2, + 5-Aza, + 5-Aza, +5-Aza + E2 and +5-Aza 
+ E2 + TAM treated cells. B: PCR validation of array profile and 
corresponding densitometry data (n=3).
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Fig 5.8 Haemoglobin alpha 2 - HBA2 A: Heatmap profile and gene probe 
box-plot from the Affymetrix database, to assess HBA2 expression in TAM- 
Wd, +E2, + 5-Aza, + 5-Aza, +5-Aza + E2 and +5-Aza + E2 + TAM treated 
cells. B: PCR validation of array profile and corresponding densitometry data 
(n=3).
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Intensity
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0 -
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Fig 5.8 C: Promoter methylation profile for HBA2 in TAM-Wd cells: 
Methylight data specific for methylated HBA2 promoter detected in TAM-Wd 
cells, +E2, + 5-Aza, + 5-Aza, +5-Aza + E2 and +5-Aza + E2 + TAM 5-Aza 
(data expressed as PMR (*p<0.001).
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>00
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Fig 5.9 Carbonic Anhydrase XII -  CA12 A: Heatmap profile and gene probe 
box-plot from the Affymetrix database, to assess CA12 expression in TAM- 
Wd, +E2, + 5-Aza, + 5-Aza, +5-Aza + E2 and +5-Aza + E2 + TAM treated 
cells. B: PCR validation of array profile and corresponding densitometry data 
(n=3).
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3
2
0
+ 5-Aza + 5-Aza +E2 + 5-Aza +E2TAM-W d + E2
+TAM
+ 5-Aza 
+E2 
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CAX11
TAM-Wd +E2 + 5-Aza + 5-Aza + 5-Aza
+E2 +E2
+TAM
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Fig 5.10 RAS-protein Activator Like 1- RASAL-1 A: Heatmap profile and 
gene probe box-plot from the Affymetrix database, to assess RASAL-1 
expression in TAM-Wd, +E2, + 5-Aza, + 5-Aza, +5-Aza + E2 and +5-Aza + 
E2 + TAM treated cells. B: PCR validation of array profile and corresponding 
densitometry data (n=3).
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Fig 5.11 Collagen type VI alpha 3 - COL6a3 A: Heatmap profile and gene 
probe box-plot from the Affymetrix database, to assess Col6a3 expression in 
TAM-Wd, +E2, + 5-Aza, + 5-Aza, +5-Aza + E2 and +5-Aza + E2 + TAM 
treated cells. B: PCR validation of array profile and corresponding 
densitometry data (n=3).
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Fig 5.12 Adenylate Cyclase 9 - ADCY 9 A: Heatmap profile and gene probe 
box-plot from the Affymetrix database, to assess ADCY9 expression in TAM- 
Wd, +E2, + 5-Aza, + 5-Aza, +5-Aza + E2 and +5-Aza + E2 + TAM treated 
cells. B: PCR validation of array profile and corresponding densitometry data 
(n=3).
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Fig 5.13 KIAA1026 - Kazrin A: Heatmap profile and gene probe box-plot 
from the Affymetrix database, to assess Kazrin expression in TAM-Wd, +E2, 
+ 5-Aza, + 5-Aza, +5-Aza + E2 and +5-Aza + E2 + TAM treated cells. B: 
PCR validation of array profile and corresponding densitometry data (n=3).
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5.3 De-methylation of genes associated with tumour progression.
Although the cell growth analysis from the previous chapter showed that the 
cumulative effect of 5-Aza and E2 co-treatment in TAM-Wd cells was 
reduced cell growth [Fig’s 4.8-4.10 and 4.12], it should be noted that due to 
the nature of 5-Aza as a non-targeted de-methylation agent, it is inevitable that 
not all genes affected will be associated with the reduction of cell growth 
observed. Interestingly, amongst the gene set selected following the pattern 
navigation of the Affymetrix database [Fig 5.1], i.e. genes up-regulated by E2, 
suppressed by TAM in MCF-7 cells and suppressed in TAM-R cells, there 
were a number of genes whose up-regulation have been associated with 
tumour progression, eg WNT1 inducible signalling pathway protein-2 (WISP- 
2) [Saxena et al, 2001; Banerjee et al, 2003; Davies et al, 2007], stromal-cell 
derived factor-1 (CXCL12) [Luker & Luker, 2006, Kang et al, 2005a; 2005b], 
sialyltransferase (ST6) [Schneider et al, 2001; Lloyd et al, 1996], 
diacylglycerol kinase (DAGK) [Filigheddu et al, 2007], LY6/PLAUR domain 
containing 3 (LYPD3) [Fletcher et al, 2003; Paret et al, 2007; Hansen et al, 
2008] and SI00 calcium binding protein A14 (S100A14) [Yao et al,2007]. 
Indeed, it has been documented that anti-hormones can suppress genes that 
may advance tumour-progression as part of their protective effect [Frasor et al, 
2003, Fan et al, 2006], and therefore there is a possibility that such genes 
could be silenced by promoter methylation following long-term treatment. 
Thus, the expression profiles of three of these genes (CXCL-12, WISP-2 and 
ST-6) in TAM-Wd, +E2, + 5-Aza, + 5-Aza, +5-Aza + E2 and +5-Aza + E2 +
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TAM treated cells was assessed using the Affymetrix data and PCR 
verification, and methylight reactions were carried out to determine promoter 
methylation status.
CXCL-12 was shown to be up-regulated in TAM-Wd cells cultured with E2 as 
assessed by both PCR and array analysis. Although the array data shows that 
5-Aza and E2 treated cells show a higher expression of CXC1-12 than non­
treated cells, the up-regulation is lower than that induced by E2 alone [Fig 
5.14a]. This observation differs from the PCR data, where up-regulation is 
similar for both treatments, and reversed when E2 and 5-Aza are used in 
combination with TAM [Fig 5.14b]. Interestingly, methylight analysis showed 
a significant reduction of CXCL-12 promoter methylation in all 5-Aza treated 
cells compared to non-5-Aza treated cells (p<0.001) [Fig 5.14c].
WISP-2 was partially induced in TAM-Wd cells challenged with E2 in both 
PCR and array data sets. The addition of 5-Aza and E2 further increased 
expression over E2-only treated cells however; the addition of TAM caused no 
reversal of expression in the array data, and further increased expression in the 
PCR data [Fig 5.15].
In a similar fashion, ST6 was partially induced in TAM-Wd cells challenged 
with E2 in both PCR and array data sets. The addition of 5-Aza and E2 
marginally further increased expression compared to E2-only treated cells in 
the array profile, though not in the PCR profile. The addition of TAM caused a 
further increase in ST6 expression in both data sets [Fig 5.16]. Methylight 
assays showed that no methylated ST6 promoter was detected in TAM-Wd 
cell DNA, and primers for accurate WISP-2 detection could not be designed.
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Interestingly, two EGFR ligands were present in the list of 37 genes identified 
as being most highly up-regulated in TAM-Wd cells treated with 5-Aza + E2 
(compared to non-treated, E2, 5-Aza + E2 + TAM treated cells) [Fig 5.5], 
namely epiregulin and transforming growth factor alpha (TGFa). This 
prompted further investigation of the impact 5-Aza + E2 co-treatment has on 
EGFR expression, and expression of other EGFR ligands. Heatmap profiles 
were selected for all 6 EGFR probes, 3 TGFa probes, and the single 
amphiregulin and epiregulin probes present on the HG-U133A Affymetrix 
chip. 2 of the 6 EGFR probes [Fig 5.17], 2 of the 3 TGFa probes [Fig 5.18] 
and the epiregulin probe [Fig 5.19] were most highly expressed in 5-Aza + E2 
treated cells compared to non-treated cells, E2, 5-Aza and 5-Aza + E2 + TAM 
treated cells. Amphiregulin was up-regulated by E2 +/- 5-Aza [Fig 5.20].
The up-regulation of EGFR expression in TAM-Wd cells in response to 5-Aza 
+ E2 was confirmed by real-time PCR (n=2). In the presence of 5-Aza, 
expression was up-regulated by 150% with E2-co-treatment, in contrast to E2- 
only treated cells, in which EGFR expression was down-regulated by 
approximately 50% (n=2) [Fig 5.21]. Parallel analysis of the MCF-7 cells 
showed that EGFR expression remained suppressed by E2 (approximately 
50%) despite the presence of the de-methylation agent.
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Fig 5.14 Stromal Cell Derived Factor 1 -  CXCL-12 A: Heatmap profile and 
gene probe box-plot from the Affymetrix database, to assess CXCL12 
expression in TAM-Wd, +E2, + 5-Aza, + 5-Aza, +5-Aza + E2 and +5-Aza + 
E2 + TAM treated cells. B: PCR validation of array profile and corresponding 
densitometry data (n=3).
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Fig 5.14 C: Promoter methylation profile for CXCL-12 in TAM-Wd cells: 
Methylight data specific for methylated CXCL-12 promoter detected in TAM- 
Wd cells, +E2, + 5-Aza, + 5-Aza, +5-Aza + E2 and +5-Aza + E2 + TAM 5- 
Aza (data expressed as PMR) (*p<0.001).
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Fig 5.15 WNT1 Inducible Signalling Pathway protein-2 -  WISP2 A: 
Heatmap profile and gene probe box-plot from the Affymetrix database, to 
assess WISP2 expression in TAM-Wd, +E2, + 5-Aza, + 5-Aza, +5-Aza + E2 
and +5-Aza + E2 + TAM treated cells. B: PCR validation of array profile and 
corresponding densitometry data (n=3).
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Fig 5.16 Sialytransferase -  ST6 A: Heatmap profile and gene probe box-plot 
from the Affymetrix database, to assess ST6 expression in TAM-Wd, +E2, + 
5-Aza, + 5-Aza, +5-Aza + E2 and +5-Aza + E2 + TAM treated cells. B: PCR 
validation of array profile and corresponding densitometry data (n=3).
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Fig 5.17 Epidermal Growth Factor Receptor -  EGFR: Heatmap profiles and 
gene probe box-plots from the Affymetrix database, to assess EGFR 
expression in TAM-Wd, +E2, + 5-Aza, + 5-Aza, +5-Aza + E2 and +5-Aza + 
E2 + TAM treated cells (n=6).
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Fig 5.17 EGFR continued
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Fig 5.18 Transforming Growth Factor alpha - TGFa: Heatmap profiles and 
gene probe box-plots from the Affymetrix database, to assess TGFa 
expression in TAM-Wd, +E2, + 5-Aza, + 5-Aza, +5-Aza + E2 and +5-Aza + 
E2 + TAM treated cells (n=3).
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Fig 5.19 Epiregulin: Heatmap profile and gene probe box-plot from the 
Affymetrix database, to assess epiregulin expression in TAM-Wd, +E2, + 5- 
Aza, + 5-Aza, +5-Aza + E2 and +5-Aza + E2 + TAM treated cells (n=T).
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Fig 5.20 Amphiregulin: Heatmap profile and gene probe box-plot from the 
Affymetrix database, to assess amphiregulin expression in TAM-Wd, +E2, + 
5-Aza, + 5-Aza, +5-Aza + E2 and +5-Aza + E2 + TAM treated cells (n=l).
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Fig 5.21 Expression of EGFR: Real-Time PCR evaluation of EGFR mRNA 
concentration in MCF-7 and TAM-Wd cells ± 5-Aza ± E2 at 10’9M for 6 days. 
Data shown represents percentage increase of EGFR detected in cells ± 5-Aza, 
following E2 challenge (n=2).
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6. DISCUSSION
It is now widely accepted that the acquisition of anti-hormone resistance is 
associated with a variety of molecular mechanisms which serve to not only to 
compensate for the growth inhibition caused by decreasing oestrogen receptor 
activity, but also further enhance the aggressiveness of the breast cancer 
phenotype [Hiscox et al, 2003; 2004]. Preliminary analysis of our cellular 
model of ER-positive tamoxifen-resistant breast cancer has shown that 
resistant MCF-7 cells possess enhanced proliferative and invasive capacities 
compared to wt-MCF-7 cells. The increased activation of a growth-factor 
receptor signalling network featuring EGFR, HER-2 and IGF-1R [Nicholson, 
et al, 2005] has been shown to contribute to both the accelerated rate of 
growth, and to a lesser extent, the motile and invasive potential of these cells. 
Interestingly however, although inhibition of these growth factor receptors, 
either alone or in combination, can provoke some growth inhibition, the 
effects on cell proliferation are incomplete and rarely promote cell kill 
[Nicholson et al, 2001; Knowiden et al, 2003; 2005]. Consequently, breast 
cancer cells survive drug treatment and resistant cell growth resumes within 
several months. The apparent shortfall of such inhibitors to meet their 
expected effectiveness in the experimental setting is indicative of additional 
mechanisms mediating the tamoxifen-resistant breast cancer cell phenotype. In 
light of this it is noteworthy that tamoxifen, through its genomic mechanism of 
action, classically acts to reduce expression of ER-regulated genes, where
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conformational changes induced by tamoxifen binding to ER provides docking 
sites for corepressors such as NCoR/SMRT [Lavinsky et al. 1998], REA 
[Montano et al, 1999], RTA [Norris et al 2002], SAFB1 [Oesterreich et al. 
2000], and Smad4 [Wu et al, 2003]. This in turn can facilitate the recruitment 
of HDACs to ERE-bearing genes causing the condensation of the surrounding 
chromatin environment and gene suppression [Hu & Lazar, 2000]. Since gene 
promoters that are silenced by histone modifications are considered vulnerable 
to permanent silencing through hypermethylation of CpG islands in their 
promoter sequences [Cheng et al, 2008], it is possible that epigenetic alterations 
(such as histone code modification and promoter hyper-methylation) to 
oestrogen regulated tumour suppressor gene promoters may contribute to the 
development of tamoxifen resistance. Although at first sight this may appear 
incongruent since oestrogens are considered mitogenic to many breast cancer 
cell-lines, the proliferative actions of oestrogens are not limitless and 
exponential cell growth in culture rapidly ceases, possibly due to the induction 
of growth suppressive pathways [Stender et al, 2007; Safe, 2001]. Oestrogen 
has been shown to induce apoptosis in other breast cancer cell models 
including oestrogen deprived cells [Song et al, 2001; Lewis et al, 2005] and 
ER-negative cells stably transfected with ER [Levenson et al, 1994; Licznar et 
al, 2003]. Furthermore, high doses of synthetic oestrogens, such as 
diethylstilbestrol (DES), have been used effectively to treat postmenopausal 
women with ER-positive breast cancer, and cause tumour-regression 
[Peethambaram et al, 1999]. Cumulatively, these reports indicate that under 
certain circumstances oestrogen can positively influence tumour suppressor/
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pro-apoptotic gene networks, and infer that the loss of function of these 
estrogen responsive genes may facilitate tumour progression.
The focus of the present study, therefore, was to determine whether oestrogen 
responsive genes associated with tumour-suppressor function, were silenced 
by promoter methylation in TAM-R cells as a direct consequence of long-term 
tamoxifen treatment, and whether re-activation of such genes could provide a 
potential therapeutic avenue for the management of tamoxifen-resistant breast 
cancer.
6.1 Long-term tamoxifen exposure is associated with a permanent 
alteration to breast cancer cell phenotype.
In order to assess the extent to which the presence of tamoxifen contributed to 
the TAM-R cell phenotype, cells were withdrawn from tamoxifen for up to 6 
months. It was reasoned that during this period, any agonistic contribution of 
the drug to TAM-R cell morphology, growth or motility would be depleted, 
whilst the effects of permanent heritable cell re-programming caused by the 
previous long-term tamoxifen treatment would remain.
6.1.1 Growth and Invasion
Significantly, following a tamoxifen withdrawal period of 1, 3 and 6 months, 
it was noted that the enhanced growth rate of the TAM-R cells compared to 
the parental MCF-7 cells was sustained in the absence of tamoxifen, as were 
features of their morphological appearance; with Tam-Wd cells demonstrating
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increased lamellipodia and filopodia formation. In contrast to these 
observations, the motile capacity of the TAM-R cells was significantly 
reduced following tamoxifen withdrawal. The divergence between the effects 
of tamoxifen withdrawal on proliferation and motility emphasises the 
differential regulation of these events in breast cancer cells and suggests that 
although the suppression of anti-invasive genes has been described in breast 
cancer [Yang et al, 2007], in this instance, it is unlikely that they have been 
permanently down-regulated in TAM-R cells by long-term tamoxifen 
treatment.
6.1.2 Assessment of the effects of tamoxifen withdrawal on ER and growth 
factor signalling.
In light of the continued proliferation of the tamoxifen withdrawn tamoxifen- 
resistant cells, their expression and use of ER, EGFR and IGF-1R signalling 
pathways was reassessed. In general terms, tamoxifen withdrawn cells were 
less sensitive to inhibitors of these pathways.
6.1.2.1 Oestrogen Receptor
Numerous reports suggest that the oestrogen receptor may be silenced through 
promoter methylation in a variety of cancers, including lung [Issa et al, 1996], 
colon [Issa et al, 1996], prostate [Sasaki et al, 2002], ovarian [O'Doherty et al, 
2002] and breast [Ottaviano et al, 1994]. Recent studies have shown that this 
phenomenon can contribute to the ER-negative status of both de-novo ER- 
negative cells, and cells that have acquired ER-negative status as a result of
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long-term anti-hormone exposure, and can facilitate an anti-hormone resistant 
phenotype. The use of 5-Aza resulted in demethylation of the ER promoter 
and re-expression of ER mRNA and functional protein in both MBA-231 ER- 
negative cells, and ER-depleted, fulvestrant-resistant-MCF-7 cells [Ferguson 
et al, 1995; Yang et al, 2001]. In the specific example of tamoxifen resistance, 
ER expression is rarely lost, though long-term tamoxifen treatment of MCF-7 
cells has been shown to irreversibly inhibit the expression of oestrogenic 
genes through chromatin remodelling [Badia et al, 2000]. In the present study, 
ER mRNA expression was reduced in the TAM-R cell-line compared to the 
anti-hormone sensitive parental cell-line; however, withdrawal of tamoxifen 
restored ER expression, suggesting no permanent gene suppression had 
occurred. Significantly, the loss of ER expression in TAM-R cells has been 
observed in cells cultured in the anti-hormone for longer periods of time. This 
occurs through a reduction in mRNA transcripts from the A, B and C ER 
promoters (Abdel Bensmail -  personal communication). This effect is 
reversible on tamoxifen withdrawal and may account for the raised ER 
expression in the TAM-Wd cells used in the present study.
Despite their increased ER expression levels, TAM-Wd cells showed reduced 
sensitivity to Faslodex (40% growth inhibition), in comparison to TAM-R 
(60%) and wt (75%) cells. They do not respond to tamoxifen re-exposure and 
are relatively insensitive to the growth promoting actions of oestradiol. 
Importantly, hyper-sensitivity to E2 stimulation was not observed in either 
TAM-R or TAM-Wd cells, contrary to findings from other groups using 
models of anti-hormone resistance, in which oestrogen can be apoptotic [Yao
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et al, 2000; Jordan et al, 2007]. In total, these data imply a diminishing 
significance for ER signalling in the tamoxifen withdrawn model.
6.1.2.2 EGFR andIGF-1R
An increased reliance of breast cancer cells on EGFR and IGF-1R has been 
linked to the development of anti-hormone resistance [Nicholson et al, 2001] 
and gefitinib resistance [Jones et al, 2004] respectively and can occur by ER 
dependent or independent mechanisms. It was deemed feasible therefore, that 
changes in the usage of these growth factor receptors in the tamoxifen 
withdrawn tamoxifen resistant cells might underpin their continued growth 
rate. This, however, was not the case since the withdrawn cells showed 
reduced sensitivity to gefitinib and ABDP, selective inhibitors of these 
pathways. Interestingly, the reduced sensitivity to gefitinib in the tamoxifen- 
withdrawn cells was associated with a parallel reduction in EGFR expression, 
indicating tamoxifen was maintaining EGFR levels; while the reverse was true 
for the expression of IGF-1R, which increased on tamoxifen withdrawal. 
Although the precise molecular mechanisms associated with this differential 
response remain to be established in the tamoxifen withdrawn cells, they are 
consistent with the cellular actions of tamoxifen in MCF-7 cells, where it 
rapidly promotes EGFR expression through the repression of oestrogen 
induced negative regulatory elements in the first intron of the EGFR gene 
[Wilson & Chrysogelos, 2002], whilst repressing the positive regulation of 
IGF-1R expression by oestradiol [Guvakova et al, 1997].
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6.2 Proof of principal that epigenetic silencing of ER regulated genes 
occurs in tamoxifen withdrawn tamoxifen resistant cells.
In concordance with observations of other research groups [Badia et al, 2000; 
Fan et al, 2006], the TAM-R cells used in the present study show significantly 
reduced E2-induction of the classically regulated, oestrogen responsive genes, 
PR and pS2, compared to the MCF-7 cells. Critically however, their 
suppression was maintained in the tamoxifen withdrawn cells, suggesting that 
the effect may be epigenetic in nature. The loss of oestrogen-regulation of 
these genes in TAM-R and TAM-Wd cells was further illustrated by their lack 
of response to oestradiol at a dose which up-regulated PR and pS2 by 40 and 4 
fold in MCF-7 cells.
Confirmation of the epigenetic nature of the suppression of PR and pS2 was 
shown by the reversal of the oestrogen induction of their expression by the 
DNA de-methylating agent 5-Aza, which enabled oestradiol to increase their 
levels 18 and 7 fold in the tamoxifen withdrawn TAM-R cells. Methylight 
assays, performed through collaboration with Dr. H. Fiegl (Medical University 
of Innsbruck), showed that the pS2 promoter was methylated in the tamoxifen- 
withdrawn TAM-R cells, and that the quantity of methylated promoter 
detected was reduced 4-fold by 5-Aza treatment. The quantity of PR expressed 
in these cells, which was observed at a much lower level than pS2 under basal 
conditions, proved undetectable in TAM-Wd cells using the Methylight 
system. In accordance with studies carried out using ER siRNA to induce 
signalling disruption [Leu et al, 2004], these data indicate that epigenetic
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silencing of classically E2-regulated genes can arise as a result of ER- 
signalling disruption caused by long-term tamoxifen challenge, and that this is 
apparent in the emerging resistant state.
6.3 Relationship between epigenetic silencing and tumour cell growth.
Although the studies on PR and pS2 clearly demonstrate that epigenetic 
silencing of ER regulated genes occurs in TAM-R cells, these genes are not 
considered to be significant regulators of cell growth. Experiments were 
conducted to determine whether other genes specifically activated in TAM- 
Wd cells by 5-Aza + E2 co-treatment in TAM-Wd cells could be associated 
with growth regulation. Care was taken to select a dose of 5-Aza which was 
not growth inhibitory since high doses of this drug can be severely cytotoxic. 
A dose of lpM  5-Aza was chosen since it had little growth inhibitory effect, 
yet, as discussed above, it reversed promoter methylation of the pS2 gene. 
Importantly, subsequent studies revealed that 5-Aza treatment of TAM-Wd 
cells switched oestradiol from being mildly mitogenic into a growth inhibitory 
agent. Thus, in contrast to oestradiol promoting an approximate 40% increase 
in cell numbers when used as a single agent, in combination with 5-Aza, cell 
number was reduced by 50% at 7 days, and had fallen below the initial 
seeding density after 14 days culture. This previously unidentified 
phenomenon appears to be ER related, since it was reversible by tamoxifen 
co-addition and was not evident in MCF-7 cells, implying it was associated 
with long-term tamoxifen treatment. Evidently, long-term tamoxifen treatment
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of breast cancer cells is able to suppress the expression of oestrogen regulated 
genes that inhibit cell growth and/or cell death. Significantly, two previous 
studies are supportive of the concept of anti-hormonal silencing of potential 
tumour suppressors. SAGE studies revealed that expression of CtIP (or 
retinoblastoma binding protein 8) was decreased in acquired tamoxifen 
resistant models, where its knockdown in MCF-7 promoted tamoxifen 
resistance, while its induction restored response [Wu et al, 2007]. Secondly, a 
study by Treeck et al, (2004) has reported that long-term tamoxifen treatment 
of MCF-7 cells decreased levels of several pro-apoptotic genes and impaired 
subsequent apoptotic response to etoposide treatment. To our knowledge, only 
two other groups have reported oestrogens to be growth inhibitory to anti­
hormone resistant breast cancer cells [Liu et al 2003; Yao et al, 2000], and 
these particular instances occurs, the growth inhibitory effect observed was 
thought to be due to cells becoming ‘addicted’ to the increased growth factor 
signalling that oestrogens subsequently suppress. Critically, our novel 
observation directly links anti-hormone induced hypermethylation of 
oestrogen regulated tumour suppressor gene promoters to anti-hormone 
resistant cell proliferation. Importantly, data suggested that this process is 
reversible with co-treatment of 5-Aza and E2, and thus the identification of 
genes associated with phenomenon could provide valuable insight into the 
mechanisms that govern the tamoxifen-resistant cell phenotype.
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6.4 Identification of oestrogen regulated genes potentially associated with 
5-Aza induced inhibition of cell growth.
Having demonstrated that the combination of 5-Aza and E2 caused the TAM- 
Wd cells to proliferate at a slower rate than 5-Aza-treated controls and 
furthermore cause cell loss over a 14 day period, we sought to identify genes 
that were being up-regulated specifically by E2 challenge in the presence of 
the demethylation agent which could be associated with this phenomenon. 
This was achieved by Affymetrix profiling of our cells, examining for 
potential tumour suppressor/pro-apoptotic genes that had the following profile:
• Oestradiol induced and anti-hormone suppressed in wt-MCF-7 cells.
• Suppressed in TAM-R and tamoxifen withdrawn TAM-R cells.
• Not induced by Gefitinib in TAM-R cells.
• Induced by E2 + 5Aza co-treatment (but not by single agent treatment) 
and reversed by tamoxifen in tamoxifen-withdrawn TAM-R cells.
Candidate genes carried forward from our microarray study for PCR 
verification and promoter methylation analysis included GDF-15, ADCY9, 
CAX11, KIAA1026, HBA2, RASAL1, COL6a3 and RGC32, and are distinct 
from the pro-apoptotic genes identified as suppressed by Treek et al (2004). 
Two of the candidate genes, namely GDF-15 and RGC32, have been shown to 
be down-stream targets of the putative tumour-suppressor, p53 [Tan et al, 
2000; Saigusa et al, 2006]. P53 functions to eliminate and inhibit the
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proliferation of abnormal cells, thereby preventing neoplastic development 
[Gasco et al, 2002]. It remains the most commonly mutated gene in many 
human cancers, with mutations (principally, but not exclusively, mis-sense) 
estimated to occur in 50% of all cancers. Interestingly, although the frequency 
of p53 mutation is lower in breast cancer than in other solid tumours; various 
regulators of p53 activity and some downstream transcriptional targets of p53 
have been reported to be silenced by both genetic and epigenetic mechanisms, 
leading to the mismanagement of this pathway in breast cancer cells, and 
hence promoting cell survival [Gasco et al, 2002]. The identification of p53 
gene targets that have been silenced by promoter hypermethylation as a result 
of long-term tamoxifen treatment is a novel observation which could have 
value in the diagnosis, prognostic assessment and, ultimately, in the treatment 
of tamoxifen resistant breast cancer.
6.4.1 Growth Differentiation Factor-15
Growth Differentiation Factor-15 (GDF-15), which is also known by other 
names including prostate-derived factor, macrophage inhibitory cytokine 1, 
placental bone morphogenetic protein, placental transforming growth factor B, 
and nonsteroidal anti-inflammatory drug-activated protein 1, is a member of 
the type |3 transforming growth factor (TGF-B) superfamily and was first 
isolated from a subtracted cDNA library enriched for genes associated with 
macrophage activation [Bootcov et al, 1997]. It has since been reported to 
inhibit prostate epithelial proliferation, induce colon and mammary epithelial 
cancer cell apoptosis in vitro and inhibit colon and glioblastoma tumor growth
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in vivo [Tan et al, 2000; Baek et al, 2001; Li et al, 2000; Graichen et al, 2002; 
Albertoni et al, 2002]. Tan et al (2000) identified GDF-15 as a p53 target gene 
that inhibits tumour cell growth via the TGFp signalling pathway. Studies 
revealed that p53 activation is mediated through two p53 binding sites in the 
promoter of GDF-15 in a p53 dose- as well as p53 binding site-dependent 
manner by wild-type p53, but not by several p53 mutants. The p53 binding 
and transactivation of the GDF-15 promoter was enhanced by etoposide, a p53 
activator, and was largely blocked by a dominant negative p53 mutant. GDF- 
15 was found to be a secretory protein, associated with the inhibition of 
tumour cell growth via p53-induced G1 arrest in both the cells secreting it 
(autocrine), and their neighbouring cells (paracrine). Indeed, conditioned 
medium collected from GDF-15-over expressing cells, but not from the 
control cells, suppressed tumour cell growth. Growth suppression was not, 
however, seen in cells that lack functional TGF-p receptors or Smad4, 
confirming that GDF-15 acts through the TGF-p signalling pathway. It is 
therefore apparent that this gene is an important link between p53 activation 
and TGFP-mediated growth suppression, and that the loss of this gene could 
contribute to tumour cell proliferation. Interestingly, Ibanez de Caceres et al 
(2006) identified GDF-15 gene promoters as being silenced by hyper- 
methylation in renal cancer cells compared to normal cells, and demonstrated 
that this gene could be de-methylated following 5-Aza treatment.
The microarray data obtained from the present study shows that GDF-15 is an 
oestrogen regulated gene in wt-MCF-7 cells, which is suppressed following 
the acquisition of tamoxifen resistance. Using Methylight technology, we have
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shown that GDF-15 gene promoter was significantly methylated in the 
tamoxifen withdrawn TAM-R cells, and that 5-Aza could be used to reverse 
the promoter’s methylated status. Indeed, microarray and PCR verification 
showed that GDF-15 was most highly expressed in tamoxifen withdrawn 
TAM-R cells treated with 5-Aza and E2 compared to non-treated, 5-Aza or E2 
treated cells. Intriguingly, the addition of tamoxifen caused a reduction in 
GDF-15 expression, in parallel with an increase in methylated promoter 
detected; indicating that silencing of GDF-15 by tamoxifen induced promoter 
methylation may indeed contribute to tamoxifen-resistant breast cancer cell 
growth.
6.4.2 Response gene to complement 32 protein.
The response gene to complement (RGC)-32 gene was first cloned from rat 
oligodendrocytes by differential display during a search conducted by Badea 
et al (1998) for genes that were differentially expressed in response to 
complement activation. Since then, several studies have reported changes in 
RGC-32 expression in a wide range of cell lines and tissues in response to a 
variety of stimuli including steroid hormones and growth factors [Vlaicu et al, 
2008; Chen et al, 2005]. It has also been reported that RGC-32 transcription is 
directly regulated by p53 in glioblastoma/astrocytoma, osteoblastic, and colon 
cancer cell lines [Saigusa et al, 2007]. The expression of RGC-32 mRNA was 
dramatically increased by exogenous p53 in p53-mutant glioma cells, and also 
by endogenous p53 in response to DNA damage in colon-cancer cells over­
expressing p53, but not in p53-deleted cells. Transiently and stably
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overexpressed RGC-32 suppressed the growth of glioma cells through the 
suspected formation of a protein complex with polo-like kinase-1 (Plk-1), thus 
inhibiting its activity. Plk-1 is a key regulator of mitosis [Barr et al, 2004], but 
is also associated with oncogenesis since expression and kinase activity of 
Plk-1 is elevated in many kinds of cancers [Takai et al, 2005]. Inactivation of 
Plk-1 by a variety of methods has caused cell-cycle arrest at mitosis and/or 
apoptosis in cancer cells of several types [Elez et al, 2000; Spankuch-Schmitt 
et al, 2002], indicating that inhibition of Plkl function might be a promising 
approach to cancer therapy [Gumireddy et al, 2005]. As RGC-32 binds to and 
is phosphorylated by Plkl in vitro, it is possible that RGC-32 may inhibit 
G2/M progression through interaction with Plkl in tumour cells. RGC-32 
expression is down-regulated in invasive prostate cancer, multiple myeloma, 
and drug-resistant glioblastoma [Vlaicu et al, 2008]. Furthermore, Takai et al 
(2005) identified RGC-32 as suppressed in 5 out of 6 endometrial cancer cell 
lines as part of a study conducted to reveal novel tumour-suppressor genes that 
are epigenetically silenced in this disease. However, other studies have shown 
that RCG-32 expression is up-regulated in cutaneous T cell lymphoma and 
colon, ovarian, and breast cancer tissue, and can act as a substrate and 
regulator of cell division cycle 2 (CDC2) kinase activity, and thus induce S- 
phase entry and mitosis in tumour cells [Vlaicu et al, 2008]. Although there is 
no evidence to explain the discrepancies between the reported findings, it is 
possible that RGC-32 may function differently among different types of cells 
depending on which activation targets were available. Further examination 
will be needed to clarify the significance of RGC-32 in anti-hormone resistant
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breast cancer, however, preliminary investigations using our microarray 
database show that Plk-1 expression is significantly up-regulated in tamoxifen 
resistant MCF-7 cells versus wild-type cells, whilst CDC2 expression remains 
consistently low in both cell-lines (data shown at the end of chapter - Fig 6.1), 
highlighting the possibility that RGC-32 could contribute to the inhibition of 
proliferation by deactivating Plk-1 in tamoxifen-resistant cells. Microarray 
data from the present study shows that RGC-32 expression is up-regulated in 
E2 challenged MCF-7 cells, and suppressed following the acquisition of 
tamoxifen resistance. Microarray and PCR verification showed that RGC-32 
was most highly expressed in tamoxifen withdrawn TAM-R cells treated with 
5-Aza and E2 compared to non-treated, 5-Aza or E2 treated cells. The addition 
of tamoxifen caused a reduction in RGC-32 mRNA expression in cells co­
treated with 5-Aza and E2; suggesting the up-regulation of Plk-1, combined 
with the epigenetic silencing of RGC32, may facilitate TAM-R cell growth 
and the re-activation of RGC-32 could serve to reverse this phenomenon.
6.4.3 Ras protein activator type 1
Another oestrogen regulated gene identified from the present study as 
potentially associated with 5-Aza induced inhibition of cell growth, is Ras 
protein activator type 1 (RASAL-1). Unlike GDF-15 and RGC-32, RASAL-1 
is not activated by p53; instead its activity is promoted in response to agonist- 
induced, intracellular Ca2+ oscillations [Walker et al, 2004]. RASAL-1 is a 
GTPase-activating protein (GAP) which is reported to normally terminate Ras 
activation, a GTP-ase oncogene which is constitutively active in
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approximately 30% of all human tumours [Downward, 2003]. As with other 
small GTPases, Ras switches between two distinct conformations, an inactive 
GDP-bound state and active GTP-bound complex. Once in the GTP-bound 
conformation, Ras engages a number of effectors that couple this GTPase to 
the regulation of multiple signalling cascades important for cellular 
proliferation, differentiation, and survival [Mitin et al, 2005]. RASAL-1 
enhances the intrinsic GTPase activity of Ras, thereby leading to its 
inactivation through the conversion of GTP into GDP. In a study conducted by 
Jin et al (2007), RASAL-1 was identified as being suppressed in several 
breast, lung, nasopharyngeal, hepatocellular and oesophageal tumour cells 
compared to normal-cells, and was subsequently found to be silenced by 
promoter hyper-methylation in a large proportion of the tumour cells, and 
corresponding tissue samples. They showed that ectopic expression of 
catalytically active RASAL-1 led to growth inhibition of these tumour cells by 
Ras inactivation, and hence provided evidence that epigenetically silencing of 
this gene represents a new mechanism of aberrant Ras activation in certain 
cancers.
In our models of anti-hormone resistant breast cancer, it has been established 
that Ras is an important transactivation target of EGFR, and it’s activation of a 
down-stream signalling cascade involving Raf, MEK and ERK, can contribute 
to TAM-R cell proliferation and survival. The loss of Ras regulators could 
therefore potentiate this event and hence, it is reasonable to assume that re- 
introduction of RASAL-1 in TAM-R cells could compromise Ras down­
stream signal transduction, and diminish the associated growth activation.
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Microarray data from the present study shows that RASAL-1 expression is up- 
regulated in MCF-7 cells in response to E2, down-regulated by tamoxifen 
treatment and potentially suppressed following the acquisition of tamoxifen 
resistance. Microarray data also showed that for all 3 gene probes, RASAL-1 
was most highly expressed in tamoxifen withdrawn TAM-R cells treated with 
5-Aza and E2 compared to non-treated, 5-Aza or E2 treated cells. The addition 
of tamoxifen caused a reduction in RASAL-1 mRNA detected in cells co­
treated with 5-Aza and E2; suggesting that long-term tamoxifen exposure may 
indeed cause epigenetic silencing of this gene, a mechanism by which cell 
growth could be facilitated. PCR verification of this observation was not 
achieved; however, the microarray gene probe profiles in question are so 
convincing, work has started on alternative RASAL-1 primer design due to the 
significant implications this observation would have on the understanding of 
the mechanisms that govern the growth of anti-hormone resistant breast cancer 
cells.
6.5 Potential induction of adverse genes by 5-Aza.
Although the cell growth analysis showed that the cumulative effect of 5-Aza 
and E2 challenge in TAM-Wd cells was reduced cell growth, it is noteworthy 
that due to the nature of 5-Aza as a non-targeted de-methylation agent, it is 
likely that not all induced genes affected will be associated with the reduction 
of cell growth observed. Indeed, EGFR, which was down-regulated following 
tamoxifen withdrawal from TAM-R cells, was greatly up-regulated by 5-Aza
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and E2 co-treatment versus E2 alone. Importantly, this was observed for 2 of 
the 6 EGFR probes on the micro-array chip, and was complemented by 
increased expression of its ligands TGFa (2 of 3 probes) and epiregulin (1 of 1 
probe). The data, subsequently confirmed by real-time PCR, contrasts with 
both the suppressive effects of E2 on EGFR levels in wt-MCF-7 and 
tamoxifen withdrawn TAM-R cells in the absence of 5-Aza, and the inability 
of E2 to induce EGFR in wt-MCF-7 cells in the presence of 5-Aza. Clearly the 
acquisition of anti-hormone resistance followed by tamoxifen withdrawal has 
facilitated a (5-Aza sensitive) reduction in the expression of the EGFR; 
presumably at a promoter site which oestrogens positively regulate the 
expression of this gene. In this context, it is noteworthy that early reports on 
the effects of oestrogens on EGFR expression suggested it was biphasic, with 
oestrogen first rapidly stimulating EGFR expression, and then inhibiting it 
[Yarden et al, 1996]. Whatever the mechanism, it is conceivable that the 
induction of EGFR (together with its ligands) in 5-Aza and E2 treated 
tamoxifen withdrawn cells may facilitate limited growth and survival 
signalling to counteract the induction of tumour suppressor/pro-apoptotic 
genes and that much greater inhibitory responses might be achieved by the 
concurrent targeting of the EGFR.
It is noteworthy that of the 24 genes selected from the first round of 
microarray analysis (i.e. up-regulated in MCF-7 cells in response to E2, down- 
regulated or suppressed in tamoxifen treated and tamoxifen resistant cells, no 
EGFR regulation), 6 adverse genes were potentially down-regulated (to the 
point of epigenetic silencing) by tamoxifen treatment, possibly as part of the
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anti-hormone’s protective effect. Genes included WISP-2 [Saxena et al, 2001; 
Banerjee et al, 2003; Davies et al, 2007], CXCL12 [Luker & Luker, 2006, 
Kang et al, 2005a; 2005b], ST6 [Schneider et al, 2001; Lloyd et al, 1996], 
DAGK [Filigheddu et al, 2007], LYPD3 [Fletcher et al, 2003; Paret et al, 
2007; Hansen et al, 2008] and S100A14 [Yao et al, 2007]. If these genes were 
indeed methylated in TAM-Wd cells, restoration of their expression could also 
limit the effectiveness of 5-Aza and E2 co-treatment. However, no evidence 
was produced to suggest that the expression any of the 3 genes selected for 
further analysis, namely CXCL-12, WISP-2 and ST-6, was significantly up- 
regulated by 5-Aza +E2 co-treatment (compared to E2 treated cells) in 
tamoxifen withdrawn TAM-R cells, suggesting they were free from epigenetic 
regulation. Interestingly however, CXCL-12 gene promoter was found to be 
significantly methylated in non-5-Aza compared to 5-Aza treated tamoxifen- 
withdrawn TAM-R cells as assessed by Methylight assay, despite the lack of 
any significant increase in mRNA expression in 5-Aza +E2 co-treated cells as 
assessed by microarray and PCR analysis. It may well be the case that 5-Aza 
has caused the demethylation of a promoter sequence that is free from 
oestrogenic regulation, and hence its reactivation in this instance is 
inconsequential.
In total, although the adverse gene candidates selected for PCR verification 
did not demonstrate sensitivity to 5-Aza + E2 co-treatment, it is likely that this 
event will occur (as is the case with EGFR). Interestingly, chromatin 
remodelling drugs (e.g. HDAC and methylation inhibitors) are of clinical 
interest in cancer although many researchers remain cautious regarding the
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broader genomic impact of such agents [Miyamoto & Ushijima, 2005], and 
thus potential restoration of tumour suppressors on an individual basis may 
prove more desirable if this can ultimately be achieved through alternative 
strategies.
6.6 Oestrogen repression of tumour suppressors: a potential role in breast 
cancer and development and progression.
Classically, E2 acts to induce expression of genes whose target promoters bear 
oestrogen response elements (EREs). However, it is transcriptional repression 
of genes that has been reported to comprise the bulk (70%) of expression 
changes associated with E2 challenge of ER-positive breast cancer models. In 
a study conducted by Frasor et al, 2003, a significant proportion of the genes 
identified as being down-regulated by E2 in breast cancer cells were 
associated with anti-apoptotic/growth-regulatory function, and therefore are 
presumably down-regulated as part of the E2-mediated activation of MCF-7 
cell growth. However, there is emerging literature to indicate that the gene- 
suppressive effects of E2 at tumour suppressors may, in some instances (e.g. 
RUNX3, Jiang et al. 2008), culminate in their epigenetic silencing and 
possibly advance breast cancer progression. Studies of several E2-repressed 
genes, including the tumour suppressor gene cyclin G l, indicate that alongside 
corepressors such as N-CoR, the E2/ER complex can recruit HDACs to gene 
promoters, creating a repressive chromatin conformation that inhibits gene 
expression [Stossi et al, 2006] and renders the promoter sequence vulnerable
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to CpG-hyper-methylation. Therefore it is reasonable to assume that de- 
methylation agents such as 5-Aza could be used in these cells to provoke re­
expression of E2-silenced tumour-suppressor genes, and consequentially 
induce growth inhibition. However, when we treated MCF-7 cells with 5-Aza 
at a concentration of 1 pM, no growth inhibition was observed and in contrast 
to the tamoxifen-withdrawn TAM-R cells, E2 remained mitogenic despite the 
presence of the de-methylation agent. It could be suggested that the gene 
promoters that are aberrantly methylated by long-term E2 exposure in MCF-7 
cells will again be suppressed by E2 despite their de-methylated status, 
rendering them unable to make an impact on the regulation of cell growth. In 
contrast, in the case of the tamoxifen-withdrawn TAM-R cells we have 
determined that tumour suppressor genes that were previously activated by E2 
in MCF-7 cells can be epigenetically silenced by long-term tamoxifen 
exposure, and that following the de-methylation of gene promoters (using 5- 
Aza), gene expression can once again be up-regulated by E2 to provoke cell- 
growth inhibition. These data therefore indicate that if the genes that were de- 
methylated by 5-Aza in MCF-7 cells were activated (by an anti-hormone) 
rather than suppressed by E2, an inhibitory growth response may be achieved. 
However, evidence from studies of Slug, an E2-repressed gene with pro 
invasive ontology indicates that adverse signalling genes can equally be 
subject to E2-driven silencing [Ye et al, 2008] and interference with such 
events could prove undesirable in the context of cancer development and 
progression.
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6.7 Might the development of tamoxifen resistance be prevented by 5-Aza 
and tamoxifen co-treatment?
In the present study, it has been shown that oestrogen-regulated tumour- 
suppressor genes have been epigenetically silenced in our MCF-7 breast 
cancer cells following long-term tamoxifen treatment; and that this event may 
contribute to anti-hormone resistant cell growth. It has previously been 
suggested that co-treatment of MCF-7 cells with 5-Aza + tamoxifen (as 
opposed to tamoxifen alone), may extend the time-taken to achieve anti­
hormone resistant cell growth, as the presence of the de-methylation agent will 
prevent such genes from becoming silenced. However, consistently throughout 
the study, we have shown that 5-Aza alone has little effect on gene expression 
itself, and merely acts to provide access for transcriptional regulation of the 
de-methylated promoter. Thus, if 5-Aza was used in combination with 
tamoxifen to prevent the onset of resistance, the de-methylation agent would 
presumably prevent epigenetic silencing of genes down-regulated by 
tamoxifen. As we have shown for GDF-15 and RGC-32 however, in our 5- 
Aza +E2 treated tamoxifen withdrawn TAM-R cells, due to the affinity of the 
anti-hormone for ER compared to physiological concentrations of oestrogen, 
the presence of tamoxifen would still cause gene suppression. Therefore, the 
presence of 5-Aza would be inconsequential and have little effect on the time 
taken to develop anti-hormone resistance. Indeed, in a study conducted by Van 
Agthoven et al (1994), the application of 5-Aza was able to accelerate the 
emergence of an EGFR-positive tamoxifen resistant cell-phenotype in ZR75-1
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breast cancer cells. Although data from the present suggests a possible 
explanation as to why 5-Aza did not prevent the emergence of an EGFR- 
positive tamoxifen resistant phenotype, it does not offer any explanation as to 
why 5-Aza accelerated this process. One possible explanation is that long-term 
5-Aza exposure could ultimately induce hypo-methylation at promoters of 
genes associated with tumour development in anti-hormone sensitive cells, 
including potential growth inducing elements. Hypo-methylation has been 
closely associated with genomic instability and the development of a multitude 
of tumours [Lund & Van Lohuizen, 2004].
6.8 Conclusion
Alongside anti-hormone-induced compensatory signalling, the data presented 
in this thesis indicates that the silencing of various E2-regulated tumour 
suppressor genes could play a significant role in limiting the growth inhibitory 
effects achieved by long-term tamoxifen treatment, and promote resistance. It 
has been shown that the growth of tamoxifen withdrawn TAM-R cells is 
inhibited following co-treatment with 5-Aza and a physiological concentration 
of oestradiol, and that this occurs in parallel with the de-methylation and 
activation of p53-activated tumour-suppressor genes GDF-15 and RGC-32, as 
well as other genes such as RASAL-1, that could serve to suppress anti­
hormone resistant cell growth and/or promote apoptosis. To date the concept 
that anti-hormones silence growth inhibitory genes has not been examined in
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clinical breast cancer, although the reversal of epigenetic events is being 
examined [Miyamoto & Ushijima, 2005].
Importantly, however, the data presented in the thesis also shows that due to 
the un-targeted mechanism of action of this combination treatment, it may also 
serve to up-regulate genes which may limit the growth inhibition achieved, in 
particular EGFR. Therapeutically, a combination of 5-Aza + E2 and gefitinib 
might be used to overcome this problem, and could even improve the growth 
inhibition realised by 5-Aza + E2 in tamoxifen-resistant breast cancer cells. 
This however is only one example of an adverse gene that was re-activated by 
5-Aza + E2 co-treatment and it is inevitable that there will be others. How this 
phenomenon might affect other aspects of the breast cancer cell phenotype 
long-term remains to be determined.
The data from this study add evidence to the theory that anti-hormones are not 
passive bystanders during the acquisition of resistance; they directly promote 
adverse compensatory mechanisms within tumour cells. This ‘dark side of 
anti-hormonal action’ has been recently reviewed by Gee et al (2008), and 
adds weight to the argument that perhaps after 30 years service, we need to 
take a new look at the way we use anti-hormonal drugs and how we treat anti­
hormone resistance, possibly moving away from single agent therapy to 
intelligent combinations of drugs targeting various aspects of the complex 
anti-hormone-induced resistance mechanism.
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6.9 Future Work
In addition to the PCR-verification of RASAL-1 as an oestrogen regulated 
gene potentially associated with 5-Aza induced inhibition of tamoxifen 
resistant cell growth, and the assessment of the effect that gefitinib has on 5- 
Aza + E2 mediated growth inhibition in these cells (which have already been 
discussed); the following lines of investigation will be pursued to further 
assess the significance of the novel observations identified in the present 
study:
Examination o f  expression and promoter methylation status o f  GDF-15, RGC- 
32 and RASAl-1 in further models o f  endocrine resistant and insensitive breast 
cancer.
The tissue culture unit of the Tenovus Centre routinely maintains multiple 
models of anti-hormone resistance/insensitivity, and it is our intention to 
screen those cell lines for the expression of the candidate genes. Where the 
genes are suppressed, we will once again assess the methylation status of their 
promoters in the presence and absence of 5-Aza, and determine the effects of 
5-Aza and oestradiol on cell growth.
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Examination o f  the functional significance o f the candidate genes in anti­
hormone resistant/insensitive cells.
It is our intention to reduce cellular levels of candidate gene mRNA using 
SiRNA knockdown. This will be primarily undertaken in our tamoxifen- 
withdrawn TAM-R cells treated with 5-Aza and oestradiol, using reversal of 
the growth inhibitory response associated with this co-treatment as the initial 
marker of biological reference of this gene. More detailed studies on the 
mechanism of reversal will subsequently be undertaken using FACS analysis, 
to determine the proliferative and apoptotic events associated with the use of 
the siRNAs, and by signalling studies, which will be driven by what is 
currently known about the genes and the availability of reagents.
Assessment o f  the importance o f  the candidate suppressor genes in clinical 
breast cancer.
The Tenovus Centre for Cancer Research and the University of Nottingham 
have enjoyed a longstanding collaboration associated with the translation of 
experimental observations into clinical studies and trials. Significantly this 
joint interest has mostly focused around the use of various endocrine therapies 
and as such, multiple breast cancer specimens relevant to our current work 
have been accumulated. These include frozen and paraffin embedded samples 
from anti-hormone treated patients, removed before, during and at relapse. 
Such material will be examined for the expression of the candidate genes
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using quantitative PCR and immunohistochemical procedures to determine 
clinical relevance.
Fig 6.1 Polo-like kinase (Plk-1) and cell division cycle 2 protein (CDC2) 
Affymetrix gene probe expression profiles (boxplots and heat-maps shown) in 
MCF-7 and TAM-R cells.
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